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1. Abbreviations 
 
AE   adverse event 
AIS   adenocarcinoma in situ 
ALK   anaplastic lymphoma kinase 
ARID1A  AT-rich interactive domain-containing protein 1A 
BEV   bevacizumab 
BRAF   B-Raf proto-oncogene 
CDKN2A  cyclin-dependent kinase Inhibitor 2A  
CHT   chemotherapy 
CI   confidence interval 
CK7   cytokeratin 7 
COPD  chronic obstructive pulmonary disease 
CR  complete response 
CRC   colorectal cancer 
CRF  case report form  
CT   computer tomography 
DLCO  diffusing capacity of the lungs for carbon monoxide 
DNA  deoxyribonucleic acid 
ECOG  Eastern Cooperative Oncology Group 
EGFR  Epidermal Growth Factor Receptor 
EMA  European Medicines Agency  
ERBB2  v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 
ERK  extracellular regulated kinases 
ESMO  European Society for Medical Oncology 
FDA   Food and Drug Administration (U.S.) 
FEV1  forced expiratory pressure in 1 second 
FVC  forced vital capacity 
GABA  gamma-aminobutyric acid 
GWAS genome wide association studies 
HIV  human immunodeficiency virus 
HLA-A human leukocyte antigens on the A locus 
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HRAS  Harvey rat sarcoma viral oncogene homolog 
KEAP1 Kelch-like ECH-associated protein 1 
KRAS  Kirsten rat sarcoma 2 viral oncogene homolog 
LA  Locally advanced 
LADC  lung adenocarcinoma 
LCC  large cell carcinoma 
LCNEC large cell neuroendocrine carcinoma 
LDCT  low dose computer tomography 
MAP2K1  mitogen-activated protein kinase kinase 1 
MEK  mitogen-activated protein kinase 
MET   met proto-oncogene (hepatocyte growth factor receptor) 
MGA   MAX gene associated 
MIA  minimally invasive adenocarcinoma 
MLL2  histone lysine methyltransferase gene KMT2D 
NA  not applicable 
nAChR nicotinic acetylcholine receptors 
NF1   neurofibromatosis type I 
NFE2L2  Nuclear factor erythroid 2-related factor 2 
NLST  National Lung Screening Trial 
NNK  4-(methylnitrosamino)-1-(13-pyridyl-1-butanone) 
NOTCH1 neurogenic locus notch homolog protein 1 
NRAS  Neuroblastoma rat sarcoma viral oncogene homolog 
NSCLC  non-small cell lung cancer 
nsNSCLC non-squamous non-small cell lung cancer 
OCS  observational cohort study  
OS  overall survival 
PAH  polycyclic aromatic hydrocarbons 
PD  progressive disease 
PDYN  prodynorphin  
PET  positron emission tomography 
PFS  progression-free survival  
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PIK3CA phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha 
PR  partial response 
PS  performance status 
PTEN  phosphatase and tensin homolog 
RAF  rapidly accelerated fibrosarcoma, receptor tyrosine kinase effector 
RAS  rat sarcoma viral analog 
RB1  retinoblastoma protein 1 
RBM10  RNA-binding protein 10 
RCT  randomized clinical trial 
RECIST response evaluation criteria in solid tumors 
RET   rearranged during transfection 
RIT1  Ras-like without CAAX 1 
ROS1   ROS proto-oncogene 1 
RTK  receptor tyrosine kinase 
SAE   serious adverse event 
SBRT  stereotactic body radiotherapy 
SCLC  small cell lung cancer 
SD   stable disease 
SD   standard deviation  
SETD2 SET domain containing 2 
SMARCA4 SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 4 
SqCC  squamous cell carcinoma 
STK11  serine/threonine kinase 11 
TB   tuberculosis 
TCGA  The Cancer Genome Atlas Program 
TNM  Tumor, node, metastasis - Internationally accepted classification of 
malignant tumors;  
TP53  tumor protein p53 
TSNA  tobacco-specific N-nitrosamine 
TTF1  thyroid transcription factor 1 
TTP  time-to-progression 
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U2AF1 U2 auxiliary factor 1 
VATS   video-assisted thoracic surgery 
VEGF  vascular endothelial growth factor  
WHO  World Health Organization 
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2. Introduction 
 
2.1. Lung cancer 
 
2.1.1. Epidemiology 
More than 8 million cancer deaths and 14 million new cancer cases were documented 
worldwide in 2012. Lung and breast cancer were diagnosed most frequently among these, 
and they represent the leading causes of cancer death overall. However, in more 
developed countries, lung cancer represents the leading cause of cancer death in 
women(1) and prostate cancer accounts for the most diagnosed malignancy.  
Lung cancer became the second most common malignant tumor in the last century. In the 
19th century and even in the beginning of the 20th century lung cancer was a very rare 
diagnosis. In the 1840s only 22 published cases could be found(2), while in 1912 Adler 
still only identified 374 published cases(3, 4). Recent statistics show that annually there 
were 1.825 million new lung cancer cases worldwide in 2012. This is a marked rise from 
1.6 million new cases in 2008(5). 409 900 of these cases were reported in Europe which 
was 13% of all cancer cases(6), however it causes more deaths than breast, prostate and 
colon cancer combined. It is estimated that the total number of deaths caused by lung 
cancer was 1.589 million worldwide, which accounts for 17% of all cancer related 
deaths(7). The incidence of lung cancer still rises worldwide, although it shows great 
variances between countries.  
Hungary has on of highest mortality rates of lung cancer in the world both in men and 
women. Hungary, unlike other developed countries, records a growing number of new 
cases. While the incidence hasn’t increased over the last few years in men, it continuously 
does in women(8). In 2014, the registered number of new cases of lung cancer in Hungary 
was 5189 (60% male, 40% female). Incidence is quite low in the population younger than 
40 years (0-12%000), however it rises drastically to 250%000 in the male population 
between 50 and 54 years of age(9).   
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2.1.2. Etiology 
2.1.2.1. Smoking 
The use of tobacco attributes to 90% of all lung cancer cases, which makes it the single 
greatest risk factor regarding lung cancer. Smokers have a 15 fold chance of developing 
lung cancer compared to non-smoking population. Based on less univoque evidence, they 
presume that work-associated carcinogens attribute for 9-15%, radon released into air for 
10% and pollution for 1-2% of cases.  
Society-wide understanding of the relationship between smoking and lung cancer  was 
achieved very slowly due to several factors. One of these factors is the long latency period 
between smoking initiation and the development of lung cancer and another interesting 
factor was the marketing activity of the tobacco industry(10). Tobacco had been used by 
people in Europe, America and Asia for centuries without significant incidence of lung 
cancer. Tobacco was regarded primarily as medicine or was used only in rituals. Tobacco 
was brought to Europe in the 15th century but cigarettes were only manufactured first in 
the 19th century. In this era, cigarettes were expensive and hand-rolled and only men used 
them occasionally(11, 12).  
The world wars had a great role in the fact that smoking got popular first in men and later 
also in women. Smoking increased dramatically after both world wars because soldiers 
were handed free cigarettes and developed nicotine addiction. At this time the negative 
effects of smoking were not know to the wide public so soldiers subsequently brought the 
habit of smoking home. Early reports already suggested a link between smoking and 
cancer in the 1920s and 1930s but these reports were not perceived widely thus they had 
no effect on consumption(13-16). The first major epidemiological studies were released 
in 1950 by Doll and Hill (17) and Wyander and Graham (18). These definitely established 
the relation between smoking and lung cancer which led to statements Royal College of 
Physicians in Great Britain in 1962 (19) and the US Surgeon General in 1964 to warn the 
public about the dangers of smoking.  
Smoking a cigar or a pipe is less dangerous than cigarettes because the tobacco smoke 
exposition is lower and deep inhalation is rare. The chance of developing lung cancer 
shows an exponential relationship with the number of cigarettes smoked and the total 
years of smoking. The length of smoking is of greater importance than the age of the 
patient and no matter how old someone is, quitting decreases the chance of lung cancer. 
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Passive smoking is also considered a risk for developing lung cancer, however a 
metanalysis comparing smoking and non-smoking couples found that passive smoking 
only increased the risk by 20%(20, 21). In Hungary an estimated 34% of the population 
is smoking (41% in male and 28% in female) which puts Hungary among the countries 
with the highest risk of lung cancer.  
Nicotine, responsible for the addictiveness of cigarettes, is a natural alkaloid acting as an 
acetylcholine agonist that binds to the nicotinic acetylcholine receptors (nAChR) in the 
nervous system, causing release of neurotransmitters into the blood stream, including 
dopamine, serotonin, norepinephrine, endorphins, and gamma-aminobutyric acid 
(GABA). Nicotine upregulates nicotinic receptors and alters gene expression causing 
dependence and also helping progression of an existing tumor(22-24). Nicotine itself is 
not regarded as carcinogen, however there are at least 60 known carcinogens produced at 
tobacco combustion. The most significant are tobacco-specific N-nitrosamines (TSNAs), 
such as 4-(methylnitrosamino)-1-(13-pyridyl-1-butanone) (NNK) and polycyclic 
aromatic hydrocarbons (PAH), including benzo[a]pyrene and nitrates(25). The 
relationship of NNK to lung cancers, specifically adenocarcinomas have been 
demonstrated(26). Combustion of tobacco produce a smoke that has a vapor phase that 
produce 1015, and a particulate phase with 1017 free radicals per gram. The damage done 
by these free radicals is one of the methods of carcinogenesis, the other is DNA adduct 
and metabolite formation(24, 25).  The carcinogenesis of smoking can be seen on Figure 
1.  
 
1. Figure – Carcinogenesis of smoking 
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2.1.2.2. Environmental risk factors 
 
2.1.2.2.1. Radon 
It has been known from the 15th century that mining carried the risk of lung disease. It 
was observed on miners working in the mountains on the German-Czech border that the 
incidence of “mountain disease” was very high. In these mines they produced cobalt, 
arsenic, bismuth, iron, silver and later in the 20th century radium. In the 20th century these 
mining communities had extremely high incidence of squamous cell lung cancer(4). 
Residential exposition to radon occurs from soil. Radon is a radioactive gas occurring 
naturally from the earth’s crust from natural decay of uranium. Usually radon level can 
rise to unsafe measures in residential basements. Cigarette smoking in the same time 
increases the relative risk of lung cancer from radon(27-29). 
 
2.1.2.2.2. Asbestos 
Asbestos is the most common occupational exposure to carcinogens but especially in 
Eastern Europe asbestos can also be still found in residential buildings. Asbestos was 
used widely in constructions since the 19th century. It contains chrysotile fibers that have 
been shown to have association with lung disease and thoracic malignancies such as 
malignant mesothelioma and lung cancer. Residential and continuous occupational 
exposure to asbestos carries a 5-fold risk of lung cancer and have a synergistic effect with 
tobacco smoking(30, 31). A closed eternity factory still produce increased risk for 
asbestos exposure for residents living in nearby villages in Hungary’s Selyp.  
 
2.1.2.2.3. Air pollution 
An adult inhales approximately 10 000 liters of air per day which means that even a small 
concentration of carcinogens can cause changes in the cellular DNA with time. Air 
pollution in big cities consist of carcinogens released from combustion of fossil fuel, 
arsenic, nickel and chrome. A study conducted in six large cities in the USA found that 
the incidence of lung cancer was 40% higher in the most polluted city compared to the 
one with the least air pollution(32). The frequently cited paper of Doll and Petro estimated 
DOI:10.14753/SE.2020.2414
 - 12 - 
that only 1-2% of lung cancer cases was due to air pollution in 1981(20). Their estimation 
is  still most probably correct.  
 
2.1.2.3. Genetic risk factors 
The fact that not all smokers develop lung cancer establishes the role of genetic 
susceptibility to lung cancer. They observed that having a positive family history for lung 
cancer increases the risk 1.7 fold(33). Genome wide association studies (GWAS) 
identified the chromosome regions connected to increased risk of lung cancer: 5p15, 
15q25-26 and 6q21(34, 35). Telomerase reverse transcriptase (TERT) is involved in cell 
replication and in the development of lung cancer it is associated with adenocarcinomas. 
TERT is encoded on the 5p15 region. Chromosome locus 6p21 regulates G-protein 
signaling, and mutations increase the risk of lung cancer development in non-smokers. 
The 15q25-26 chromosome locus is known for mutations that are positively linked to 
nicotine dependence and susceptibility for lung cancer(36, 37).  
It is interesting that there have been a change in lung cancer histology throughout the 
years: in the early 20th century squamous cell lung carcinoma was the most frequent, 
while since the 1970s the incidence of lung adenocarcinoma rose and incidence of 
squamous cell carcinomas decreased. The background of this change is not entirely 
known, however several authors contribute this change to the wide use of filters in 
cigarettes. The use of filters decreased the amount of inhaled PAHs but on the other hand 
the deeper inhalation increased the amount of nitrogen-oxides and nitrosamines(32).    
 
2.1.2.4. Coexisting diseases and infections 
Previous lung injury caused by chronic obstructive pulmonary diseases (COPD) and lung 
fibrosis also plays a role in lung cancer development, however it is challenging to study 
their effect separately because smoking also has a role in COPD. Both diseases can cause 
lung injury through inflammatory pathways and it was also shown that infections such as 
tuberculosis (TB) were associated with a 1.7 fold increase in risk for lung cancer(38).  
Human immunodeficiency virus (HIV) infection also carries a risk among other diseases 
for lung cancer. Lung cancer is the most common malignancy in patients with HIV 
infection and it also accounts for 30% of cancer deaths related with HIV(39, 40). The 
HIV virus itself has not been connected directly to oncogenesis, however the 
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immunosuppression caused by it defiantly plays a role since organ transplant recipients 
and HIV patients have a similar increase in cancer rates(41). Declining CD4 counts were 
found to be the reason for higher lung cancer rate. 42% of HIV patients also smoke, 
however HIV-infected patients have a 2.5 fold greater risk of developing lung cancer 
regardless of the smoking status(42).  
 
2.1.3. Histology and molecular background of lung cancer 
The histopathological diagnosis of lung cancer is based on morphologic features. Two 
main histopathological groups were made: small cell lung cancer (SCLC) and non-small 
cell lung cancer (NSCLC). SCLC accounts for approximately 15% of cases, while 
NSCLC accounts for 85%. NSCLC is usually subcategorized into adenocarcinoma, 
squamous cell carcinoma and large cell carcinoma, even though more and more evidence 
suggests that that these are molecularly heterogenous diseases(43).  
Histological classification was last updated in 2015 by the World Health Organization 
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1. Table – WHO 2015 classification of lung epithelial tumors 
Adenocarcinoma Large cell carcinoma 
 Lepidic adenocarcinoma Adenosquamous carcinoma 
 Acinar adenocarcinoma Pleomorphic carcinoma 
 Papillary adenocarcinoma Spindle cell carcinoma 
 Micropapillary adenocarcinoma Giant cell carcinoma 
 Solid adenocarcinoma Carcinosarcoma 
 Variants of adenocarcinoma Pulmonary blastoma 
 Invasive mucinous adenocarcinoma Other and unclassified carcinomas 
 Mixed invasive mucinous and non-mucinous  
adenocarcinoma Lymphoepithelioma-like carcinoma 
 Colloid adenocarcinoma NUT carcinoma 
 Fetal adenocarcinoma Salivary gland-type tumors 
 Enteric adenocarcinoma Mucoepidermoid carcinoma 
 Minimally invasive adenocarcinoma Adenoid cystic carcinoma 
 Non-mucinous Epithelial–myoepithelial carcinoma 
 Mucinous Pleomorphic adenoma 
 Preinvasive lesions Papillomas 
 Atypical adenomatous hyperplasia Squamous cell papilloma 
 Adenocarcinoma in situ Exophytic 
 Non-mucinous Inverted 
 Mucinous Glandular papilloma 
Squamous cell carcinoma (SqCC) Mixed squamous cell and glandular papilloma 
 Keratinizing SqCC Adenomas 
 Non-keratinizing SqCC Sclerosing pneumocytoma 
 Basaloid SqCC Alveolar adenoma 
 Preinvasive lesion Papillary adenoma 
 SqCC in situ Mucinous cystadenoma 
Neuroendocrine tumors Mucous gland adenoma 
 Small cell carcinoma   
 Combined small cell carcinoma   
 Large cell neuroendocrine carcinoma (LCNEC)   
 Combined LCNEC   
 Carcinoid tumors   
 Typical carcinoid   
 Atypical carcinoid   
 Preinvasive lesion   
 Diffuse idiopathic pulmonary neuroendocrine cell   
 Hyperplasia   
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2.1.3.1. Adenocarcinoma 
Adenocarcinoma is currently the most common malignancy of the lung and it is a 
heterogenic group of tumors. In Hungary adenocarcinoma accounts for 47% of all lung 
cancer incidence(44). The common in all adenocarcinomas is the glandular structure and 
some level of mucin production. The growing pattern can be variable, the most common 
is lepidic growth that follows the alveolar wall, acinar, papillary or solid. Several of these 
patterns can be present within one tumor but usually one is dominant. The diagnosis of 
adenocarcinoma is often proven by immunohistochemistry (TTF1, Napsin-A, CK7) and 
mucin staining.  
Adenocarcinoma in situ (AIS) was introduced as a new precancerous category. These 
tumors are smaller than 3 cm in diameter, they are solitary, the show clearly lepidic 
growth pattern and they do not invade the pleura, stromal cells or the vessels.  
Minimally Invasive Adenocarcinoma (MIA) was also introduced as a new precancerous 
category. These tumors are not greater than 3 cm in diameter, they are solitary, they show 
dominantly lepidic growth pattern and they only show minimal (smaller than 5mm) 
stromal, vascular or pleural invasion.  
The nomenclature do not use bronchiolo-alveolar carcinoma and mixed adenocarcinoma 
anymore(45).  
DOI:10.14753/SE.2020.2414
 - 16 - 
 
2. Figure – Histologic subtypes of lung adenocarcinoma: A, Predominantly lepidic pattern with 
lepidic growth on the right with invasive acinar adenocarcinoma on the left; B, Proliferation along 
the alveolar wall (type II pneumocytes and Clara cells); C, Invasive acinar adenocarcinoma; D, 
oval-shaped malignant glands invading the fibrous stroma in invasive acinar adenocarcinoma; E, 
Papillary adenocarcinoma; F, Small papillary clusters of glandular cells in a micropapillary 
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The most common significantly mutated pathways include the EGFR, FGFR, VEGFR, 
NTRK, EPHA/B and INSR genes as seen in Figure 3.  
 
 
3. Figure – Significantly mutated pathways in lung adenocarcinoma. Oncoproteins are indicated 
in pink to red and tumor suppressor proteins are shown in light to dark blue. The darkness of the 
colors shows the number of tumors with genetic alterations.(47)  
 
18 significant somatic mutations were identified in lung adenocarcinoma by 
comprehensive molecular profiling of 230 tumors by  The Cancer Genome Atlas Program 
(TCGA) in 2014: TP53 (46%), KRAS (33%), KEAP1 (17%), STK11 (17%), EGFR(14%), 
NF1 (11%), BRAF (10%), SETD2 (9%), RBM10 (8%), MGA (8%), MET (7%), ARID1A 
(7%), PIK3CA (7%), SMARCA4 (6%), RB1 (4%), CDKN2A (4%), U2AF1 (3%), and 
RIT1 (2%). A mean of 8.9 mutations were reported per megabase which is considered 
very high. This widened the possibility of targeted therapy. 75% of the examined 
adenocarcinomas contained genetic changes to the RTK/RAS/RAF signaling pathway 
and 62% of them had driver genetic alterations that promote this cascade. The most 
common driver mutations were KRAS, EGFR and BRAF with 32, 11 and 7% respectively 
in this study. Other promoter mutations included MET exon 14 skipping (4.3%), ERBB2 
mutation (1.7%), ROS1 fusion (1.7%), ALK fusion (1.3%), MAP2K1 mutation (0.9%), 
RET fusion (0.9%), NRAS mutation (0.4%), and HRAS mutation (0.4%).  
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4. Figure – A: Co-mutation plot of variants of known significance within the RTK/RAS/RAF 
pathway in lung adenocarcinoma. B: New candidate driver oncogenes (blue: 13% of cases) and 
known somatically activated drivers events (red: 63%) that activate the RTK/RAS/RAF pathway 
in the majority of the 230 adenocarcinoma cases. Adopted form the TCGA. (48) 
 
The DNA copy numbers were also examined in the remaining 38% of cases were driver 
mutation was not found. It showed amplification of oncogenes in the RTK/RAS/RAF 
pathway: MET amplification (2.2%) and ERBB2 amplification (0.9%). New genetic 
alterations were also identified in this study: NF1 and RIT1 mutations, comprising 8.3% 
and 2.2% respectively. Altogether 75% of lung adenocarcinomas have genetic driver 
alterations to the RTK/RAS/RAF pathway. This comprehensive study also conducted 
mRNA profiling, DNA methylation profiling and protein profiling(49).  
 
2.1.3.2. Squamous Cell Carcinoma 
In Hungary SqCC accounts for 25% of all lung cancer incidence(50). Squamous Cell 
Carcinomas are classified as keratinizing SqCC, non-keratinizing SqCC, and basaloid 
SqCC. Classification is only possible from resected samples. To detect basaloid SqCC 
immunohistochemistry testing of p63 and p40 is needed.  
Comprehensive molecular testing of lung SqCC was performed in 2012 by TCGA. 178 
cases of lung SqCC were profiled and complex genetic alterations were identified. Most 
patients were heavy smokers which caused the high number of genetic changes: a mean 
of 360 exonic mutations, 165 genetic rearrangements and 323 segments of copy number 
alterations per tumor. 11 statistically significant mutations were found: TP53, CDKN2A, 
PTEN, PIK3CA, KEAP1, MLL2, HLA-A, NFE2L2, NOTCH1, RB1, and PDYN. The 
incidence of TP53 was 90%.  
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This comprehensive study also conducted pathway analysis, mRNA profiling, DNA 
methylation profiling and protein profiling(51). 
 
2.1.3.3. Large Cell Carcinoma 
Large Cell Carcinomas (LCC) are rare, in Hungary LCC accounts for only 2% of all lung 
cancers. The diagnosis can only be made from resected specimen which can often cause 
a clinical problem is advanced cases were normally only fine needle or core biopsy would 
be taken. By definition LCC is a NSCLC that does not show signs of glandular or 
squamous differentiation(45). Immunohistochemistry has an important role in the 
diagnosis of LCC because most poorly differentiated tumors can be classified as either 
adenocarcinoma or SqCC with the right immunopanel (TTF1, Napsin-A, p40, p63, 
CK5/6).  
 
2.1.3.4. Neuroendocrine tumors 
This category “neuroendocrine tumors” was established in the 2015 WHO classification. 
It consist of three subtypes: SCLC (20%), large cell neuroendocrine carcinoma (LCNEC 
– 3%), and carcinoid tumors. Carcinoids tumors can be divided in atypical (0.2%) and 
typical (2%) groups. Clinical behavior of neuroendocrine tumors can greatly vary, thus 
the distinction between high-grade neuroendocrine tumors, such as SCLC and LCNEC, 
and a carcinoid tumors is very important. The prognosis of the latter group is usually 
benign and these tumors frequently occur in non-smoking population, whereas high-grade 
neuroendocrine tumors are usually the most aggressive and the patients are usually heavy 
smokers.  
In the pathological diagnosis of neuroendocrine tumors chromatin structure, the presence 
of necrosis and proliferative activity (mitosis number) are important.  
 
2.1.3.4.1. Small Cell Lung Cancer 
SCLC consists of small cells with typical dust-like chromatin, decreased cytoplasm and 
high mitosis number (›11/2mm2) is seen.  
Two groups reported full genomic analysis of SCLC. SOX2 was reported as a frequently 
amplified gene in SCLC by Rudin et al(52). It was also shown that in vitro suppression 
of SOX2 blocked the proliferation of SOX2-amplified SCLC cell lines. Peifer et al. on 
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the other hand, found mutations in the CREBBP, EP300, and MLL genes that encode 
histone modifiers. This suggest that histone modification is an important process in 
SCLC(53). In 2015, George et al. found complex genetic alterations in SCLC, such as 
C:G>A:T transversions (in 28% of all cases), inactivation of TP53, RB1 and the NOTCH 
family genes (25% of all cases)(54, 55). These changes are often seen in heavy smokers.  
 
2.1.4. Screening, clinical diagnosis, staging and prognosis of lung cancer 
 
2.1.4.1. Screening 
Screening for lung disease traditionally existed in most developed countries for the 
screening of infectious diseases such as tuberculosis (TB). Radiological screening with 
roentgen started widely after the II. World War when the price of the radiological 
examination was lowered(56). In Hungary, yearly lung screening was mandatory for 
every person of the age of 14 or older form 1960 to 2004. Screening examinations were 
done in a separate lung-screening network with yearly notifications via post. 
 
 
5. Figure - Lung screening X-rays conducted in Hungary from 1954 to 2014(57)  
 
 Screening included chest x-ray and in some cases cytology and bacteriological culture 
from sputum. This system was primarily set up to find TB cases, however it helped in the 
discovery of lung cancer as well. With the notable decrease in TB cases and the worsening 
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financial system in the Hungarian health care, the screening network has been partially 
dismantled since 2004 and screening is not mandatory anymore. In the late 1990’s lung 
cancer screening became an important topic in the developed countries. The first country 
to introduce a modern screening system with computer tomography (CT) was Japan and 
the first dedicated program was the Early Lung Cancer Action Program in the USA(58, 
59).  
Several countries, including the USA, Netherlands, Japan, Denmark conducted 
observational trials and the conclusion was always the same: lung cancer can be found in 
an earlier stage with low-dose CT (LDCT) screening(60). To acquire reliable mortality 
data a randomized trial was warranted. The National Cancer Institute (US) founded the 
National Lung Screening Trial (NLST), a multi-center randomized study that was 
conducted from 2002 to 2009 and enrolled a total of 53,456 participants (from 2002 to 
2004). Only heavy smokers (more than 30 pack year) were included between the ages of 
55 to 75. Approximately 50% of cases were randomized to a chest x-ray arm, while the 
other 50% to a low dose screening arm. 309 deaths per 100,000 persons-year was 
observed in the chest radiography arm, while 247 in the LDCT arm, which means a 20% 
relative reduction in lung cancer mortality. Since LDCT screening is a relatively 
expensive option, population wide LDCT screening is not affordable for most countries. 
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2. Table - Approximate 10-year risk of developing lung cancer.  
Adopted from Bach PB et al. (61) 
 
 
Duration of smoking 













smoking, %  
1 pack per day smokers 
55  <1  1  3  5  NA  NA  
65  <1  2  4  7  7  10  
75  1  2  5  8  8  11  
2 packs per day smokers 
55  <1  2  4  7  NA  NA  
65  1  3  6  9  10  14  
75  2  3  7  10  11  15  
 
Several models were made to predict the risk of lung cancer development. Bach et al. 
proposed a risk assessment model which primarily counts smoking history (in Table 2.). 
Later the Spitz model (62) and the Liverpool Lung project (LLP) (63) model were also 
published. These models take several factors in consideration: age, age, smoking 
duration, exposure to carcinogens, diagnosed emphysema, prior diagnosis of pneumonia, 
prior diagnosis of malignant tumor, family history of cancer in first-degree relatives. 
D’Amelio et al conducted a validation study including the Bach, the Spitz and the LLP 
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models. The latter two proved to be more discriminative, accurate and clinically more 
utilizable(64).  
Screening with LDCT after lung cancer risk calculation is an affordable and efficient way 
of early lung cancer detection and thus a way to decrease lung cancer mortality. It raises 
some ethical considerations, however. Using the above mentioned risk assessment 
models mean that non-smokers will most probably be excluded from lung cancer 
screening. Considering the fact that non-smokers can also develop lung cancer, although 
the chance is thinner, raises concerns about the above described system. No financially 
feasible, more effective and ethically non-objectionable method has been developed 
however. In Hungary, currently no lung screening program is available and this situation 
must be addressed sooner than later.  
 
2.1.4.2. Clinical diagnosis of lung cancer  
 
Lung cancer detection in early stage is the most important step to achieve good results 
with treatment. 85% of the cases however, are only detected when symptoms occur and 
in 57% the diagnosis is only made when metastases are already present (65). The problem 
is that in most cases lung cancer does not cause early symptoms. Symptoms can be 
divided to subgroups (66):  
• Symptoms related to endobronchial growth: Cough (8% to 75%), dyspnea (3% to 
60%), pain, wheezing (0% to 2%), poststenotic pneumonia, hemoptysis (6% to 
35%), stridor (0% to 2%). 
• Symptoms related to intrathoracic extension: Chest pain (20% to 49%), 
hoarseness (recurrent nerve involved), diaphragm paralysis – raised diaphragm 
(phrenic nerve involved), upper airway inflow obstruction, dysphagia (esophagus 
involved), pleural effusion (carcinosis pleurae), pericardial effusion (pericardium 
involved), superior vena cava syndrome (v. cava superior involved), Horner triad, 
chronic shoulder pain (in Pancoast tumors).  
• Systemic cancer symptoms: Weight loss (0% to 68%), fatigue, fever (0% to 20%), 
night sweats.  
• Symptoms of distant metastases: Bone pain (6% to 25%), headache, neurological 
or psychiatric abnormalities, hepatomegaly, pathological fractures. 
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• Paraneoplastic syndromes: Cushing syndrome, Lambert-Eaton syndrome, Perre-
Marie-Bamberger syndrome, syndrome of inappropriate ADH secretion, etc.  
 
Lung cancer can be detected after the previously mentioned symptoms occur or in 
asymptomatic changes. Detection is most commonly done by chest x-ray or CT, however 
MRI (Magnetic Resolution Imaging) and PET (Positron Emission Tomography) are also 
more frequent.  
Lung cancer diagnosis is often made from CT morphology and optionally the level of 
FDG uptake on PET, when a spiculated mass is seen, however pathological verification 
is also needed, primarily to distinguish between SCLC and NSCLC because the treatment 
strategies are very different. SCLC in most cases presents in a later stage with lymph node 
involvement. Generally small, central lung lesions with extensive lymphatic involvement 
always raise the concern for SCLC. The pathological diagnosis can be made from biopsies 
or after operation depending on the stage and treatment plan.  
 
 
6. Figure – CT  axial section of a spiculated mass in the left lower lobe (segment 6). Picture 
obtained from the Department of Thoracic Surgery, National Institute of Oncology, Budapest. 
DOI:10.14753/SE.2020.2414
 - 25 - 
 
Lung cancer workup includes flexible bronchoscopy for the intrabronchial evaluation of 
anatomy and tumor spread. Bronchial washing and brushing can be done, which is ideal 
for intrabronchial or central tumors. Biopsies can be made through the bronchoscope with 
x-ray or ultrasound guidance (TBNA – trans-bronchial needle aspiration, EBUS – endo-
bronchial ultrasound). The primary lesion and most regional lymph node stations can be 
reached with EBUS and also endoscopic ultrasound (EUS) guided biopsy can be of help.  
In case of peripheral lesions, transthoracic fine needle aspiration or core biopsy under 
image guidance (usually CT) can be performed to get diagnosis and even the molecular 
characteristics of the tumor. Thoracentesis can also be of help in case of pleural fluid as 
a palliative and diagnostic tool. When none of the above mentioned methods yield a 
result, invasive, surgical techniques can be considered like mediastinoscopy, VATS 
biopsy or thoracotomy.  
To provide adequate treatment it is important to assess how far the tumor have spread 
(staging) and to estimate the physical condition of the patient.  
 
2.1.4.2.1. Functional evaluation of patients diagnosed with lung cancer 
 
Physical evaluation of patients have to include the assessment of comorbidities, general 
performance (Karnofsky-index and the Eastern Cooperative Oncology Group (ECOG) 
status is most commonly used) and lung function. The most important comorbidities to 
take into account are cardiac, liver and renal diseases that can affect the feasibility and 
the result of certain treatment options. Cardiac echographia with the measurement of 
cardiac output and in selected cases cardiac stress test is often needed. Liver and renal 
function is tested with laboratory workup.  
The evaluation of lung function is most important before surgical treatment, where the 
risk of the treatment and the quality of life achieved have to be taken into consideration. 
Generally, Forced Expiratory Volume in 1 second  (FEV1), Forced Vital Capacity (FVC) 
and Diffusing Capacity (DLCO) are measured. Patients with FEV1 of more than 80% of 
the normal (adjusted for size and age) and DLCO more than 80% are suitable for surgical 
treatment (including pneumonectomy) without further tests. In case either of these values 
are under 80% spiroergometry is recommended. If the maximum oxygen consumption is 
above 20mL/min/kg or 75% of normal, the patient can be referred for surgery (including 
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pneumonectomy). When the maximum oxygen consumption is below 40% of the 
expected (or ‹ 10mL/min/kg) functional inoperability is established. In case the maximum 
oxygen consumption is between 40% and 80%, postoperative FEV1 are calculated on the 
basis of quantitative ventilation and perfusion on lung scintigraphy. If the estimated FEV1 
after the procedure is higher than 40% of normal, the operation can be performed; if it is 
below 40% functional inoperability has to be assumed.  
 
 
7. Figure – Algorithm of functional evaluation recommendation of the European Society for 
Medical Oncology (ESMO); 2017 (67) 
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2.1.4.3. Staging of lung cancer 
 
To evaluate the extent of the disease CT, PET CT, bone scintigraphy, brain MRI, 
abdominal ultrasound and biopsies are used. The staging is made following the actual 
international guideline. The latest staging system for lung cancer is the 8th tumor, node, 
metastasis (TNM) classification which was introduced after examining 77.156 cases and 
their outcome regarding survival and relapse (68).  
T stage is determined by the size of the primary tumor and its involvement of the adjacent 
structures: 
 
3. Table - T value in the 8th edition of TNM staging. Adopted from: International Association for 
Study of Lung Cancer, 2015. [69] 
 
N stage determines the lymph node involvement of lung cancer in the hilar and 
mediastinal regions. Lymph node involvement separates cases by prognosis and thus have 
a great effect on treatment. 
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4. Table - N value in the 8th edition of TNM staging. Adopted from: International Association for 
Study of Lung Cancer, 2015. (69) 
 
The N categories were made after the survival was assessed in pathological classified 
cases. N1 was divided into N1a (single station, ipsilateral hilum) and N1b (multiple 
stations); and N2 into N2a1 (single N2 station without N1 involvement), N2a2 (single N2 
station with N1 involvement) and N2b (multiple N2 stations). The 5-year survival rates 
were the following: N1a, 59%; N1b, 50%; N2a1, 54%; N2a2, 43%; and N2b, 38%. A 
single-stage mediastinal nodal disease without N1 disease has the same prognosis as 
multiple N1 station involvement.  
M stage defines distant metastases beyond the regional lymph nodes.  
 
5. Table - M value in the 8th edition of TNM staging. Adopted from: International Association for 
Study of Lung Cancer, 2015. (69) 
 
 
M1b was introduced as a separate category for the single extrathoracic metastases, since 
this patients had a significantly better survival (with a mean survival of 11.4 months 
instead of 6.3 months)(70). The treatment strategy also differs for these patients, since in 
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selected oligometastatic cases better survival can be achieved with aggressive local 
therapy, whereas in M1c cases systemic therapy has better results.  
 
The appropriate stage is given from the TNM values according to the following table: 
 
6. Table – Staging according to the 8th TNM. Adopted from: International Association for Study 
of Lung Cancer, 2015. (71) 
T/M Subcategory N0 N1 N2 N3 
T1 T1a IA IIB IIIA IIIB 
  T1b IA IIB IIIA IIIB 
 
T1c IA IIB IIIA IIIB 
T2 T2a IB IIB IIIA IIIB 
 
T2b IIA IIB IIIA IIB 
T3 T3 IIA IIIA IIIB IIIC 
T4 T4 IIIA IIIA IIIB IIIC 
M1 M1a IVA IVA IVA IVA 
 
M1b IVA IVA IVA IVA 
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2.1.4.4. Prognosis of lung cancer 
 
The prognosis depends highly on the histology, most importantly the distinction between 
SCLC and NSCLC, the biological behavior of the cancer and the stage.   
 
2.1.4.4.1. Prognosis of SCLC 
 
For the staging of SLCL currently the 8th TNM system is used, however another approach 
classifies SCLC into two groups: Limited Disease (LD) and Extensive Disease (ED). This 
classification reflects the clinical behavior and the spread of the tumor rather well, since 
LD patients have significantly superior survival when compared to ED patients. One 
contributing factor is that often small, accidentally found lesions turn out to be SCLC 
after final pathological examination. In these cases the surgical removement is done in a 
very early stage. The TNM system gives a more accurate estimation of the prognosis, 
however very few cases are found in early stages. When creating the 8th TNM for SCLC, 
Shirasawa et al. included 277 patients in a retrospective cohort and compared their 
prognosis. In this cohort 65.7% of the patients were classified as ED and 34.3% as LD, 
the OS was 37.2 (95% CI 25.7–48.7) and 13.7 (95% CI 11.9–15.5) months, respectively 
(this can be seen of Figure 8A). On Figure 8B. OS can be seen according to the TNM 
stages. OS drops markedly between stages, comparison of the curves reveals significant 
difference between every line (P values were the following: stage I vs II, P=0.04; I vs III, 
P=0.02; I vs IV, P<0.001; II vs III, P=0.47; II vs IV, P=0.009; III vs IV, P<0.001). It is 
important to know however, that the distinction between IVA and IB stage is also 
important because the change of M descriptor was also significantly associated with OS.  
OS of stage IVB patients with the M1c descriptor was inferior to that of the stage III and 
IVA patients with the M0, M1a, or M1b descriptors (Figure 9A-B) (72).  
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8. Figure - Kaplan–Meier analysis-based estimates of survival based on staging system in SCLC 
patients (n=277). (A) Comparison of survival between LD (n=91; gray) and ED (n=186; black) 
SCLC patients (P<0.001). (B) Comparison of survival between patients in TNM stages I to IV. 
Adopted from (72). 
 
 
9. Figure - Kaplan–Meier analysis-based estimates of survival for ED SCLC patients. (A) 
Comparison of survival between patients in stages III (n=10, gray solid line), IVA (n=70, gray 
dotted line), and IVB (n=106, black solid line) (B) Comparison of survival according to the M 
descriptor of the 8th TNM. Adopted from (72). 
 
2.1.4.4.2. Prognosis of NSCLC 
The average 5-year survival in NSCLC is approximately 15%. This dismal result is due 
to the fact that most cases are found in latter stages (73) as previously mentioned. When 
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recently validation the 8th TNM Yun et al. compared the survival of 3950 following lung 
cancer resection. All TNM stages showed significant differences (except IIA and IIB 
where the difference was not significant). The 5-year median survival was 90.7%, 79.9%, 
68%, 58.7% and 44.9% for IA, IB, IIA, IIB and IIIA stages, respectively according to the 
7th TNM, however, reassessing the patients with the 8th TNM the 5 year median survival 
was quite different: 96.1%, 92.3%, 87.9%, 81.1%, 74.7%, 67.2%, 47.5% and 38.3% for 
IA1, IA2, IA3, IB, IIA, IIB, IIIA and IIIB stages, respectively. These results can be seen 
on Figure 10. The 8th TNM distinguishes better between both early and advanced stage 
NSCLC patients according to Yun et al (74).  
 
 
10. Figure – Survival curves of OS according to the 8th TNM in the cohort of Yun et al. (74) 
 
The 8th TNM was not yet validated in regards to stage IIIB and IV. However, available 
survival data shows significantly worse survival in these groups. The 5-year survival is 
reported to be 19%, while the median survival is 16 months in IIIB stage. The median 
survival drops to 6 months in IV. stage with the 5-year survival only 6%(75). This is 
already and improved results as 5-year survival virtually never existed in IV. stage before. 
Further development and superior survival results are to be expected with the introduction 
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2.1.5. Treatment of lung cancer 
 
2.1.5.1. Treatment options for SCLC 
 
The TNM staging system is useful to select patients for surgical treatment, however only 
very few cases are suitable for removal, reportedly less than 5%(76). Most of these 
patients are operated for an unknown lesion in the lung. These patients have superior 
outcome with 5-year survival up to even 50% is some reports (77, 78). Surgical approach 
can only be selected in these cases when lymph node involvement is ruled out with 
adequate mediastinal staging with PET-CT, EBUS and or mediastinoscopy. Postoperative 
adjuvant chemotherapy (CHT) is indicated even in T1-2,N0,M0 cases. Usually 4 cycles 
of CHT is administered. In case of unexpected N1 or N2 disease postoperative 
radiotherapy should be considered depending on the completeness of lymphadenectomy 
performed by the surgeon.  
In cases with N2 disease, even without distant metastases (M0) surgery has no role. Total 
gross tumor volume proved to be an independent prognostic factor independent on the 
local therapy(79). N2 patients should undergo combined concurrent chemoradiotherapy.  
Prophylactic cranial irradiation (PCI) should be considered at al T1-2,N0-1,M0 patients 
in case they responded to initial treatment.   
Patients with T1-4,N0-3, M0 SCLC should be treated with chemotherapy and thoracic 
radiation concurrently in case the performance status (PS) allows. 70 Gy in daily fractions 
or 1.5 Gy in 30 fractions twice a day are usually selected options for radiotherapy. For 
the planning of radiotherapy to choose the target volume a PET CT is usually used.  
For patients with metastatic SCLC the treatment is palliative. Most commonly a 
combination of CHT is used. A big meta-analysis reviewed the data of 19 randomized 
trials and shown that cisplatin was superior in terms of outcome in combination therapy 
when compared to other agents(80). Another collecting the data of 36 randomized trials 
concluded that etoposide, especially in combination with cisplatin showed longer OS than 
regimens without these two agents(81). The above mentioned results led to the clinical 
practice of etoposide-cisplatin combination therapy for SCLC as a standard of care. 
Usually 4-6 cycles are administered in first line treatment.  
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PCI has led to significantly longer OS and less symptomatic brain metastases in 
randomized trials (82), thus patients responding well to initial CHT are usually offered 




11. Figure – First line treatment algorithm for SCLC (ESMO 2013). Adopted from (83). 
 
Second-line treatment for SCLC is only recommended in patients who respond to the 
first-line therapy. In patients who progress during chemotherapy and non-responders 
(early relapse within 6 weeks) outcomes are poor and further systemic therapy does not 
yield significant benefit. For these patients best supportive care is offered. Topotecan, a 
topoisomerase-I inhibitor, is a drug used for previously treated patients with SCLC. Its 
efficacy in terms of longer OS and better quality of life (better symptom control) was 
proven in a phase III trial (84). 8 years later the oral version of the drug was also tested 
in a phase III trial and was found to be equally efficient(85).  
Targeted therapies were studied in extent for SCLC both in combination with 
chemotherapy and as a single agent, however very few studies managed to meet the 
primary endpoint. The examined drugs included: bevacizumab (86), vandetanib (87) and 
aflibercept (88) (anti-angiogenesis agents), panobinostat (89) (histon deacetylase 
inhibitor), oblimersen (90) (an agent targeting apoptosis) and cixutumumab and 
vismodegib (91) (agents targeting cell signaling).  Alisertib, an aurora kinase inhibitor 
and sunitinib, a multi-targeted receptor tyrosine kinase inhibitor (TKI; targeting VEGFR, 
PDGFR and KIT) are the only agents showing preliminary signs of efficacy in SCLC(92, 
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93). The latter also showed improvements in PFS, however it is still not clear whether 
they will impact the standard of care.  
 
2.1.5.2. Treatment of NSCLC 
 
2.1.5.2.1. Treatment of early stage NSCLC 
 
Surgical removal remains the first choice of treatment in localized, resectable NSCLC 
(Stage I and II). First-line surgery provides the best survival. As previously mentioned 5-
year survival is between 90.7% (IA) and 58.7% (IIB)(74).  
The choice of upfront surgery is made after staging, assessment of technical operability 
and tissue biopsy when needed. The algorithm of lymph node staging recommended by 
ESMO can be seen on Figure 15.  
 
 
12. Figure – ESMO 2017: recommended algorithm for staging in patients with M0 NSCLC (FDG 
-  fluorodeoxyglucose; LN - lymph node, NPV - negative predictive value; VAM -  video-assisted 
mediastinoscopy) Adopted  from (94). 
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Surgical techniques have improved significantly in the last twenty years. Most of the 
traditional thoracic operations were first described between 1900 and 1950. The first 
anatomical dissection of hilar structures, as lobar vein, artery and bronchus was first done 
in 1933 by Rienhoff, which was a big step to achieve fewer complications. The  
techniques improved quickly and anatomical segmentectomy (Churchill and Belsey in 
1939) and even sleeve lobectomy was developed by 1947 (Price Thomas) (95). From the 
1950s to the 1980s new surgical instruments were developed, but the main types of lung 
operations were not changed.  
Wedge resection is an atypical resection of lung parenchyma most often done by surgical 
staplers. Atypical in this sense means that the resection line does not follow anatomical 
structures or borders. It is mainly used for inflammatory, benign, metastatic or unknown 
lung lesions. Segmentectomy means the selected resection of one or several pulmonary 
segments. This procedure requires precise surgical technique and was mainly used in 
situations when the pulmonary function did not allow more extensive parenchyma 
resection. Lobectomy is the gold standard operation for the removal of primary lung 
malignancies. Lobectomy means the central dissection and ligation or stapling of the 
lobar pulmonary artery(s), vein and bronchus. Lobectomy is also often used when the 
parenchyma of a complete or near complete lobe is damaged by inflammatory diseases 
or when a secondary tumor is deep in the parenchyma and a wedge resection is not 
possible. Pneumonectomy is the most extensive operation performed on a single lung, it 
means the complete removal of the lung on one side by centrally closing the main 
pulmonary artery, lower and upper lobe veins and the main bronchus.  
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13. Figure – The main four types of pulmonary resections (Education material from the University 
of South Carolina; access: cts.usc.edu) 
 
All of the above mentioned procedures were done through a thoracotomy, when the 
thoracic cavity is approached through a rib space. To get appropriate access to preform 
complicated operations, long wounds had to be made and the ribs had to be either resected 
or pushed apart from each other. Thoracotomy was and still is a painful operation and it 
can have significant complications which sour the patients life. Most pain is caused by 
damaging the intercostal nerves. Neuralgic pain can last for years after the operation. A 
less invasive way to operate the chest was introduced very early: the first thoracoscopic 
procedures are attributed to Jacobeus (1910), who used a cystoscope to evacuate pleural 
fluids and to take pleural biopsies, although Sir Francis Richard Cruise was the first to 
apply and endoscope in the chest in 1865. Despite the early thoracic application of the 
technique, major thoracic procedures were only performed in the late 1980s, early ‘90s, 
after the video camera was invented. Rovario performed and described the first lobectomy 
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done by Video Assisted Thoracic Surgery (VATS) in 1991 (96). Later McKenna 
presented already 1000 cases of VATS lobectomy and in 2008 the first VATS sleeve 
lobectomy as well (97). VATS can be done through several small incisions, most 
commonly three, however newer techniques emerged: Gonzales-Rivas performed the 
first lobectomy in 2011 through one port (uniportal or single-port) (98). Ever since there 
was a shift towards single-port and less invasive surgery. At the beginning VATS was 
only used for small or benign lesions and there was a general view that VATS is less 
radical. However, later several study proved that OS was comparable after VATS 
lobectomy as with an open procedure (99-103) and the amount of lymph nodes taken out 
was also not different (104). In the US centers often choose another minimal-invasive 
technique instead of VATS, the Robotic Assisted Thoracic Surgery. Robotic surgery got 
widely accepted as a form of minimal-invasive surgery first in the US. Postoperative pain 
is reported to be comparable with VATS and the OS comparable with VATS and 
thoracotomy (105, 106).  
 
 
14. Figure – Thoracotomy versus VATS. Comparison of (A) intraoperative access and incision 
and (B) postoperative wound length (Pictures taken in the Department of Thoracic Surgery, 
National Institute of Oncology, Budapest) 
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The real advantage of VATS or robotic thoracic surgery is shown in the early 
postoperative phase when patients are pain-free and can leave the hospital on the 
postoperative second day. This leads to less pulmonary complications (107), and some 
studies suggest that even less immunosuppression and thus better resistance against 
cancer (108). Ceppa et al. used the national database in the US, in their meta-analysis 
they showed that the greatest benefit of VATS can be seen in patients with poor 
pulmonary function. The incidence of pulmonary complications in patients with 
compromised pulmonary reserves, was higher after thoracotomy than after VATS (109), 
as can be seen on the figure below.   
 
 
15. Figure – Pulmonary complications after thoracotomy (grey) and VATS (black). The 
difference of pulmonary complications after surgery is most significant in patients with poor 
pulmonary function (FEV1 lower than 50%). Adopted from (109). 
 
It is not yet widely accepted that OS is better after VATS or robotic thoracic pulmonary 
resection and most guidelines do not differentiate, data suggest that minimal invasive 
resection should be the gold standard of care for early lung cancer (108). 
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16. Figure – OS is longer in patients who had VATS resection for early lung cancer when 
compared with those who underwent resection through thoracotomy (left). The difference is still 
visible after propensity crossmatching, although it is not statistically significant (right). (Figures 
adopted from Berry et al. (108)) 
 
Although imaging, surgical and staging techniques have significantly changed in the last 
two decades, still the Lung Cancer Study Group (LCSG) 821 trial remains the ground for 
surgical treatment. According to this trial lobectomy is the cornerstone of surgical therapy 
for stage I and II NSCLC, as local recurrence was found more frequently after less radical 
operations (wedge resection and segmentectomy) (110). This data and along that our 
current practice will most probably be updated as the new TNM distinguishes between 
several types of stage I NSCLC. Based on large collected cohorts segmentectomy seems 
equally appropriate for T1a tumors. In squamous cell carcinoma lobectomy was found to 
be superior even in early stages, however in adenocarcinoma equivalent results were 
reported after anatomical segmentectomy (111). Of note, in another study anatomical 
segmentectomy was also found to be equally effective in T1c adenocarcinoma (112). 
Altogether it can be anticipated that in selected early NSCLC anatomical segmentectomy 
will be the choice of treatment, however no hard data is available to support this yet. Two 
major randomized studies are underway (CALGB 140503 and JCOG0802/WJOG4607L) 
(113, 114). The preliminary results have been published of the latter about the safety and 
feasibility of segmentectomies (simple and complex as well), their results show that 
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segmentectomy is not inferior in any of the examined parameters (complications, length 
of hospital stay, duration of air leak etc.)  (115). 
Lymph node management during surgery is also controversial. In early stages, the 
removal of lymph nodes is mainly necessary for staging purposes, to get a guaranteed R0 
resection and an accurate mediastinal staging. The latest ESMO recommendation implies 
surgical evaluation of at least six lymph node stations, three of which are mediastinal, 
including the sub-carinal station. If all of these are negative on pathological report than 
R0 and N0 can be safely stated (116). It is widely accepted that in early stages, especially 
stage I OS and PFS, as well as local recurrence might not be influenced by the type of 
surgical lymph node assessment, however in stage II and particularly IIIA intraoperative 
nodal dissection is recommended (117). The extent of dissection is also up to debate, the 
most common technique is lobe specific lymph node dissection, though perioperative 
lymph node assessment (EBUS, mediastinoscopy) can also be of effect. 
 
For high-risk patients, or for patients who are unwilling to take the risk of an operation, 
or patients with unresectable tumors primary stereotactic body radiotherapy (SBRT) can 
be recommended(67). The reported local control rate of SBRT is between 79-90.9% at 5 
years (118, 119). The recommended dose is a biologically equivalent tumor dose of 100 
Gy. The toxicity using this dose SBRT for stage I or II peripheral NSCLC is low and 
acceptable, even in elderly and patients with severe chronic obstructive pulmonary 
disease (COPD) (120). Data is available on outcomes of SBRT in patients who underwent 
the procedure for peripheral stage I tumors and are generally fit for surgery, however, 
there is no evidence to currently to recommend SBRT over up front surgery (121, 122). 
One problem with SBRT is the lack of pathological confirmation after the procedure. 
Randomized studies are being conducted, although three have failed to complete its plan 
(123). Two studies that have concluded reported comparable recurrence-free survival 
three years after the procedure . Given, that the toxicities are tolerable and the quality of 
life is good after SBRT, patient opinion should be more included in the discussion to 
recommend personalized treatment in the future.  
 
DOI:10.14753/SE.2020.2414
 - 42 - 
 
17. Figure – SBRT distribution plan for NSCLC. Adapted from (124). 
 
Multiple primary tumors should also be assessed with curative intent and complete 
surgical resection is recommended when feasible. In patients with borderline risk, 
combination of surgery and SBRT has been proven efficient(125).  
In case a patient has contraindication against both surgery and SBRT radiofrequency 
ablation (RFA) might be the reasonable choice of treatment, however the level of 
supporting evidence is from observational cohorts only (126). 
Postoperative radiotherapy is rarely indicated in stage I and II cases. It was found 
detrimental in cases without lymph node invasion (127). Cases with unexpected N1 and 
N2 disease are not clear. Postoperative radiotherapy (concurrent with chemotherapy) 
seem a reasonable choice when R0 resection is suspected (mainly because of N1 lymph 
nodes) or when the N2 lymph nodes are involved. To support this recommendation a large 
clinical trial is underway (128).  
 
Adjuvant platinum based chemotherapy was found to have beneficial effect on survival 
for stage II NSCLC patients(129). Altogether a 4-5% improvement in 5-year survival was 
reported in N1 and N2 disease. The adjuvant regimen used was 300mg/m2 of cisplatin in 
three to four cycles (130). The best timing of adjuvant chemotherapy is not entirely clear, 
although most protocols say 6 weeks after surgery, recent data form the National Cancer 
Database (United States of America – US) show comparable results after longer interval 
between resection and chemotherapy (131).  
Based on this knowledge, patients with completely resected stage II tumors are 
recommended adjuvant chemotherapy within 6-8 weeks after surgery. On the other hand, 
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in stage IA, chemotherapy has not been proven to be beneficial in an adjuvant 
setting(132). In IB a small benefit was seen in OS and an in depth analysis showed that 
this was due to patients with tumors >4 cm (133).  
In stage IA NSCLC is therefore only followed up after resection, in IB, however adjuvant 
chemotherapy can be recommended in cases when the tumor size is over 3-4cm.   
As of today, no evidence suggest that the use of targeted agents, such as TKIs for EGFR 
mutant cases, yield a benefit in an adjuvant setting. Prospective studies are being 
conducted, however until their result is presented, targeted agents are not recommended 
as adjuvant CHT. 
There is less experience with neoadjuvant CHT in early NSCLC, most studies found no 
survival comparing neoadjuvant and adjuvant modalities (134, 135). In some, selected 
cases when downstaging or size reduction is needed for surgical removal, neoadjuvant 
regimens can potentially be of use (less extensive surgical procedure is possible after) 
(136).  
Both adjuvant and neoadjuvant trials have been initiated using immunotherapy (anti-PD-
1 and anti-PD-L1 checkpoint inhibitors) for early lung cancer (trials NCT NCT02504372, 
NCT02273375 and NCT02998528) on the basis of the promising results in second line 
curative therapy. This might change the clinical practice in the near future.  
 
2.1.5.2.2. Treatment of locally advanced (stage III) NSCLC 
 
Stage III or locally advanced (LA) NSCLCs can be divided in two groups: surgically 
resectable LA NSCLC and unresectable LA NSCLC. The treatment strategy is 
understandably different.  
Resectable LA NSCLC usually occurs in three instances: 1) single-station N2 lymph node 
involvement is suspected or confirmed by biopsy (other stations were found negative with 
PET and biopsy). In these cases complete lymphadenectomy and postoperative CHT has 
shown superior outcome compared to surgery or chemotherapy alone (137). However, it 
is not clear whether surgery or SBRT is the better option in these cases. In the limited 
number of studies comparing the two modalities of local control no clear advantage was 
shown for either (138, 139).  
2) T4N0 tumors where R0 resection is considered feasible. In these cases up front surgery 
(generally open technique) and postoperative CHT is recommended. Potentially 
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resectable superior sulcus tumors should first be treated with neoadjuvant concurrent 
radio-chemotherapy and followed by resection. The same can apply to central T4 cases. 
Surgery should not be more than 4 weeks after radiotherapy in these cases (139).  
3) in cases with multiple level N2 involvement who underwent neoadjuvant 
chemotherapy and regression is confirmed by CT. In these cases surgery is recommended 
followed by definitive CHT (140).  
Standard cisplatin based systemic therapies were found to be the most effective in an 
adjuvant setting in stage III, although immunotherapy is currently being evaluated. 
Pemetrexed-cisplatin failed to show benefit in OS versus the standard cisplatin-etoposide 
(141). 
In unresectable LA NSCLC (in cases of stage III patients where R0 resection is not 
considered possible by a multidisciplinary team) concurrent chemo-radiotherapy was 
shown to have the best results (142, 143). There is no data regarding targeted therapy in 
stage III patients with driving mutations such as EGFR or ALK. No conclusion can be 
drawn from the two studies examining this subject (144, 145). 
 
2.1.5.2.1. Treatment of metastatic NSCLC 
The treatment strategy for stage IV NSCLC varies greatly on histology, molecular 
pathology, age, comorbidities – performance status (PS) and patient preference. Most 
cases are offered systemic therapy when the ECOG PS is below 2, with some notable 
exceptions. Smoking cessation is important in any stage of lung cancer and it should be 
encouraged in stage IV as well, as it can interfere with some of the systemic treatments 
(146, 147).   
Patients with newly diagnosed metastatic NSCLC should be evaluated by 
multidisciplinary tumor boards. The first to consider is the PS: PS 0-2 patients are 
recommended systemic treatment, whereas 3-4 patients are generally offered best 
supportive care (BSC). Molecular testing should be done in patients, selected for systemic 
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18. Figure – Treatment algorithm of stage IV NSCLC. Recommendation by ESMO, 2018 (148). 
The best established oncogenic target in advanced stage NSCLC is EGFR mutation (149, 
150). First- (erlotinib and gefitinib) and also second generation (afatinib) TKIs were 
compared with standard CHT and were found superior in terms of disease control, OS 
and PFS (151-155). Patients with poor PS (3 or 4) can also benefit from TKI therapy 
when an EGFR mutation is present (156). Clinically stable patients, who have previously 
benefited from TKI therapy should continue receiving EGFR TKI, even when 
radiological progression occurs (157). Local control (surgery or radiotherapy) should be 
considered when radiological progression is only seen in one distant site. It is not clear 
whether the administration of second generation TKIs yield a significant benefit for 
patients. Most studies reported improved PFS, however OS was not affected (158-
160).Third generation TKIs are being introduced into standard care. Osimertinib is in the 
most advanced stage, as it was reported to improve both PFS and OS (161). The addition 
of antiangiogenesis agents, such as bevacizumab was also investigated. Seto et al. 
reported improved PFS, however the difference was not seen in OS (162). Other studies 
are also investigating combinations with encouraging early results (163, 164).  
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19. Figure - Treatment algorithm for stage IV NSCC, molecular tests positive 
(ALK/BRAF/EGFR/ROS1). ESMO recommendation (148).  
ALK rearrangement is also a well-tested target for advanced NSCLC. Crizotinib was the 
first to be tested against other treatment options. Significant advantage was seen in both 
objective response rate (ORR) and PFS in two multicenter single-arm studies (165, 166). 
Second generation ALK inhibitors like alectinib and certinib were found to be more 
effective in terms of PFS and intracranial activity (167, 168). Patients, treated with 
crizotibin should be offered next-generation ALK TKIs when they show progression.  
Crizotinib and ceritinib were showed to also be effective in ROS1-rearranged NSCLC 
(169-172), while brigatinib, lorlatinib, repotrectinib and entrectinib were also found to 
have potential anti-ROS activity in preclinical studies (173).  
BRAF mutation was also successfully targeted in advanced adenocarcinoma. V600E 
(Val600Glu) is the most commonly observed mutation with and incidence of 1-2% in 
lung adenocarcinomas and with a higher incidence in smokers (174, 175). Three agents, 
vemurafenib, dabrafenib and sorafenib were all found to be effective with a mean ORR 
of 53% (176).  
 
In patients who do not harbor known targetable genetic changes, immune checkpoint 
inhibitors showed great promise recently. A phase III study, the KEYNOTE-024 
established pembrozilumab as a standard first-line treatment for advanced NSCLC when 
PD-L1 expression is higher than 50% and EGFR mutation and ALK translocation is 
absent. ORR, PFS, OS, safety and quality of time all favored pembrolizumab over 
standard CHT (177-179). 
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20. Figure - Treatment algorithm for stage IV NSCC, when molecular tests are negative 
(ALK/BRAF/EGFR/ROS1) (148). 
 
CHT with platinum doublets is still standard therapy in all advanced NSCLC patients 
who do not harbor targetable genetic changes and do not have major comorbidities. A 
23% reduction of risk of death, 9% 1-year survival gain, 1.5 month increase in absolute 
median survival and improved quality of life were observed in two big meta-analyses 
(180-182). 
Antiangiogenic agents showed efficacy as additional therapy (described in detail later).  
Most studies in advanced squamous cell carcinoma did not report any benefit from 
targeted therapy (181), thus platinum-based combinations with the addition of a third-
generation cytotoxic agent, such as gemcitabine, vinorelbine or taxanes, are 
recommended.  
 
Role of surgery 
Oligometastatic disease was introduced as a new subcategory in advanced NSCLC. M1b 
disease was defined in contrast to patients with multiple metastases (M1c) (183). 
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Prospective studies suggest that surgery only has a role in oligometastatic disease, when 
complete (R0) resection can be reached. Nodal disease means poor prognosis (184-186).  
 
 
2.2. Vascular endothelial growth factor and bevacizumab 
 
Vascular endothelial growth factor (VEGF) is a key factor to endothelial cell growth and 
one of the most important regulators of angiogenesis. Increased expression of VEGF can 
be demonstrated in most solid tumors including NSCLC (187). In many cases, VEGF 
overexpression is associated with an increased risk of relapse and metastasis (188-191). 
According to preclinical studies, anti-VEGF monoclonal antibodies are capable of 
inhibiting the growth of human tumor xenografts both in monotherapy and in 
combination with chemotherapy (192-195).  
 
 
21. Figure – VEGF signaling pathways and receptor binding specificity. Adopted from: 
https://www.bocsci.com/vegf-signaling-pathway.html 
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Bevacizumab (BEV; Avastin®; Genentech/Roche, South San Francisco, CA, USA) is a 
humanized monoclonal antibody that acts by binding and neutralizing the VEGF-A 
isoform, thus preventing VEGF ligand-receptor binding. It has demonstrated its efficacy 
in colorectal (196, 197), ovarian (198), breast(199, 200) and renal cancer (201, 202). This 
has also been the first and only antivascular drug to be licensed for the treatment of 
NSCLC so far. 
According to a phase II study (203), bevacizumab treatment in combination with 
chemotherapy in NSCLC was more effective than chemotherapy alone. The combination 
was also well tolerated, however, the incidence of lung hemorrhage increased. In a post 
hoc multivariate analysis, squamous cell histology was identified as an independent risk 
factor for bleeding (204). Consequently, patients with squamous cell histology were 
excluded from most of the clinical trials of bevacizumab in NCSLC. 
Subsequent to the above Phase II study, the Eastern Cooperative Oncology Group 
(ECOG) E4599 trial was initiated (205). This study, which was the first published Phase 
III randomized trial of an antiangiogenesis agent in combination with chemotherapy in 
patients with advanced NSCLC, randomized chemotherapy-naive patients with 
predominantly non-squamous cell histology were included. In the bevacizumab treatment 
arm, following completion of chemotherapy, single-agent bevacizumab was continued 
until disease progression. Results showed that the addition of bevacizumab was 
associated with a significant improvement in the median overall survival (OS) compared 
with chemotherapy alone. Progression-free survival (PFS) was also significantly 
improved. 
A second Phase III trial (Avastin® in Lung; AVAiL), evaluating bevacizumab in 
combination with cisplatin and gemcitabine (206) (another commonly used and 
efficacious regimen in NSCLC) was originally initiated with a primary end point of OS. 
However, after the positive OS results of E4599, the study design was amended so as to 
change the primary end point from OS to PFS. Patients were randomly assigned to receive 
cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus low-dose 
bevacizumab (7.5 mg/kg), high-dose bevacizumab (15 mg/kg) or placebo every 3 weeks 
until disease progression. PFS was significantly prolonged with bevacizumab. 
Interestingly, according to the final efficacy analysis, OS was > 13 months in all treatment 
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groups, which is the longest OS reported for advanced non-squamous NSCLC in a clinical 
trial setting, although it did not yield a statistically significant prolongation with either 
bevacizumab dose (207).  
As a result of the above trials, bevacizumab in combination with platinum-based 
chemotherapy was approved for the first-line treatment of patients with advanced NSCLC 
by the European Medicines Agency (EMEA) in August 2007. 
Although bevacizumab was approved with platinum-based chemotherapy in NSCLC in 
2007, so far no Hungarian data have been available. The AVALANCHE (ML21783) 
study was undertaken to assess the clinical outcomes of first-line bevacizumab combined 
with standard platinum-based regimens in Hungarian clinical practice. 
 
2.3. KRAS mutation and antivascular treatment 
 
KRAS protein, encoded by the KRAS proto-oncogene, is a small GTPase which plays a 
key role in regulating various cell functions (208). Alterations of the KRAS gene are 
typically missense mutations that can lead to the oncogenic conversion of KRAS resulting 
in the constitutive activation of its effector pathways and thus cancer development and 
progression (209). KRAS is frequently mutated in pancreatic and colorectal cancer (CRC) 
and in lung adenocarcinoma (LADC). With an incidence of up to 30%, KRAS mutation 
is the most common driver mutation in LADC. The most prevalent G12C and G12V 
KRAS mutation subtypes are associated with smoking-, while the G12D subtype has been 
observed in never-smokers (210, 211). Several other rare mutations of KRAS codon 12, 
13 and 61 have also been reported (210). 
The prognostic and predictive power of KRAS mutation in non-small cell lung cancer 
(NSCLC) patients remains controversial. It was first reported in the late 1980s that KRAS 
mutation is associated with poorer survival (212, 213) and since then several groups 
confirmed these findings (214, 215). However, most of these studies were rather 
heterogeneous in terms of histology, tumor stage and methodologies of KRAS mutation 
detection. Although two different meta-analyses concluded that KRAS mutation is a 
negative prognosticator in LADC (216, 217), the most comprehensive study of more than 
1500 NSCLC patients (including 300 KRAS mutant cases) from four trials of adjuvant 
chemotherapy (CHT) reported that KRAS mutation had no clear prognostic or predictive 
relevance with regards to response to CHT (218). 
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Previously, our group performed a mutation subtype-specific analysis of 505 stage III–
IV LADC patients treated with platinum-based CHT and found that there were no 
significant differences in progression-free survival (PFS) and overall survival (OS) 
among patients with wild type (WT), codon 12 and codon 13 KRAS mutations. 
Importantly, however, G12V KRAS mutant patients tended to have a higher response rate 
and a modestly longer median PFS (219).  
The importance of subtype-specific KRAS mutation analysis was further highlighted in 
the preclinical study of Garassino et al. These authors investigated the role of different 
KRAS mutation subtypes (G12C, G12V and G12D) in the in vitro chemosensitivity of 
human NSCLC cells and found that the expression of G12C was associated with a 
reduced response to cisplatin and an increased sensitivity to taxol and pemetrexed. In the 
same study, G12D mutation led to resistance to taxol and sensitivity to sorafenib, whereas 
the G12V mutation sensitized the cells to cisplatin (220). 
Increased expression and the negative prognostic role of vascular endothelial growth 
factor (VEGF, the key angiogenic cytokine) have been reported in most solid tumors 
including NSCLC (187) (221). Several phase 2 and 3 clinical trials demonstrated that the 
addition of BEV to CHT improves PFS and OS of NSCLC patients (203, 205, 206, 222, 
223). Accordingly, BEV in combination with platinum-based CHT was approved for the 
first-line treatment of patients with advanced-stage NSCLC by the FDA (U.S. Food and 
Drug Administration) and the EMA (European Medicines Agency) in 2006 and 2007, 
respectively. The efficacy of BEV in a real-life setting in Hungary was shown in the 
Avalanche study (224). 
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22. Figure – EGFR signaling pathway and the connection to the RAS/RAF/MEK/ERK cascade. 
Adopted from (225). 
Although the RAS/RAF/MEK/ERK signaling pathway has been implicated in the 
regulation of VEGF expression and angiogenesis (226), only very few studies 
investigated the effect of KRAS mutation on the efficacy of BEV therapy. Most studies 
focused on CRC, where the addition of BEV to CHT prolonged survival regardless of 
KRAS mutational status (227-230). Two different groups, however, demonstrated that 
G12V, G12A (231) and G12D (232) KRAS mutations are associated with poor outcome 
in metastatic CRC patients receiving BEV. As for nonsquamous NSCLC, in a phase 2 
trial evaluating the addition of neoadjuvant BEV to CHT, Chaft et al. found that no patient 
(0 out of 10) with KRAS mutation showed pathological response to neoadjuvant 
BEV/CHT, in comparison to 11 of 31 KRAS WT patients (233). In another small study 
of stage IV NSCLC, BEV therapy was associated with improved OS and PFS in KRAS 
WT (n=26) but not in KRAS-mutant (n=16) patients (234). No study was done on a large 
cohort of patients to examine the amino acid substitution-specific KRAS mutational 
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3. Objectives 
 
Bevacizumab is a relatively new treatment option in advanced LADC. The addition of 
BEV to standard platinum based chemotherapy was validated in several international 
randomized trials, however no Hungarian data was available.  
Despite the research effort no validated predictive or prognostic biomarker is known 
regarding antivascular treatment in NSCLC.  
 
3.1. The safety and efficacy of bevacizumab in addition to platinum based 
chemotherapy in patients with advanced NSCLC 
 
Although BEV was approved with platinum‑based chemotherapy in NSCLC in 2007, so 
far no Hungarian data have been available. The AVALANCHE study (ClinicalTrials.gov, 
identifier: NCT03170284) was undertaken to assess the clinical outcomes of first‑line 
BEV combined with standard platinum‑based regimens in Hungarian clinical practice. 
To achieve results that represent the Hungarian practice, a multi-institutional, single-arm 
observational study was conducted.  
The primary endpoint of the study was PFS, the time from first administration of BEV to 
disease progression. Secondary endpoints included tumor response, OS and safety.  
 
3.2. KRAS mutation as a biomarker for anti-VEGF therapy in NSCLC 
 
Based on international literature and previous findings form a sub-cohort of the 
AVALANCHE study, anti-VEGF therapy is not effective in all patients. The exact 
mechanisms of therapy resistance and furthermore, a predictive and prognostic biomarker 
for antivascular therapy is not yet known.  
The molecular connection between the KRAS signaling cascade and the VEGF signaling 
pathway has been established, however its clinical relevance is not yet studied. The aim 
of this study was to analyze whether KRAS mutation could be used as a biomarker for 
anti-VEGF therapy in NSCLC. We examined the amino acid substitution-specific KRAS 
mutational status in a large cohort of BEV/CHT-treated stage III-IV Caucasian patients 
and its effect on PFS and OS. Our aim was to show the clinical relevance of subtype 
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specific KRAS mutational status in anti-VEGF therapy and furthermore to establish a 
predictive biomarker that can help identify therapy resistant patients and thus to give 
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4. Methods 
4.1. General ethical consideration 
 
Patient data, including pathological reports, clinicopathological variables and data 
regarding outcome was collected in the following institutions:  
 
• Bács-Kiskun County Hospital, Kecskemét, Hungary 
• Békés County Institute of Pulmonology, Gyula, Hungary 
• Borsod-Abaúj-Zemplén County Szent Ferenc Hospital, Miskolc, Hungary 
• Clinical Center, University of Pécs, Pécs, Hungary 
• Csongrád County Hospital of Chest Diseases, Deszk, Hungary 
• Fejér County Szent György Hospital, Székesfehérvár, Hungary 
• Institute of Pulmonology, Törökbálint, Hungary 
• Jász-Nagykun-Szolnok County Hetényi Géza Hospital and Clinic, Szolnok, 
Hungary 
• Kaposi Mór Teaching Hospital, Kaposvár, Hungary 
• Municipality of the City of Budapest Uzsoki Street Hospital, Budapest, Hungary 
• National Korányi Institute of Pulmonology, Budapest, Hungary 
• Petz Aladár County Teaching Hospital, Győr, Hungary 
• Semmelweis University, Budapest, Hungary 
• Szabolcs-Szatmár-Bereg County Jósa András Hospital and Clinic, Nyíregyháza, 
Hungary 
• Szent Borbála Hospital, Tatabány, Hungary 
• Tolna County Balassa János Hospital, Szekszárd, Hungary 
• Vas County Markusovszky Hospital, Szombathely, Hungary 
• Veszprém County Institute of Pulmonology, Veszprém, Hungary 
• Zala County Hospital, Zalaegerszeg, Hungary 
 
All data collection and analyzes was approved by the local or national ethical committees. 
No individual patient data is identifiable in the respective publications or in this thesis. 
All methods included in this thesis were performed in accordance with the relevant 
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guidelines and regulations. All experiments that were reported in this thesis were done 
complying with all mandatory laboratory health and safety procedures. 
 
4.2. The safety and efficacy of bevacizumab in addition to platinum based 
chemotherapy in patients with advanced NSCLC 
 
4.2.1. Study design 
 
AVALANCHE (ClinicalTrial.gov Identifier NCT03170284) was a multi-center single-
arm observational study designed to assess the efficacy and safety of bevacizumab 
therapy in patients with advanced, unresectable, metastatic or recurrent nsNSCLC (non-
squamous, other than predominantly squamous cell histology) in the routine oncology 
practice in Hungary. Further objective of the study was to assess and identify possible 
treatment-related prognostic factors. 
 
4.2.2. Patients 
This study was originally projected to enroll 150 patients from 40 Hungarian study 
centers. The planned number of patients was later increased to 300 in order to obtain 
stronger and more representative real-life efficacy and safety data with bevacizumab 
therapy in Hungary.  
Patients with histology or cytology proven unresectable advanced, metastatic or recurrent 
(stage IIIB/IV) NSCLC other than predominantly squamous cell histology were included 
in the present study. 
Exclusion criteria were as stated in the Hungarian prescribing information. 
The study was done in accordance with the Declaration of Helsinki, Good Clinical 
Practice International Conference on Harmonization Tripartite Guidelines, laws and 
regulations of the participating institutes’ country. The study was approved by the 




Eligible patients received first-line bevacizumab with cisplatin or carboplatin in 
accordance to the approved and reimbursed bevacizumab indication in Hungary 
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(bevacizumab 7.5 mg/kg, every 3 weeks with any platinum-doublet for up to 6 cycles) 
then non-progressors proceeded to receive bevacizumab until disease progression or 
unacceptable toxicity. The third component of the combination chemotherapy was one of 
the following: paclitaxel, gemcitabine, docetaxel or vinorelbine. Based on the therapeutic 
protocol, patients were followed up until the first progression of their primary disease, or 
death, or withdrawal of consent, or loss of contact with the patient, or closure of the study, 
whichever occurred first. 
 
4.2.4. Progression-free and overall survival  
Investigators seemed to be frequently using progression-free survival (PFS) and time-to-
progression (TTP) interchangeably in clinical trials in the early 2000s (235). The protocol 
of our study defined TTP as the time elapsed from the date of enrolment until the first 
documented progression or the death of the patient from any cause which is in accordance 
with the current definition of PFS. To avoid confusion, PFS will be used hereinafter for 
the denomination of the primary endpoint of the study. Progression was determined by 
the investigator at the routine clinical practice follow-up examinations. PFS was 
calculated from the start of bevacizumab treatment. 
Secondary endpoints included best tumor response (complete remission (CR), partial 
remission (PR), stable disease (SD), progressive disease (PD)), OS (based on 
retrospective analysis) and indicators of safety (serious and non-serious adverse events). 
ORR (Objective Response Rate) was calculated from patients experiencing complete or 
partial remission. 
Basic demographic data, basic vital parameters, primary disease-related historical data, 
ECOG performance status, data related to bevacizumab treatment, results of the staging 
assessments as well as the patient’s comorbidities and concomitant treatments were 
recorded in an electronic case-report form.  
Following the closure of the study, data for the assessment of the primary study parameter 
(PFS) were available for 252 patients. As per the amended protocol, the secondary 
endpoint (OS) was retrospectively analyzed based on data from 250 patients. 
During the treatment period regular monitoring visits were conducted to ensure high-
quality data collection. Data related to bevacizumab treatment, blood pressure, body 
weight, concomitant treatments and adverse events were registered.  
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The following data were recorded at the end-of-treatment visit: end date of bevacizumab 
treatment, reason for ending treatment, ECOG status, best tumor response observed 
during treatment, concomitant treatments administered during bevacizumab treatment 
and adverse events observed during bevacizumab treatment. 
 
4.2.5. Statistics 
PFS (primary study endpoint) and OS in the total population were analyzed using Kaplan-
Meier curves. Log-rank test was used for comparison between groups. When sufficient 
data were available, an extended analysis using Cox-regression was also performed. 
PFS was defined as the time elapsed from the date of enrolment until the first documented 
progression or the death of the patient from any cause. For study subjects who had not 
shown progression and had not died by the closure of the study, the data were censored 
at the date of the last contact. 
OS was defined as the time elapsed from the date of enrolment until the death of the 
patient from any cause. Regarding subjects who had not died by the closure of the study, 
the OS data were analyzed retrospectively after the end of the study in the knowledge of 
their dates of death. Otherwise, data were censored at the date of the last contact. 
 
4.3. KRAS mutation as a biomarker for anti-VEGF therapy in NSCLC 
 
4.3.1. Study population 
In this single-center, retrospective study, 501 consecutive patients with advanced lung 
adenocarcinoma (LADC) were included who underwent first-line platinum-based 
(cisplatin or carboplatin) doublet chemotherapy (CHT) with or without BEV at the 
National Korányi Institute of Pulmonology, Budapest between 2007 and 2016 (Table 10, 
Figure 23). The addition of BEV to CHT was individually decided by the treating 
physician in line with the proof of concept BEV clinical trials [16,18] and with the EMA 
summary of BEV characteristics. According to our inclusion criteria, cytologically or 
histologically verified unresectable stage IIIB or IV LADC patients were included. 
Patients with uncontrollable hypertension, hypertensive encephalopathy, arterial or grade 
4 venous thromboembolism, nephrotic syndrome (grade 4 proteinuria), pulmonary 
bleeding, gastrointestinal perforation, need for major surgery or with hypersensitivity to 
BEV were considered not eligible for BEV therapy (Figure 23).   
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23. Figure - Consort diagram for advanced LADC cases. Consort diagram to demonstrate 
the selection of stage IIIB/IV LADC cases for BEV/CHT or CHT alone in this study. 
Where patients were excluded, the reasons for exclusion are indicated. 
 
In the BEV/CHT group (n=247), platinum was given together with paclitaxel (84.7%) or 
gemcitabine (15.3%). In order to rule out the potential confounding effect of different 
treatment regimens, patients receiving other non-platinum partners, such as pemetrexed 
or docetaxel, were excluded from the CHT group (n=254). Additionally, all patients 
receiving tyrosine-kinase inhibitors in any further line of treatment were also excluded. 
According to the therapy guidelines of the host institute, only ECOG (Eastern 
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Cooperative Oncology Group) performance status (PS) 0 or 1 LADC patients were 
included in this study, since higher PS contradicted the use of cytotoxic chemotherapy. 
Smoking status, TNM stage and molecular tumor characteristics (EGFR and KRAS 
mutational status) were defined at the time of diagnosis. For the calculation of PFS and 
OS, date of the first CHT was used. Patients with known EGFR mutations were excluded. 
Clinical follow-up was closed on the 1st of August, 2017. Median follow up was 21 
months in the BEV/CHT group, while 10 months in the CHT group. The study and all 
treatments were conducted in accordance with the current National Comprehensive 
Cancer Network guidelines, based on the ethical standards prescribed by the Helsinki 
Declaration of the World Medical Association and with the approval of the national level 
ethics committee that included a waiver for this retrospective study (52614-4/2013/EKU). 
Due to the retrospective study design and the anonymity of the patient records, an 
informed consent was not recommended.  
 
4.3.2. Molecular diagnosis 
All mutational analyses were performed at the time of diagnosis at the 2nd Department 
of Pathology of the Semmelweis University as previously described (219, 236, 237). 
DNA isolation was performed from formalin fixed paraffin-embedded (FFPE) tissue 
blocks or cytological specimens of primary tumors or lymphatic or organ metastases 
(including pleural effusion).  
KRAS exon 2 mutations were identified by microcapillary-based restriction fragment 
length analysis as described (219, 236). Briefly, tumor-rich microscopic area on H&E 
staining had been determined by pathologists prior to macro dissection from FFPE tissue 
or cytological smears. DNA was extracted using the MasterPure™ DNA Purification Kit 
(Epicentre Biotechnologies, WI) according to the instructions of the manufacturer. The 
microfluid-based restriction fragment detection system characterized by 5% mutant 
tumor cell content sensitivity. Density ratio of the mutated band to the WT one was 
calculated and samples containing >5% of the non-WT band were considered mutation 
positive due to the sensitivity threshold. The base-pair substitution in the mutant samples 
were verified and determined by sequencing on the ABI 3130 Genetic Analyzer System 
(Life Technologies, Carlsbad, CA) with the BigDye® Terminator v1.1 Kit.  
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4.3.3. Statistical methods 
Categorical parameters, such as gender (male vs. female), smoking status (never vs. ever 
smoker), ECOG PS (0 vs. 1), and KRAS mutation status (KRAS-mutant vs. WT) were 
statistically analyzed by Chi-square test or Fisher’s exact test. Age as a continuous 
variable was analyzed in the different KRAS mutational groups by Mann-Whitney U test 
as the data was not normally distributed in each group (as per the Shapiro-Wilk normality 
test). Kaplan-Meier survival curves and two-sided log-rank tests were used for univariate 
survival analyses. Median follow-up time was calculated by using the reverse Kaplan-
Meier approach. The Cox proportional hazards model was used for uni- and multivariate 
survival analyses to detect the impact of both continuous and categorical factors and to 
calculate the hazard ratios (HR) and corresponding 95% confidence intervals (CI). For 
multivariate survival analyses, the Cox regression model was adjusted for age (as a 
continuous variable), gender (female versus male), smoking (never- versus ever-smoker), 
ECOG PS (0 versus 1) and stage (IIIB versus IV). In order to establish potential predictive 
factors, interaction terms were calculated between KRAS status and other variables (age, 
sex, smoking status, ECOG PS and stage) in the adjusted multivariate Cox regression 
model. P values are always given as two-sided and were considered statistically 
significant below 0.05. Metric data are always shown as median or mean and 
corresponding range or, in case of OS and PFS, as median and corresponding 95% CI. 
All statistical analyses were performed using the PASW Statistics 18.0 package 
(Predictive Analytics Software, SPSS Inc., Chicago, IL, USA). Graphs were created with 
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5. Results 
5.1. The safety and efficacy of bevacizumab in addition to platinum based 
chemotherapy in patients with advanced NSCLC 
 
5.1.1. Baseline Characteristics of the Patients 
 
A total of 284 patients with corresponding diagnosis were identified at the Hungarian 
study sites, and were subsequently enrolled into the study between 17th June 2008 and 
3rd May 2011, out of which data of 283 patients were evaluable. From among the 41 
study centers originally involved, no patients were enrolled at 16 sites, thus in fact 25 
centers participated actively. The highest number of patients enrolled at one center was 
36, whereas the smallest was 1. One patient did not comply with all the inclusion and 
exclusion criteria: the patient’s histological diagnosis was squamous cell carcinoma; 
therefore evaluable patient population was 283. Central localization of the primary tumor 
was reported in 61 patients (21.6%) and cavitated tumor in 4 patients (1.4%) in the total 
patient population. 
The study population had to be reduced to 252 in case of PFS and 250 regarding OS. In 
case of PFS 31 patients and in case of OS 33 patients had to be excluded from the data 
assessment due to missing or incomplete information. These information could not be 
recovered retrospectively. 
The demographic characteristics of the enrolled and evaluable patients are summarized 
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7. Table - Patient demographics and treatment in the Avalanche study 
Characteristic n (%) Treatment n (%) 
Number of patients   Previous Treatment   
Evaluable patient 
population 
283 (99.6%) Previous surgery 64 (22.6%) 
Patient population 






evaluable in terms of OS 
250 (88%) Radiotherapy 18 (6.4%) 












Docetaxel 18 (6.4%) 
Gender   Vinorelbine 2 (0.7%) 
Male 143 (50.5%) Other 7 (2.5%) 
Female 135 (47.7%) No data 13 (4.6%) 
No data 5 (1.8%) Reported reasons for ending the study 
Histologic type   
Progression of primary 
disease 
172 (60.8%) 




Loss of contact with the 
patient 
7 (2.5%) 
Squamous cell carcinoma 1 (0.4%) 
Adverse event related to 
Bevacizumab treatment 
13 (4.6%) 
Stage   Patient’s decision 17 (6.0%) 
III B 52 (18.4%) Patient’s death 16 (5.7%) 
IV 226 (79.9%) Other 45 (15.9%) 
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5.1.2. Treatment 
 
Prior to enrolment, 64 patients (22.6%) had undergone surgical intervention, 18 patients 
(6.4%) had received adjuvant/neoadjuvant chemotherapy, and 18 patients (6.4%) had 
received radiotherapy (Table 4).  
Patients received cisplatin (N=148, 52.3%) or carboplatin (N=124, 43.8%) treatment in 
accordance with the protocol in approximately half-and-half proportion during the study. 
No data are available for 11 patients (3.9%). The other components of the combination 
chemotherapy are shown in Table 4.  
The vast majority of patients (N=262, 92.6%) received bevacizumab in 3-weekly cycles. 
A treatment of different cycle frequency was applied in two patients (0.7%), and no data  
were available for 19 patients (6.7%). The median number of bevacizumab treatment 
cycles in the retrospectively evaluated patient population was 6. 
The most common reason for ending the study was documented as progression of the 
primary disease in more than half of the study subjects (60.8%). Patient’s decision, 
patient’s death, adverse event related to bevacizumab therapy, loss to follow-up, and 
symptom deterioration accounted for ending the study in 6.0%, 5.7%, 4.6%, 2,5% and 
1.4% of the cases, respectively. Other reasons behind ending the study occurred in 15.9%; 
no data were available in 3.2% of cases. 
 
5.1.3. Efficacy analysis  
5.1.3.1. Progression-free survival 
The PFS in the total study patient population was 7.162 ± 0.282 (CI95%: 6.609-7.715) 
months (Figure 24). The subgroup-analysis of PFS by gender showed that the survival 
time with bevacizumab treatment was longer in women (median: 7.589 ± 0.647, CI95%: 
6.321-8.858 months) than in men (median: 6.669 ± 0.375, CI95%: 5.934-7.405 months). 
This difference, however, was not significant (p=0.542).  
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24. Figure - Progression-free survival in the total population (Kaplan-Meier) 
 
The median PFS was higher in patients with an ECOG status of 0 at enrolment (median: 
7.326 ± 0.535, CI95%: 6.278 ± 8.375 months) than in patients with a baseline ECOG 
status of 1 (median: 6.702 ± 0.597 months, CI95%: 5.531-7.873 months). However, the 
difference between the two groups was not remarkable (p=0.123). 
Similarly, PFS was not significantly influenced by the localization of the tumor (central 
vs. non-central, p=0.813). 
Interestingly, the median PFS in patients who had undergone surgical intervention prior 
to enrolment (median: 8.411 ± 0.947, CI95%: 6.554-10.267 months) was notably higher 
(p=0.017) compared with patients with no such prior intervention (median: 6.834 ± 0.265, 
CI95%: 6.314-7.353 months). In contrast, neither adjuvant/neoadjuvant chemotherapy 
(p=0.165) nor radiotherapy (p=0.165) applied prior to enrolment had a significant impact 
on median PFS. 
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The platinum derivative used had no significant influence on median PFS, either 
(p=0.199). 
Nearly 10% of the patient population with evaluable data were over 70 years of age at the 
time of enrolment. The median PFS was not significantly different between patients under 
or above 70 years of age (p=0.541). 
 
 
25. Figure - Analysis of progression-free survival. A: in different tumor stages; B: 
According to gender; C: by ECOG PS and D: by history of surgery (Kaplan-Meier). 
Avalanche study. 
 
Of note, median PFS was significantly higher (p<0.001) in patients receiving 
bevacizumab maintenance therapy (median: 9.166 ± 0.601, CI95%: 7.988-
10.345 months) compared with those who received no maintenance therapy (median: 
5.815 ± 0.574, CI95%: 4.690-6.940 months) (Figure 26). 
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26. Figure - Analysis of progression-free survival by BEV maintenance therapy 
(Kaplan-Meier) 
 
5.1.3.2. Secondary endpoints 
 
5.1.3.2.1. Tumor response 
Disease control was achieved in a remarkable 86.5% with CR in 2.3%, and PR in 44.4% 
of the cases with evaluable data. PD was recorded in 13.5% of evaluable cases and 
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8. Table - Best tumor response reached during the first-line treatment in the Avalanche 
study 
 
 Tumor response N 
Patient population 
with evaluable data 
Total patient 
population 
N = 133 N = 216 
(%) (%) 
Complete remission (CR) 3 2.3% 1.5% 
Partial remission (PR) 59 44.4% 29.9% 
Stable disease (SD) 53 39.8% 26.9% 
Progressive disease (PD) 18 13.5% 9.1% 
Not assessable (NA) 83  -  32.6% 
 
 
27. Figure - Overall survival in enrolled and evaluated patients (Kaplan-Meier) in the Avalanche 
study 
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5.1.3.2.2. Overall survival 
The median OS in the total study population was 15.179 ± 1.377 months (CI95%: 12.480-
17.877) (Figure 27).  
As with PFS, we performed subgroup-analysis of OS by gender, ECOG status, prior 
surgical procedure and chemotherapy.  
The localization of the tumor had no impact on OS (p=0.992) in the patient population 
studied. 
Surprisingly, we found a tendency towards a higher median OS for patients over 70 years 
of age (18.398 ± 3.869 months, CI95%: 10.815-25.982 months) compared with patients 
younger than 70 years (15.014 ± 1.329 months, CI95%: 12.410-17.619 months), although 
this difference remained not significant (p=0.638). 
 
 
28. Figure - Analysis of overall survival. A: According to gender; B: by ECOG PS; C: by history 
of surgery and D: according to the platina derivate used (Kaplan-Meier). Avalanche study. 
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A remarkably longer (p<0.001) OS was observed in patients receiving bevacizumab 
maintenance therapy (median: 26.218 ± 3.946 months, CI95%: 18.484-33.952 months) 
than in those without maintenance bevacizumab therapy (median: 10.152 ± 0.975 months, 
CI95%: 8.240-12.064 months) (Figure 29).  
 
29. Figure - Analysis of overall survival by Avastin® maintenance therapy (Kaplan-
Meier) 
 
5.1.3.2.3. Safety and adverse events 
As per the protocol, possible adverse events (AE) encountered during the study were 
recorded in the Case Report Form. Data on AE were recorded from the start of treatment 
until the end of treatment.  
During the study, a total of 157 AEs were reported for 59 patients, 14 of which were 
serious (sAE) (Table 6). 
DOI:10.14753/SE.2020.2414
 - 71 - 
Of all the adverse events, 63 (40.1%) events resolved without sequelae, the investigators 
reported improvement for 61 cases (38.9%) and the event resolved with remaining 
symptoms in 7 cases (4.5%). 2 AEs (1.3%) had not resolved, 14 AEs (8.9%) persisted 
unchanged from observation until the last follow-up of the patient, 5 AEs (3.2%) led to 
the death of the patient, and the outcome was unknown for 4 AEs (2.5%). 
Of the above-mentioned AEs, 14 were categorized as sAE, which were the following: 
Anemia (3 cases), pulmonary embolism (3 cases), hemoptysis (2 cases), deep vein 
thrombosis (2 cases), hypertension (1 case), neutropenia (1 case), thrombocytopenia (1 
case), uremia (1 case). 5 of these (two cases of pulmonary embolism, hemoptysis, 
hypertension and uremia) led to the death of the patient. 
During the study period, 16 (5.6%) of the 283 enrolled and evaluable patients died. The 
investigators reported the cause of death as disease progression in 11 cases (3.8%), while 
a serious adverse event was behind the death of the patient in 5 cases (1.7%). 
In summary, the participating investigators did not encounter and report on any new 
information on the safety profile of bevacizumab. Indeed, the rate of reported adverse 
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9. Table - Adverse events reported in the study (summary) 
Adverse event N (%) Adverse event N (%) 
Anemia 23 (14.7%) Dermatitis (forehead, back) 1 (0.7%) 
Thrombocytopenia 14 (9%) Dermatitis (generalized) 1 (0.7%) 
Neutropenia 12 (7.7%) Cholesterol increased  1 (0.7%) 
Hypertension 7 (4.5%) Exsiccosis 1 (0.7%) 
Nausea 7 (4.5%) Ulcer (in the mouth, tongue) 1 (0.7%) 
Epistaxis 6 (3.9%) Gastroesophageal reflux disease 1 (0.7%) 
Chest pain 5 (3.2%) Weakness 1 (0.7%) 
Acute bronchitis 4 (2.6%) Vomiting 1 (0.7%) 
Weight loss 4 (2.6%) Abdominal pain 1 (0.7%) 
Bone pain 3 (2%) Ileus 1 (0.7%) 
Diarrhea 3 (2%) Ischemic cerebral vascular lesions 1 (0.7%) 
Pulmonary embolism 3 (2%) Arthralgia 1 (0.7%) 
Hemoptysis 3 (2%) Swelling of arm 1 (0.7%) 
Hyponatremia 3 (2%) Hand swelling 1 (0.7%) 
Deep vein thrombosis 3 (2%) Leg swelling 1 (0.7%) 
Hoarseness 3 (2%) Laryngotracheitis 1 (0.7%) 
Cough 2 (1.3%) Febrile neutropenia 1 (0.7%) 
Fever 2 (1.3%) Prostration 1 (0.7%) 
Respiratory infection 2 (1.3%) Leukopenia 1 (0.7%) 
Obstipation 2 (1.3%) Breast swelling 1 (0.7%) 
Pneumonia 2 (1.3%) Esophageal ulcer 1 (0.7%) 
Pyuria 2 (1.3%) Duodenal ulcer 1 (0.7%) 
Tachycardia 2 (1.3%) Suffusion without trauma 1 (0.7%) 
Throat pain 2 (1.3%) Dizziness 1 (0.7%) 
Lung abscess 1 (0.7%) Thrombosis (left femoral vein) 1 (0.7%) 
Agranulocytosis 1 (0.7%) Uremia 1 (0.7%) 
Acute osteomyelitis 
(jaw) 
1 (0.7%) Urticaria 1 (0.7%) 
Allergic dermatitis 1 (0.7%) Iron deficiency 1 (0.7%) 
Allergic reaction 1 (0.7%) Bleeding following superficial injury 1 (0.7%) 
Hip pain (right-sided) 1 (0.7%) Clear-cell renal carcinoma 1 (0.7%) 
Decubitus 1 (0.7%) Numbness (of the soles) 1 (0.7%) 
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5.2. KRAS mutation as a biomarker for anti-VEGF therapy in NSCLC 
 
5.2.1. Incidence of KRAS mutations in LADC patients treated with bevacizumab and 
chemotherapy 
 
All patients had advanced LADC and Caucasian background. Patients with tumors 
harboring an EGFR mutation were excluded. One hundred and seventy patients of the 
full cohort of 501 cases were identified as KRAS-mutant (33.9%) and 331 (66.1%) as 
KRAS WT, Table 7 and Table 8). 38.5% (n=95) of the patients treated in the BEV/CHT 
group were KRAS-mutant (Table 7), whereas in the CHT group (Table 8) this ratio was 
29.5% (n=75) (P=0.012). There were no significant differences between the BEV/CHT 
and CHT groups with respect to age (P=0.193), smoking status (p=0.072), gender 
(p=0.506) or tumor stage (P=0.610) (data not shown). The only difference was seen is 
performance status, where there were more ECOG 0 (vs. EVOG 1) patients in the 
BEV/CHT group than in the CHT alone group (P=0.031; data not shown), which might 
be due to the BEV selection criteria. In the BEV/CHT sub-cohort, 35 (36.8%), 19 (20%) 
and 20 (21%) cases were classified as G12C, G12D and G12V mutants, respectively 
(Table 9). Other rare (i.e. n<3) KRAS exon 2 mutation subtypes (G12A, G12R, G12S, 
G13C, G13D) were also found in the BEV group. Subtype specific mutations were 
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10. Table – Patient characteristics in the BEV/CHT group 
  
No. of patients 
(%) 
  KRAS status 
P valuea 






          
247   152 (61.5%) 95 (38.5%)   
Age (years)b   
Median: 62 58 
0.09 SD*:  9.2 8.2 
Range: 53 44 
Smokingc           
Never-smoker 30 (12%)   24 6 
0.008 
Ever-smoker 167 (68%)   93 74 
No data (n=50)           
Genderc           
Female 106 (43%)  52 54 
0.002 
Male 141 (57%)  100 41 
ECOGc           
0 139 (56%)   87 52 
0.056 
1 108 (44%)   65 43 
Stagec           
III 55 (22 %)  38 17 
0.16 
IV 192 (78%)  114 78 
Survivald           
Median PFS (months)     8.63 7.03 0.0255 
Median OS (months)     21.57 14.23 0.0186 
a) P value is calculated between wild type and all mutant groups, b) Mann-Whitney test is used in 
case of continuous variable (age) as the data are not normally distributed (Saphiro-Wilk test), c) 
Fisher's exact test is used between categorical variables, d) survival difference between the wild type 
and the mutant group was calculated using log rank regression analysis, e) PFS was not determined 
in the CHT group, *SD: standard deviation 
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11. Table – Patient characteristics in the CHT only group 
  
No. of patients 
(%) 
  KRAS status 
P valuea 





All patients 254 







 Median: 63 61 
0.297  SD*: 7.8 8.7 
 Range: 46 46 
Smokingc           
Never-smoker 21 (8%)   15 6 
0.435 
Ever-smoker 188 (74%)   135 53 
No data (n=45)           
Genderc       
Female 118 (46.5%)  79 39 
0.27 
Male 136 (53.5%)  100 36 
ECOG           
0 128 (50.5%)   94 34 
0.335 
1 126 (49.5%)   85 41 
Stage       
III 66 (26%)  44 22 
0.351 
IV 188 (74%)  135 53 
Survivald,e           
Median OS 
(months) 
    11 10 0.6771 
a) P value is calculated between wild type and all mutant groups, b) Mann-Whitney test is used in 
case of continuous variable (age) as the data are not normally distributed (Saphiro-Wilk test), c) 
Fisher's exact test is used between categorical variables, d) survival difference between the wild type 
and the mutant group was calculated using log rank regression analysis, e) PFS was not determined 
in the CHT group, *SD: standard deviation 
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In order to study the clinical relevance of KRAS mutations, we performed comparative 
statistical analyses of KRAS status and clinicopathological variables in both the 
BEV/CHT (Table 7) and the CHT sub-cohorts (Table 8). As for the BEV/CHT group, 
ever-smoking and KRAS mutational statuses showed a significant positive association 
(P=0.008, Table 7). KRAS mutation was also significantly more common in female 
BEV/CHT patients (vs. males; P=0.002, Table 8). ECOG status and clinical stage did not 
differ between KRAS-mutant and KRAS WT patients in the BEV/CHT group 
significantly (P=0.056 and P=0.16, respectively, Table 7). The presence of KRAS 
mutation did not associate with age in the BEV/CHT group (P=0.09, Table 8). Of note, 
we did not detect significant associations of KRAS mutational status with age, smoking 
status, gender, ECOG status, stage or OS in the CHT group (Table 8). While reasons for 
the differences in the associations between KRAS mutational status and 
clinicopathological variables in the BEV/CHT vs. the CHT sub-cohorts are not entirely 
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12. Table - Correlation of clinicopathologic features, outcome variables and KRAS codon 
12 subtypes in patients with advanced LADC treated with BEV (n = 95) 
All patients 
  G12C G12D G12V Rare mutation P 
valuea   35 19 20 21 
Age (years)b Median: 61 61 56 56 
0.579  SD*: 7.7 7.1 8.7 7.2 
 Range: 32 30 31 19 
Smokingc             
Never-smoker   2 0 2 2 
0.182 Ever-smoker   33 15 12 14 
No data (15)           
Genderc           
 
Female  21 6 12 15 
0.072 
Male  14 13 8 6 
ECOGc             
0   17 7 11 17 
0.594 
1   18 12 9 4 
Stagec           
 
III  12 3 1 1 
0.071 
IV  23 16 19 20 
Survivald             
Median PFS (months)   8,53 3,77 8,17 6.77 0,0057 
Median OS (months)   19,20 7,27 14,97 12.97 0.0414 
 
a P value is calculated between KRAS codon 12 subtypes, b  Kruskal-Wallis test, c Chi-square test, d 
log rank regression analysis, *SD: Standard Deviation 
 
 
5.2.2. The presence of KRAS mutations has clinical utility in predicting disease outcome 
in LADC patients receiving concurrent antiangiogenic and chemotherapy 
 
As expected, patients in the BEV/CHT group had significantly longer median OS than 
those receiving CHT only (P<0.0001, log-rank test; Figure 30). This difference was even 
more remarkable when only KRAS WT patients were compared (P<0.0001, log-rank test, 
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Figure 31A). Notably, the addition of BEV to CHT was also associated with significant 
benefit in OS if KRAS-mutant patients were compared with those in the CHT alone sub-
cohort (P=0.0002, log-rank test, Figure 31A).  
 
30. Figure - Comparison of survival outcomes in patients with advanced LADC according to 
treatment regimen. Advanced LADC patients receiving BEV/CHT showed significantly higher 
median OS compared to those treated with CHT only (median OSs were 24 vs. 10 months, 
respectively, P<0.0001, log-rank test). 
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31. Figure - Kaplan-Meier plots for the OS (A) and PFS (B) in LADC patients according to KRAS 
mutation status. (A) LADC patients with KRAS WT tumors and receiving BEV/CHT had 
significantly increased median OS (vs. those with KRAS WT tumors and receiving CHT only; 
median OS 21.57 vs. 14.23 months, respectively, P=0.0186, log-rank test). Median OS was also 
increased in KRAS-mutant LADC patients receiving BEV/CHT compared to those treated with 
CHT only (median OSs were 18 vs. 10 months, respectively, P=0.0002, log-rank test). No 
significant differences in OS have been observed for patients receiving CHT only and with KRAS 
WT versus KRAS-mutant tumors (median OSs were 11 vs. 10 months, respectively P=0.6771, 
log-rank test). Of note, in the BEV/CHT group, patients with KRAS WT LADC had a 
significantly better OS than those with tumors harboring KRAS mutations (median OSs were 39 
vs. 18 months, respectively, P=0.0186, log-rank test). (B) Similarly, in the BEV/CHT group, 
patients with KRAS WT LADC had significantly longer median PFS (vs. those with KRAS-
mutant tumors; median PFSs were 8.63 vs. 7.03 months, respectively, P=0.0255, log-rank test). 
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We next investigated if KRAS mutational status influences the efficacy of CHT with or 
without BEV in advanced LADC. There was no difference in OS between patients with 
KRAS-mutant versus KRAS WT tumors in the CHT alone group (P=0.6771, log-rank 
test, Figure 31A). Importantly, however, in the BEV/CHT group we found that KRAS-
mutant LADC patients had significantly shorter median PFS and OS than did KRAS WT 
patients (P=0.0255 and P=0.0186, respectively, log-rank test; Figures 31B and 31A). In 
support of this, multivariate Cox regression analyses revealed that KRAS status (mutant 
vs. WT) at diagnosis influenced OS (HR 0.645, 95% CI 0.458-0.908, P= 0.012) and PFS 
(HR 0.597, 95% CI 0.402-0.887, P= 0.011) independently from age (continuous; P values 
were 0.081 and 0.628, respectively), gender (female vs. male; P values were 0.005 and 
0.001, respectively), smoking status (never- vs. ever-smoker; P values were 0.907 and 
0.835, respectively), ECOG PS (0 vs. 1; P values were 0.193 and 0.177, respectively) and 
tumor stage (III. vs. IV; P values were 0.048 and 0.617, respectively; Table 13). These 
analyses also identified more advanced tumor stage as a significant independent negative 
prognostic factor for OS but not for PFS (P values were 0.048 and 0.617, respectively, 
Table 13). Gender proved to be an independent prognosticator for both OS and PFS in a 
multivariate Cox regression model as well (P values were 0.005 and 0.001, respectively, 
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13. Table - Clinicopathological variables and PFS and OS of LADC patients treated with 
BEV/CHT in the multivariate Cox proportional hazards model 




HR 0.628 0.978 
 
95% CI 0.966-1.021) (0.955-1.003) 
 
P 0.628 0.081 
Gender (female vs. male) 
 
 
HR 0.248 0.390 
 
95% CI (0.125-0.494) (0.203-0.751) 
 
P 0.001 0.005 
Smoking (never- vs. ever-smokers) 
 
 
HR 0.944 0.968 
 
95% CI (0.548-1.626) (0.562-1.669) 
 
P 0.835 0.907 
ECOG PS (0 vs. 1) 
 
 
HR 0.765 0.772 
 
95% CI (0.518-1.129) (0.523-1.140) 
 
P 0.177 0.193 
Stage (III vs. IV) 
  
 
HR 0.879 0.603 
 
95% CI (0.531-1.455) (0.365-0.996) 
 
P 0.617 0.048 
KRAS status (WT vs. mutant) 
 
 
HR 0.597 0.645 
 
95% CI (0.402-0.887) (0.458-0.908) 
 
P 0.011 0.012 
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5.2.3. Distinct efficacy of BEV/CHT in advanced LADC patients with different subtype-
specific KRAS mutations 
 
Next, we looked at the clinicopathological characteristics of KRAS codon 12-mutant 
LADC patients receiving BEV/CHT and performed a statistical analysis on their 
associations with amino acid-specific mutational status. We identified 35 (36.8%) G12C, 
19 G12D (20%), 20 G12V (21%), 3 G12A (3.2%%), 1 G12S (1%), 1 G12R (1%), 3 G13D 
(3.1%), and 1 G13C (1%) cases. Significant associations of subtype-specific KRAS 
mutational status with age, smoking status, gender, ECOG PS or tumor stage were not 
detected (Table 9). Importantly, patients with KRAS G12D mutant tumors had 
significantly shorter OS than those presenting with KRAS WT or with other KRAS codon 
12 or 13 mutant (G12/13x) tumors (P=0.0223 and P=0.0144, respectively; log-rank test, 
Figure 32A). In line with the OS data, KRAS G12D mutation conferred a significant 
disadvantage for PFS when compared with KRAS WT (P<0.0001; log-rank test, Figure 
2B) or all the other codon 12 or 13 KRAS (G12/13x) mutations (P=0.0032; log-rank test, 
Figure 32B). Of note, the OS of G12D KRAS mutant patients in the BEV/CHT group 
was comparable to that of patients in the CHT alone sub-cohort (Figure 33).  
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32. Figure - Kaplan-Meier plots for the OS (A) and PFS (B) in LADC patients receiving 
BEV/CHT according to subtype-specific codon 12 KRAS mutations. (A) KRAS G12D mutation 
was associated with significantly shorter OS in LADC patients (vs. KRAS G12x and 13x 
mutations or WT KRAS; median OSs were 7.2, 16.1 and 21 months, respectively, P values were 
0.0144 and 0.0223, respectively, log-rank test). (B) LADC patients with tumors harboring KRAS 
G12D mutations had also significantly shorter median PFS than those with other codon 12 (G12x) 
and 13 (G13x) KRAS mutant or with KRAS WT tumors (median PFSs were 3.7, 8.27 and 11.7 
months, respectively; P values were 0.0032 and <0.0001, respectively, log-rank test). 
DOI:10.14753/SE.2020.2414
 - 84 - 
 
33. Figure - Kaplan-Meier curves for the OS of LADC patients treated with CHT alone and LADC 
patients with KRAS G12D mutations in the BEV/CHT sub-cohort. Patients with tumors harboring 
KRAS G12D mutations and treated with BEV/CHT had comparable OS to that of patients with 
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6. Discussion 
 
6.1. The safety and efficacy of bevacizumab in addition to platinum based 
chemotherapy in patients with advanced NSCLC 
 
Various randomized trials showed superior survival data and acceptable safety results 
with the use of bevacizumab in NSCLC(205, 206, 238, 239). Most of these trials, 
however, were not concluded in an unselected, real-world environment. Of note, there 
are still several questions yet to be answered regarding the drug's safety, efficacy and 
optimal treatment protocol. The AVALANCHE observational cohort study (OCS) 
provided an opportunity to examine the safety and efficacy of bevacizumab in 
combination with chemotherapy in a real-life setting in Hungarian everyday practice.  
Generally the results of observational studies cannot be directly compared with those of 
a randomized study. However, the indicators of effectiveness in the AVALANCHE study 
(which included a higher variety of patients) are consistent with those of several 
randomized trials shown in Table 14.   
 
Survival data:  
The median PFS and OS in our study were longer than in the AVAiL (206, 207), the 
E4599 (205) or the ARIES(238) studies. These OS outcomes are also comparable with 
the results of the phase IV SAiL trial conducted between 2006 and 2008 in Europe. SAiL 
reported 14.6 months (95% CI, 13.8–15.3) OS, that was shorter than the reported OS in 
AVALANCHE. The PFS in AVALANCHE was 7.162 ± 0.282 months (CI95%: 6.609-
7.715). SAiL trial reported time-to-progression of 7,8 months (95% CI, 7.5-8.1) but not 
PFS. The SAiL study let the choice of platinum doublet chemotherapy regimen to the 
investigator’s decision similarly to our study. However, non-platinum doublets and 
single-agent chemotherapy regimens were also allowed in SAiL study unlike in 
AVALANCHE. Other differences included that SAiL enrolled a selected patient 
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Treatment response: 
ORR outcomes in AVALANCHE were also comparable with the ORR results of the 
above-mentioned studies. The 46.7% ORR was higher than the 34.6%, 37.8% and the 
34.9% of the AVAiL 7.5mg/kg, AVAiL 15mg/kg and the E4599 trials, respectively. The 
SAiL and ARIES trials showed higher ORR. SAiL reported 3% CR and 48% PR (239) 
which is also comparable to the 2.3% CR and 44.4% PR rate of AVALANCHE.  
 
Survival analysis by different patient subgroups: 
Sandler et al. reported that women had significantly lower OS in the E4599 trial. They, 
however, also stated that this difference could be the result of imbalances of treatment 
regiments or baseline prognostic factors between the two groups (205). The AVAiL 
studies (207) and our AVALANCHE trial, on the other hand, found comparable results 
between women and men. Women had longer PFS and OS than men in the 
AVALANCHE, however, only OS was on the boundary of significance (p=0.071). 
Although, OS was reported higher in both AVAiL studies and the AVALANCHE trial, 
this survival advantage of women can also be accounted for by the generally longer 
survival of women with lung cancer that has been previously reported in statistical reports 
(7, 240).  
As for the patients' age, nearly 10% of the patient population with evaluable data were 
over 70 years of age and no significant difference was found between the two groups 
regarding PFS. Surprisingly, however, OS was reported to be longer in patients over 70 
years of age, although this difference was not significant.  Contrary to our findings, the 
E4599 study found that patients older than 65 years of age had a significantly higher HR 
for death and suggested that these patients might not benefit from bevacizumab treatment 
(205). The AVAiL studies reported similar HRs for OS in both groups. One concern in 
previous studies was that the risk of bleeding could be higher in older patients, however 
neither the E4599, nor the AVAiL studies nor the SAiL study back up this hypothesis 
(241). 
We observed higher PFS and OS in patients with an ECOG status of 0 at enrolment, 
although only OS showed a significant difference. This result is not surprising in light of 
the fact that ECOG performance status is an important prognostic factor in lung cancer 
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(242-245). Of note, the E4599 and the AVAiL studies did not find a significant difference 
in the HR for OS between the ECOG 0 and the ECOG 1 group (205, 207).  
Johnson et al. assumed that central tumor location might cause pulmonary hemorrhage 
more often thus decreasing the OS (203). However, this was not supported by subsequent 
data. Neither SAiL, nor ARIES showed significantly more pulmonary bleeding with 
centrally located tumors (246, 247). Based on a retrospective analysis of the E4599 study 
data, Sandler et al. suggested that pulmonary hemorrhage was connected to cavitation of 
NSCLC instead of central location (248). Further studies did not support this assumption. 
Our data do not reinforce any of these suggestions. Neither the PFS, nor the OS was 
significantly longer with central tumors, and cavitated tumors were not assessed 
separately.  
Although previous chemo- or radiotherapy did not influence PFS or OS, we found 
significantly longer PFS and OS in the patient group that underwent surgery before 
enrolment in this study. There is no available data to back up this finding. The most 
probable reason behind it is that the number of cancer sites is lower in these patients. 
Further assessment would be needed to draw further conclusions.  
Platinum based chemotherapy has been shown in multiple studies to result in a small but 
significant survival benefit when compared to supportive care (249, 250). The most 
commonly used platinum derivatives are cisplatin and carboplatin. Neither of the above 
mentioned two drugs were associated with higher PFS, OS or lower toxicity when 
compared to each other(251-256). Interestingly, patients treated with cisplatin were found 
to have a longer OS (16.953±1.775 months) than those receiving carboplatin (OS: 12.977 
± 1.692 months). The statistical difference was on the boundary of significance (p=0.06). 
Santana-Davila et al. showed that oncologists more often administered cisplatin to 
relatively younger patients with less comorbidities. This could be a reason for the longer 
OS. However, it has also been shown that morbidity is higher in patients receiving 
cisplatin and they experience a higher need for health care (252). 
Our patients receiving bevacizumab maintenance therapy showed significantly higher 
PFS and OS, which correlates with previous results published by Reck et al (206). In 
addition, Dranitsaris et al. found that bevacizumab maintenance therapy contributed to a 
significant OS benefit (257). In the Phase IIIB AvaALL study, bevacizumab was 
administered even after disease progression. A significantly higher PFS of 10.1 months 
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was achieved in this experimental arm compared to the control arm where only supportive 
care was used after disease progression (258). There are several trials debating whether 
bevacizumab or bevacizumab with pemetrexed is more effective for maintenance therapy. 
AVAPERL and POINTBREAK, two phase III trials designed to evaluate bevacizumab 
maintenance therapy with or without pemetrexed, showed significantly longer PFS, 
however the difference regarding OS was not significant in either of them (223, 259).  
Our rate of reported adverse events falls behind that of expected based on previous trials. 
Lynch et al. reported that in the ARIES trial 19.7% of patients experienced one or more 
protocol-specified adverse event (238), which is somewhat lower than the 20.8% of 
patients reported in AVALANCHE. However, when looking at the serious adverse 
events, the 10.9% reported in ARIES is appreciably higher than the 0.5% reported in 
AVALANCHE. Notably, the study protocols can vary in the qualification of serious 
adverse events. Crinò et al. reported a rate of 38% for serious adverse events, although 
only 13% was deemed related to bevacizumab by the investigators (239). There is a 
special interest in similar studies regarding pulmonary bleeding, one of the most common 
serious adverse event following bevacizumab therapy. AVAiL 7.5mg/kg, AVAiL 
15mg/kg, E4599, ARIES and SAiL reported 4%, 5%, 4.7%, 4.1% and 9.5% for the 
prevalence of any grade pulmonary hemorrhage, respectively.  In contrary to this, 
pulmonary hemorrhage only occurred in 2 patients (0.7%) in AVALANCHE. 
In summary, patients in Hungary commonly receive bevacizumab for advanced NSCLC 
in combination with a range of chemotherapeutics. Despite the less strictly selected 
patient population and treatment regimens survival outcomes and treatment response 
rates are comparable with those of the previous large RCT (randomized clinical trials). In 
our study, both PFS and OS were significantly longer and ORR significantly higher in 
patients who received bevacizumab maintenance therapy. The adjuvant/neoadjuvant 
chemotherapy or radiotherapy received prior to enrolment, the localization of the primary 
tumor, the presence of metastases or the age of the patient had no influence on the efficacy 
of bevacizumab treatment. On the other hand, previous surgery and cisplatin 
chemotherapy were associated with better outcomes. We also found low rates of adverse 
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Limitations 
The study design did not allow the comparison of PFS and OS assessed in the study, with 
placebo or any active comparator, and the comparative assessment of the significance of 
the prognostic factors studied, either. Due to the high censoring rate, the median OS could 
not be determined after the closure of the study; therefore, a retrospective data collection 
was required.   
The Avalanche study, like most OCSs had limitations such as reporting errors, missing 
data, potential biases regarding data entry and confoundment. In this study, reporting 
centers were asked to enroll all eligible patients to reduce selection bias, however, 
unintended selection bias cannot be excluded. All known strong confounders were 
collected and analyzed to reduce confounding bias. Clinical reporting errors were reduced 
by systematic data reviews occurring every 3 months.  
A further limitation of the current study was that in 12/40 planned sites, due to their lower 
patient turnover, we did not identify eligible patients within the recruiting period. Thus, 
representing the real life setting, not all centers enrolled patients and there were also 
smaller centers where fewer patients were recruited. 
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1. Table - Baseline patient characteristics and effectiveness of Bevacizumab with First-Line Chemotherapy for nsNSCLC in the AVALANCHE OCS, ARIES 
OCS, the Phase IV SAiL Study, and the Phase III Clinical Trials E4599 and AVAiL 
 
a: Patients experiencing a complete response or a partial response. b: AVAiL -  Avastin in Lung; c: E4599 - Eastern Cooperative Oncology Group 4599; d: Safety of 
Avastin in Lung, The SAiL study reported time to progression (TTP) outcomes instead of PFS. e: ARIES - Avastin Regimens: Investigation of Effectiveness and Safety; 










Median OS (months) ORR
a 
(%)
Female Male 0 1 2 IIIB IV Recurrent
AVAiLb 7.5mg/kg
(n=345 ITT) < 65: 70.95% 
(n=307 PP) > 65: 29.05%
AVAiL 15mg/kg
(n=351 ITT) < 65: 69.92%
(n=285 PP) > 65: 30.08%
E4599c





(n=1967) > 65: 51.5% Metastatic**
> 75: 18.8% 83.4%
AVALANCHE
(n=283)














496,6  (6.3-6.9) 13 (12,2 - 13,8)
Gemcitabine + 
Cisplatin
≥ 7 for PFS                  
≥ 12,5  for OS
6,7 13,6 (11,8 - 15,8)
Baseline patient characteristics Results
Gender
Investigator`s choice n.a.
7.162 ± 0.282 
(6.609-7.715)
15.179 (12.480-17.877) 
Investigator`s choice 12,5 (SD, 7.1-12.5) 7,8 (7.5-8.1) 14,6 (13,8 - 15,3)




19 6,2 12,3 (11,3 - 13,7)
Gemcitabine + 
Cisplatin
≥ 7 for PFS                 
≥ 12,5  for OS         
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6.2. KRAS mutation as a biomarker for anti-VEGF therapy in NSCLC 
 
Although KRAS is the most frequently mutated oncogene in NSCLC, our knowledge on 
the effect of KRAS mutation on response to BEV in lung cancer is very limited. 
Biomarkers of BEV efficacy including imaging markers and circulating levels of 
angiogenic cytokines have been tested both in preclinical and clinical studies. For 
instance, VEGF levels in immunodepleted plasma of cancer patients were found to be 
significantly reduced following BEV treatment (260). However, VEGF-A, as measured 
by using an ELISA that recognizes all VEGF-A isoforms, was not predictive in a 
comprehensive evaluation of four phase III trials of BEV in CRC, NSCLC and renal 
cancer (261). Interestingly, recent data suggest use of TP53 status as a biomarker for 
response to BEV in NSCLC (262, 263). Nevertheless, as in other solid tumor types, a 
reliable biomarker to identify patients with LADC who will benefit from BEV is yet to 
be discovered. Here we analyzed the KRAS exon 2 mutational status in a large Caucasian 
patient cohort (n=501) with stage III–IV, EGFR WT LADC treated with platinum-based 
chemotherapy alone or in combination with BEV. 
In the current LADC cohort, 33.9% of the patients had KRAS mutation. The incidence 
of KRAS mutation was higher in the BEV/CHT-treated group as compared to the CHT 
group (38.5% vs. 29.5%, respectively, P=0.012). With an incidence of 36.8% G12C was 
the most frequent subtype in the BEV/CHT group, followed by the G12V (21.1%) and 
the G12D (20%) subtypes. Other rare mutational subtypes (i.e. G12A, G12R, G12S, 
G13C, G13D) were identified in 22.1% of the patients. These findings are in line with 
data previously reported by us and by others in large NSCLC studies (219, 264).  
Next, we investigated if KRAS mutational status had an effect on response to BEV. 
Although KRAS status had no impact on OS of LADC patients receiving CHT alone, in 
the BEV/CHT group patients carrying KRAS mutation had significantly shorter OS. 
Multivariate analysis also confirmed the role of KRAS as a negative predictor of response 
to BEV. In lung cancer, so far only two studies addressed the impact of KRAS mutation 
on the efficacy of BEV. Results coming from both of these studies are in line with our 
data. Chaft et al. treated 50 stage IB-IIIA NSCLC patients in the neoadjuvant setting in 
combination with CHT and evaluated their pathological response (265). None of the 10 
KRAS mutant patients responded, in comparison to 11 of 31 KRAS WT cases. Although 
these authors administered BEV in combination with CHT, based on our current data and 
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also on previous reports from our group and others, the efficacy of CHT is not affected 
by KRAS status in NSCLC (218, 219). Thus, the better response rate in the KRAS WT 
group of the Chaft study can be attributed to BEV and not to CHT (233). In further support 
of this, Brady et al. studied 93 stage IV NSCLC patients receiving CHT alone or in 
combination with BEV and observed that while CHT was as effective in KRAS WT 
patients as in those with KRAS-mutant tumors, BEV improved OS and PFS only in 
patients with KRAS WT but not with KRAS-mutant tumors (234).  
Mechanisms of resistance to antiangiogenic agents such as BEV include hypoxia-
mediated mechanisms (266), the downregulation of target receptors and the activation of 
compensatory angiogenic pathways (267-269), proangiogenic hematopoietic or 
endothelial progenitor cell release from the bone marrow (270), inadequate intratumoral 
distribution of antiangiogenic drugs (271), and also a switch from endothelial sprouting 
to a nonangiogenic vascularization mechanism such as vessel cooption (a frequently 
occurring vascularization pattern in primary and secondary lung tumors that mediates 
resistance to anti-angiogenic therapy) (272-275).) It is not completely clear, though, 
whether and how KRAS mutation can contribute to these resistance mechanisms. 
Notably, however, tumor spread through air spaces (STAS) (276) and "tumor islands" 
(277) are closely related morphological features to vessel cooption (278) and were found 
to be significantly associated with KRAS mutations in NSCLC (276, 277). Moreover, 
mutant KRAS has been shown to induce the expression of VEGF in transformed 
fibroblasts or epithelial cells in vitro. KRAS mutation led to increased expression of other 
angiogenic growth factors such as TGF-beta and alpha (279). Elevated VEGF mRNA 
levels were detected in tumor cell lines expressing mutant KRAS (92). Genetic disruption 
of the mutant KRAS allele in human colon carcinoma cells resulted in decreased VEGF 
secretion (92). Transfection of human pancreatic epithelial cells with KRAS12V induced 
the expression of VEGF and CXC chemokines through Erk and c-Jun signaling and 
enhanced endothelial tube formation in co-cultures, which could be inhibited by CXCR2 
or VEGF targeting (280). And lastly, doxycycline withdrawal led to tumor regression and 
endothelial apoptosis in a doxycycline-inducible RAS-driven INK4a deficient murine 
model of melanoma (226). 
In CRC patients receiving BEV, results on associations between KRAS mutational status 
and outcome have been inconsistent, with a larger number of studies reporting no 
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associations (227, 229, 230, 281, 282) than those demonstrating significant associations 
(231, 232). Interestingly, however, in a recent CRC study, Fiala et al. demonstrated that 
G12V and G12A mutation were predictors of shorter PFS and OS, while patients with 
tumors harboring other KRAS mutations had similar outcome to those with KRAS WT 
tumors (231). Notably, another group reported that the presence of KRAS G12D mutation 
was significantly associated with poorer outcome in CRC patients receiving BEV 
containing regimens (283). As for NSCLC, Scheffler et al. found recently that patients 
with KRAS G12D mutation exhibit a high frequency of co-occurring mutations in the 
angiogenesis-associated PDGF (platelet derived growth factor receptor) / PDGF-receptor 
pathway (284). In line with this, amongst the three major codon 12 KRAS mutation 
subtypes (G12C, G12V and G12D) G12D proved to be a predictor of poor outcome in 
our BEV/CHT sub-cohort. Patients with LADC harboring this mutation had significantly 
worse PFS and OS than those with tumors harboring other KRAS mutations or WT 
KRAS.  
The biological importance of KRAS mutational subtypes has been demonstrated in a 
study by Figueras et al. who introduced either codon 12 or codon 13 KRAS mutation into 
NIH3T3 cells and analyzed the VEGF levels and the activity of VEGF promoter in these 
transfected sublines. Despite the lower VEGF expression, codon 12 mutant tumors 
exhibited higher microvessel density, while tumors harboring the codon 13 mutation 
developed angiogenic sprouts with larger diameters (285).  
In our cohort, only two patients carried codon 13 mutation of KRAS, thus we could not 
evaluate the BEV response in this subgroup. Nevertheless, our study suggests that 
specific KRAS mutation subtypes can have a major impact on tumor vascularization and, 
potentially, on response to anti-angiogenic treatment. 
Like all retrospective analyses, our study has limitations. First, although we excluded 
patients with EGFR mutant tumors from our study, we did not analyze KRAS-WT 
patients for additional oncogenic driver mutations. Second, we did not study KRAS 
mutant patients for co-occurring mutations in additional tumor-associated pathways 
(284). Third, because this large retrospective cohort did not include reliable RECIST data 
(286) for all patients, we did not investigate the correlation of KRAS mutational status 
with tumor response according to RECIST criteria. Finally, because there is a massive 
body of literature on the predictive and prognostic role of KRAS mutations in CHT-
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treated LADC patients (216-220, 284, 286-288) and the main aim of the current study 
was to investigate the relationship between KRAS status and the efficacy of BEV, only 
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7. Conclusion 
7.1. The safety and efficacy of bevacizumab in addition to platinum based 
chemotherapy in patients with advanced NSCLC 
 
To conclude the results of the AVALANCHE study, it can be stated that comparable 
results were seen in the Hungarian clinical practice as in former international studies. 
Marked improvement was seen in PFS and OS of patients with locally advanced, 
metastatic, or recurrent non-small cell lung cancer other than predominantly squamous 
cell histology when BEV was added to standard platinum based CHT. In the meantime, 
combination therapy with BEV proved to be safe, with acceptable amount of adverse 
events and low percentage of treatment discontinuation. BEV is a valid option in the 
treatment of stage IIIB and IV nsNSCLC in the Hungarian clinical setting.  
 
7.2. KRAS mutation as a biomarker for anti-VEGF therapy in NSCLC 
 
In conclusion, when combined with standard first-line chemotherapy, BEV has led to 
increased OS and thus has been approved in patients with advanced or recurrent 
nsNSCLC without targetable molecular abnormalities (203, 205, 222, 223, 289, 290). 
However, although serious efforts have been made to identify patients responsive to BEV, 
there is as yet no validated predictive biomarker in this field.  
Here, we present novel evidence for use of BEV in stage III-IV LADC patients with 
KRAS-mutant tumors -and especially with KRAS G12D-mutant tumors -, demonstrating 
inferior activity of this drug compared to that in LADC patients with non–KRAS-mutant 
tumors. Our data may not only help to improve the efficacy of BEV, but through better 
patient selection, could also help to decrease the unnecessary use of this expensive agent 
in subgroups of KRAS-mutant human LADC patients. Unnecessary and ineffective use 
of BEV can potentially even harm patients through adverse events while achieving no 
PFS, OS or quality of life benefit and also putting a financial strain of health care.  
Subtype specific KRAS mutational status can be an easily accessible marker, since its 
already part of the routine molecular testing in NSCLC. Using subtype specific KRAS 
mutation status as a biomarker could help clinicians to administer individualized therapy. 
To validate this potential biomarker prospective studies are needed.   
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8. Summary 
Although angiogenesis has long been regarded as essential to tumor progression, anti-
angiogenics have provided only modest clinical results so far. The current thesis is based 
on two different studies on the clinical efficacy of bevacizumab (BEV), an antiangiogenic 
inhibitor, in lung adenocarcinoma (LADC) patients.  
In the first study (AVALANCHE; NCT03170284), advanced LADC patients received 
BEV with any platinum-doublet for up to 6 cycles. Primary endpoint was progression-
free survival (PFS), secondary endpoints included overall survival (OS), tumor control 
rate and safety. Longer PFS and OS were observed in patients who received BEV therapy 
(median OS, 26.2 versus 10.2 months (p<0.001); median PFS, 9.2 versus 5.8 months 
(p<0.001)). Response rate: complete remission / partial response / stable disease / 
progressive disease /not reported were: 1.5/29.9/26.9/9.1/32.6% of all patients. These 
clinical outcomes were consistent with pivotal studies. 
In the second study, our aim was to investigate the prognostic and predictive role of 
KRAS (Kirsten rat sarcoma 2 viral oncogene homolog) mutations in human LADC 
patients treated with BEV. To this aim, the association between KRAS status and 
clinicopathological variables was retrospectively analyzed in 501 stage IIIB-IV LADC 
patients receiving first-line platinum-based chemotherapy (CHT) with or without BEV. 
Comparing the 247 BEV/CHT and the 254 CHT patients, we only found difference in OS 
between patients with KRAS-mutant versus KRAS wild-type tumors in the BEV/CHT 
group: patients with KRAS-mutant tumors demonstrated significantly shorter PFS (p = 
0.0255) and OS (p = 0.0186) in response to BEV/CHT compared to KRAS wild-type 
patients. KRAS mutation was an independent predictor of shorter PFS (hazard ratio (HR), 
0.597; p = 0.011) and OS (HR, 0.645; p = 0.012) in the BEV/CHT group. G12D KRAS-
mutant patients receiving BEV/CHT showed significantly shorter PFS (3.7 months versus 
8.27 months in the G12/13x group; p = 0.0032) and OS (7.2 months versus 16.1 months 
in the G12/13x group; p = 0.0144). BEV treatment was associated with significantly 
longer PFS and OS, however KRAS-mutant advanced LADC patients receiving 
BEV/CHT treatment exhibited inferior PFS and OS compared to those with KRAS wild-
type LADC. G12D mutations may define a subset of KRAS-mutant LADC patients 
unsuitable for antiangiogenic therapy with BEV. 
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9. Összefoglalás 
Annak ellenére, hogy régóta ismert az angiogenezis nélkülözhetetlen szerepe a tumor 
növekedésében, az érképződést gátló kezelések eddig csak szerény klinikai eredményeket 
hoztak tüdőrákok esetén. Jelen tézis két különböző kutatás eredményei alapján készült, 
amik a bevacizumab (BEV), egy angiogenezis inhibitor, klinikai hatékonyságát 
vizsgálták tüdő adenocarcinomás (LADC) betegeknél.  
Az első klinikai vizsgálatban (AVALANCHE; NCT03170284) előrehaladott LADC 
betegek kaptak 6 ciklus BEV-ot a standard platina alapú kezelés mellett. A vizsgálat 
elsődleges végpontja a progressziómentes túlélés (PFS), míg másodlagos végpontjai az 
össztúlélés (OS), a terápiára adott klinikai válasz  és a biztonság voltak. Hosszabb PFS és 
OS volt megfigyelhető azokban a betegekben, akik BEV terápiában részesültek (medián 
OS, 26.2 vs 10.2 hónap (p<0.001); medián PFS, 9.2 versus 5.8 hónap (p<0.001)). A 
terápiás válasz tekintetétben a teljes remisszió / részleges válasz / stabil betegség / 
progresszív betegség / nem jelentett: 1.5/29.9/26.9/9.1/32.6% volt. Ezek a klinikai 
eredmények összemérhetőek voltak a korábbi meghatározó vizsgálatok eredményeivel.   
A második vizsgálatban az volt a célunk, hogy megfigyeljük a KRAS (Kirsten rat 
sarcoma 2 viral oncogene homolog) mutáció prognosztikai és prediktív értékét 
előrehaladott LADC betegekben, akik BEV terápiában részesülnek. Ennek elérése 
érdekében retrospektívan elemeztük 501 IIIB-IV. stádiumú LADC beteg 
klinikopathológiai paramétereit, akik platina alapú kemoterápiás (CHT) kezelésben 
részesültek BEV-el vagy nélküle. Amikor összehasonlítottuk a 247 BEV/CHT terápiában 
részesülő beteget a 254 csak CHT beteggel, azt találtuk, hogy csak a BEV/CHT 
csoportban okozott túlélési különbséget a KRAS mutáció: a KRAS mutáns betegek PFS-
e (p = 0.0255) és OS-e (p = 0.0186) is szignifikánsan alacsonyabb volt, mint a KRAS 
wild-type betegeké. A KRAS mutáció önálló prediktív faktornak bizonyult a rövidebb 
PFS (hazard ratio (HR), 0.597; p = 0.011) és OS (HR, 0.645; p = 0.012) tekintetében is a 
BEV/CHT csoportban. A G12D KRAS mutációt hordozó betegek szignifikánsan 
rövidebb PFS-t (3.7 hónap vs 8.27 hónap a G12/13x csoportban; p = 0.0032) és OS-t (7.2 
hónap vs 16.1 hónap a G12/13x csoportban; p = 0.0144) mutattak BEV/CHT terápia 
esetén, mint a bármely más KRAS mutációt hordozók. A G12D KRAS mutáció a LADC 
betegek egy olyan alcsoportját jelezheti, akiknél az angiogenezis gátló terápia BEV-el 
hatástalan.   
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Abstract. The previous results of former clinical studies 
confirmed that first‑line bevacizumab (BEV) in combination 
with chemotherapy improves clinical outcomes in patients 
with advanced non-squamous non-small cell lung cancer. 
The AVALANCHE study (ClinicalTrials.gov Identifier 
NCT03170284) was undertaken to assess the clinical outcomes 
of first‑line BEV combined with standard platinum‑based 
regimens in the Hungarian clinical practice. This observational 
study was conducted in 28 Hungarian sites, with patients enrolled 
between July 2008 and April 2011. Patients with untreated 
locally advanced, metastatic or recurrent lung adenocarcinoma 
received BEV (7.5 mg/kg, q3w) with any platinum‑doublet for up 
to 6 cycles, and then non‑progressors proceeded to receive BEV 
until disease progression or unacceptable toxicity. The primary 
endpoint was time-to-progression, and secondary endpoints 
included overall survival (OS), tumour control rate and safety. 
Patients were also analysed as two cohorts (non‑progressors 
vs. progressors) based on whether or not they received BEV 
maintenance therapy following completion of first-line 
chemotherapy plus BEV. The study enrolled 283 patients (median 
age: 58.2 (18‑78) years; males: 50.5%; stage: III/B: 18.4%, IV: 
79.9%; adenocarcinoma/other: 95.8/4.2%; ECOG PS 0/1/2/≥3: 
30.8/59.7/2.6/1.4%). Centrally located tumours were reported 
in 21.6%. Cisplatin/carboplatin‑based regimens: 53.8/46.2%. A 
total of 43% of patients received BEV maintenance therapy. The 
median number of BEV cycles was 6. Median progression‑free 
survival (PFS) was 7.2 months and OS was 15.2 months for the 
entire cohort. Longer PFS and OS were observed in patients 
who received BEV maintenance therapy [median OS, 26.2 
vs. 10.2 months (P<0.001); median PFS, 9.2 vs. 5.8 months 
(P<0.001)]. Contrary to the results of previous OCS no 
significant difference was recorded in the different age groups 
or gender. Best tumour response: Complete remission/partial 
remission/stable disease/progressive disease/not reported were: 
1.5/29.9/26.9/9.1/32.6% of all patients. In conclusion, clinical 
outcomes obtained in this real‑life population were consistent 
with pivotal studies. BEV maintenance treatment was associated 
with a significantly longer PFS and OS.
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disease; SD, standard deviation; TNM, Internationally accepted 
classification of malignant tumours; TTP, time‑to‑progression; VEGF, 
vascular endothelial growth factor; WHO, World Health Organization
Key words: bevacizumab, non‑small cell lung cancer, first‑line, 
observational study
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Introduction
Lung cancer is the second most common malignant tumour. 
However it causes more deaths than breast, prostate and colon 
cancer combined (1). Hungary has the highest mortality rates 
of lung cancer in the world regarding both men and women. 
Hungary, unlike other developed countries, records a growing 
number of new cases. While the incidence hasn't increased over 
the last few years in men, it continuously does in women (2).
Survival rates remain poor in non-small cell lung 
cancer (NSCLC) with 49% 5‑year survival rate with early 
(stage IA) NSCLC and 1% 5‑year survival rate in stage IV. One 
reason for such poor survival is that more than 50% of patients 
are diagnosed with advanced disease (3).
Although many advances have been made in the treatment 
of unresectable (stage IIIB), metastatic (stage IV) or recur-
rent NSCLC, such as the introduction of targeted therapy 
for specific oncogenic drivers (EGFR, ALK mutations etc.), 
platinum‑based chemotherapy (with or without radiotherapy) 
still remains the first choice in most cases.
Targeted therapies showed superior survival data, demon-
strated improved response rates and are associated with less 
toxicity. Druggable mutations for EGFR and ALK mutation, 
however, only occur in 25 and 5%, respectively (4,5). Vascular 
endothelial growth factor (VEGF) is a key factor to endothelial 
cell growth and one of the most important regulators of angio-
genesis. Increased expression of VEGF can be demonstrated in 
most solid tumours including NSCLC (6). In many cases, VEGF 
overexpression is associated with an increased risk of relapse and 
metastasis (7-10). According to preclinical studies, anti‑VEGF 
monoclonal antibodies are capable of inhibiting the growth of 
human tumour xenografts both in monotherapy and in combina-
tion with chemotherapy (11-14). Bevacizumab (BEV) (Avastin®; 
Genentech/Roche, San Francisco, CA, USA) is a humanized 
monoclonal antibody that acts by binding and neutralizing 
the VEGF‑A isoform, thus preventing VEGF ligand‑receptor 
binding. It has demonstrated its efficacy in colorectal (15,16), 
ovarian (17), breast (18,19) and renal cancer (20,21). This was the 
first antivascular drug to be licensed for the treatment of NSCLC.
According to a phase II study (22), BEV treatment in combi-
nation with chemotherapy in NSCLC was more effective than 
chemotherapy alone. The combination was also well tolerated, 
however, the incidence of lung haemorrhage increased. In a 
post hoc multivariate analysis, squamous cell histology was 
identified as an independent risk factor for bleeding (23). 
Consequently, patients with squamous cell histology were 
excluded from most of the clinical trials of BEV in NCSLC.
Subsequent to the above Phase II study, the Eastern 
Cooperative Oncology Group (ECOG) E4599 trial was initi-
ated (24). This study, which was the first published Phase III 
randomized trial of an antiangiogenesis agent in combina-
tion with chemotherapy in patients with advanced NSCLC, 
randomized chemotherapy‑naive patients with predominantly 
non‑squamous cell histology were included. In the BEV treat-
ment arm, following completion of chemotherapy, single-agent 
BEV was continued until disease progression. Results showed 
that the addition of BEV was associated with a significant 
improvement in the median overall survival (OS) compared 
with chemotherapy alone. Progression‑free survival (PFS) was 
also significantly improved.
A second Phase III trial (Avastin® in Lung; AVAiL), evalu-
ating BEV in combination with cisplatin and gemcitabine (25) 
(another commonly used and efficacious regimen in NSCLC) 
was originally initiated with a primary end point of OS. 
However, after the positive OS results of E4599, the study 
design was amended so as to change the primary end point 
from OS to PFS. Patients were randomly assigned to receive 
cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to 
six cycles plus low‑dose BEV (7.5 mg/kg), high‑dose BEV 
(15 mg/kg) or placebo every 3 weeks until disease progres-
sion. PFS was significantly prolonged with BEV. Interestingly, 
according to the final efficacy analysis, OS was >13 months 
in all treatment groups, which was the longest OS reported 
for advanced non-squamous NSCLC in a clinical trial setting, 
although it did not yield a statistically significant prolongation 
with either BEV dose (26).
As a result of the above trials, BEV in combination with 
platinum‑based chemotherapy was approved for the first‑line 
treatment of patients with advanced NSCLC by the European 
Medicines Agency (EMA) in August 2007.
Although BEV was approved with platinum‑based chemo-
therapy in NSCLC in 2007, so far no Hungarian data have been 
available. The AVALANCHE study (ClinicalTrials.gov, identifier: 
NCT03170284) was undertaken to assess the clinical outcomes 
of first‑line BEV combined with standard platinum‑based 
regimens in Hungarian clinical practice.
Patients and methods
Study design. AVALANCHE (ClinicalTrials.gov, identifier: 
NCT03170284) was a multi‑centre single‑arm observational 
study designed to assess the efficacy and safety of BEV 
therapy in patients with advanced, unresectable, metastatic 
or recurrent nsNSCLC (other than predominantly squamous 
cell histology) in the routine oncology practice in Hungary. 
Further objective of the study was to assess and identify 
possible treatment‑related prognostic factors.
Patients. This study was originally projected to enrol 
150 patients from 40 Hungarian study centres. Fortunately, 
however, due to the high number of patients recruited by some 
centres, nearly 300 patients were enrolled.
Patients with histology or cytology proven unresectable 
advanced, metastatic or recurrent (stage IIIB/IV) NSCLC 
other than predominantly squamous cell histology were 
included in the present study. There were 143 male (50.5%) 
and 135 female (47.7%) patients and no data on gender was 
available in 5 patients (1.8%) (Table I).
The exclusion criteria were the following: i) hypersen-
sitivity to the active substance or to any of the excipients 
of Avastin®; ii) hypersensitivity to products derived from 
Chinese hamster ovary (CHO) cells or to other recombinant 
human or humanized antibodies; iii) pregnancy and iv) pres-
ence of untreated central nervous system metastases. The 
present study was done in accordance with the Declaration 
of Helsinki, Good Clinical Practice International Conference 
on Harmonisation Tripartite Guidelines, laws and regulations 
of the participating institutes' country. The present study was 
approved by the Hungarian Ethics Committee and Health 
Authority. All patients provided written informed consent.
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Treatment. Eligible patients received first‑line BEV with 
cisplatin or carboplatin in accordance to the approved and 
reimbursed BEV indication in Hungary (BEV 7.5 mg/kg, 
every 3 weeks with any platinum‑doublet for up to 6 cycles) 
then non‑progressors proceeded to receive BEV until disease 
progression or unacceptable toxicity. The maintenance therapy 
regimen was 7,5 mg/kg every 3 weeks until PD or intolerable 
toxicity. The third component of the combination chemo-
therapy was one of the following: paclitaxel, gemcitabine, 
docetaxel or vinorelbine. Based on the therapeutic protocol, 
patients were followed up until the first progression of their 
primary disease, or death, or withdrawal of consent, or loss 
of contact with the patient, or closure of the study, whichever 
occurred first.
Progression‑free and OS. Investigators seemed to be frequently 
using PFS and time‑to‑progression (TTP) interchangeably 
in clinical trials in the early 2000s (27). The protocol of our 
study defined TTP as the time elapsed from the date of enrol-
ment until the first documented progression or the death of 
the patient from any cause which is in accordance with the 
current definition of PFS. To avoid confusion, PFS will be used 
hereinafter for the denomination of the primary endpoint of 
the study. Progression was determined by the investigator at 
the routine clinical practice follow‑up examinations. PFS was 
calculated from the start of BEV treatment.
Secondary endpoints included best tumour response 
(complete remission (CR), partial remission (PR), stable disease 
(SD), progressive disease (PD)), OS (based on retrospective 
analysis) and indicators of safety (serious and non‑serious 
adverse events). Objective response rate (ORR) was calculated 
from patients experiencing complete or partial remission.
Basic demographic data, basic vital parameters, primary 
disease-related historical data, ECOG performance status, 
data related to BEV treatment, results of the staging assess-
ments as well as the patient's comorbidities and concomitant 
treatments were recorded in an electronic case-report form.
Following the closure of the study, data for the assessment 
of the PFS were available for 252 patients. As per the amended 
protocol, the secondary endpoint (OS) was retrospectively 
analysed based on data from 250 patients.
During the treatment period regular monitoring visits were 
conducted to ensure high-quality data collection. Data related 
to BEV treatment, blood pressure, body weight, concomitant 
treatments and adverse events were registered.
The following data were recorded at the end-of-treatment 
visit: End date of BEV treatment, reason for ending treat-
ment, ECOG status, best tumour response observed during 
treatment, concomitant treatments administered during BEV 
treatment and adverse events observed during BEV treatment.
Statistical analysis. Continuous variables were compared with 
Student's t‑tests if the sample distribution was normal or with 
Mann‑Whitney U test if the sample distribution was asym-
metric. Categorical data were compared using Fisher's exact 
probability and χ2 tests. PFS (primary study endpoint) and 
OS in the total population were analysed using Kaplan‑Meier 
curves. Both PFS and OS were assessed separately in subgroups 
according to gender, age, ECOG status, the platinum derivate 
used, the use of maintenance therapy and weather prior 
surgical intervention was done. Log‑rank test was used for 
comparison between the above mentioned groups.
PFS was defined as the time elapsed from the start of BEV 
treatment until the first documented progression or the death 
Table I. Patient demographics and treatment.
Characteristics No. of patients, n (%)
Evaluable patient population 283 (99.6)
Patient population evaluable in terms 252 (88.7)
of PFS
Patient population evaluable in terms 250 (88)
of OS
Age (years) 
  Mean 58.16±9.032
  Men 58.30±8.986
  Women 58.02±9.113
Gender 
  Male 143 (50.5)
  Female 135 (47.7)
  No data 5 (1.8)
Histologic type 
  Adenocarcinoma 271 (95.8)
  Bronchoalveolar carcinoma 11 (3.9)
  Squamous cell carcinoma 1 (0.4)
Stage  
  III B 52 (18.4)
  IV 226 (79.9)
  No data 5 (1.8)
Previous treatment 
  Previous surgery 64 (22.6)
  Adjuvant/neoadjuvant chemotherapy 18 (6.4)
  Radiotherapy 18 (6.4)
Chemotherapeutic agent during study 
  Paclitaxel 132 (46.6)
  Gemcitabine 111 (39.2)
  Docetaxel 18 (6.4)
  Vinorelbine 2 (0.7)
  Other 7 (2.5)
  No data 13 (4.6)
Reported reasons for ending the study 
  Progression of primary disease 172 (60.8)
  Deterioration of symptoms 4 (1.4)
  Loss of contact with the patient 7 (2.5)
  Adverse event associated with 13 (4.6)
  BEV treatment
  Patient's decision 17 (6.0)
  Mortality 16 (5.7)
  Other 45 (15.9)
  No data 9 (3.2)
PFS, progression‑free survival; OS, overall survival; BEV, bevaci-
zumab.
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of the patient from any cause. For study subjects who had 
not shown progression and had not died by the closure of the 
study, the data were censored at the date of the last contact.
OS was defined as the time elapsed from the date of enrol-
ment until the death of the patient from any cause. Regarding 
subjects who had not died by the closure of the study, the OS 
data were analysed retrospectively after the end of the study 
in the knowledge of their dates of death. Otherwise, data were 
censored at the date of the last contact.
P<0.05 was considered to indicate a statistically signifi-
cant difference. All statistical analyses were conducted 
using Statistica 8.0 (StatSoft, Inc., Tulsa, OK, USA) software 
program.
Results
Baseline characteristics of the patients. A total of 284 patients 
with corresponding diagnosis were identified at the Hungarian 
study sites, and were subsequently enrolled into the study 
between 17th June 2008 and 3rd May 2011, out of which data of 
283 patients were evaluable. From among the 41 study centres 
originally involved, no patients were enrolled at 16 sites, thus 
in fact 25 centres participated actively. The highest number of 
patients enrolled at one centre was 36, whereas the smallest 
was 1. One patient did not comply with all the inclusion and 
exclusion criteria: The patient's histological diagnosis was 
squamous cell carcinoma; therefore evaluable patient popu-
lation was 283. Central localization of the primary tumour 
was reported in 61 patients (21.6%) and cavitated tumour in 
4 patients (1.4%) in the total patient population.
The study population had to be reduced to 252 in case of 
PFS and 250 regarding OS. In case of PFS 31 patients and 
in case of OS 33 patients had to be excluded from the data 
assessment due to missing or incomplete information. These 
information could not be recovered retrospectively.
The demographic characteristics of the enrolled and evalu-
able patients are summarized in Table I.
Treatment. Prior to enrolment, 64 patients (22.6%) had under-
gone surgical intervention, 18 patients (6.4%) had received 
adjuvant/neoadjuvant chemotherapy, and 18 patients (6.4%) 
had received radiotherapy (Table I).
Patients received cisplatin (N=148, 52.3%) or carboplatin 
(N=124, 43.8%) treatment in accordance with the protocol in 
approximately half‑and‑half proportion during the study. No 
data are available for 11 patients (3.9%). The other components 
of the combination chemotherapy are shown in Table I.
The vast majority of patients (N=262, 92.6%) received BEV 
in 3‑weekly cycles. A treatment of different cycle frequency 
was applied in two patients (0.7%), and no data were available 
for 19 patients (6.7%). The median number of BEV treatment 
cycles in the retrospectively evaluated patient population was 6.
The most common reason for ending the study was docu-
mented as progression of the primary disease in more than 
half of the study subjects (60.8%). Patient's decision, patient's 
death, adverse event related to BEV therapy, loss to follow‑up, 
and symptom deterioration accounted for ending the study 
in 6.0, 5.7, 4.6, 2,5 and 1.4% of the cases, respectively. Other 
reasons behind ending the study occurred in 15.9%; no data 
were available in 3.2% of cases.
Figure 1. Kaplan‑Meier plots of (A) PFS in the total population. (B) OS in enrolled and evaluated patients. (C) Analysis of PFS by Bevacizumab maintenance 
therapy. (D) Analysis of OS by Bevacizumab maintenance therapy. OS, overall survival; PFS, progression‑free survival.
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Efficacy analysis
PFS. The PFS in the total study patient population was 
7.162±0.282 (CI95%: 6.609‑7.715) months (Fig. 1A). The 
subgroup‑analysis of PFS by gender showed that the survival 
time with BEV treatment was longer in women (median: 
7.589±0.647, CI95%: 6.321‑8.858 months) than in men (median: 
6.669±0.375, CI95%: 5.934‑7.405 months). This difference, 
however, was not significant (P=0.542).
The median PFS was higher in patients with an ECOG 
status of 0 at enrolment (median: 7.326±0.535, CI95%: 
6.278±8.375 months) than in patients with a baseline 
ECOG status of 1 (median: 6.702±0.597 months, CI95%: 
5.531‑7.873 months). However, the difference between the two 
groups was not remarkable (P=0.123).
Similarly, PFS was not significantly influenced by the 
localization of the tumour (central vs. non‑central, P=0.813).
Interestingly, the median PFS in patients who had 
undergone surgical intervention prior to enrolment (median: 
8.411±0.947, CI95%: 6.554‑10.267 months) was notably higher 
(P=0.017) compared with patients with no such prior inter-
vention (median: 6.834±0.265, CI95%: 6.314‑7.353 months). 
In contrast, neither adjuvant/neoadjuvant chemotherapy 
(P=0.165) nor radiotherapy (P=0.165) applied prior to enrol-
ment had a significant impact on median PFS.
The platinum derivative used had no significant influence 
on median PFS, either (P=0.199).
Nearly 10% of the patient population with evaluable data 
were over 70 years of age at the time of enrolment. The median 
PFS was not significantly different between patients under or 
above 70 years of age (P=0.541).
Of note, median PFS was significantly higher (P<0.001) 
in patients receiving BEV maintenance therapy (median: 
9.166±0.601, CI95%: 7.988‑10.345 months) compared with those 
who received no maintenance therapy (median: 5.815±0.574, 
CI95%: 4.690‑6.940 months) (Fig. 1C).
Secondary endpoints
Tumour response. Disease control was achieved in a 
remarkable 86.5% with CR in 2.3%, and PR in 44.4% of 
the cases with evaluable data. PD was recorded in 13.5% 
of evaluable cases and sufficient data was not available in 
32.6% (Table II).
OS. The median OS in the total study population was 
15.179±1.377 months (CI95%: 12.480‑17.877) (Fig. 1).
As with PFS, we performed subgroup‑analysis of OS by 
gender, ECOG status, prior surgical procedure and chemo-
therapy. Results can be seen on Table III.
The localization of the tumour had no impact on OS 
(P=0.992) in the patient population studied.
Surprisingly, we found a tendency towards a higher median 
OS for patients over 70 years of age (18.398±3.869 months, CI95%: 
10.815‑25.982 months) compared with patients younger than 
70 years (15.014±1.329 months, CI95%: 12.410‑17.619 months), 
although this difference remained not significant (P=0.638).
A remarkably longer (P<0.001) OS was observed in 
patients receiving BEV maintenance therapy (median: 
26.218±3.946 months, CI95%: 18.484‑33.952 months) than 
in those without maintenance BEV therapy (median: 
10.152±0.975 months, CI95%: 8.240‑12.064 months) (Fig. 1D).
Safety and adverse events. As per the protocol, possible adverse 
events (AE) encountered during the study were recorded in the 
Case Report Form. Data on AE were recorded from the start 
of treatment until the end of treatment.
During the study, a total of 157 AEs were reported for 
59 patients, 14 of which were serious (sAE) (Table IV).
Of all the adverse events, 63 (40.1%) events resolved 
without sequelae, the investigators reported improvement 
for 61 cases (38.9%) and the event resolved with remaining 
symptoms in 7 cases (4.5%). 2 AEs (1.3%) had not resolved, 
14 AEs (8.9%) persisted unchanged from observation until 
the last follow‑up of the patient, 5 AEs (3.2%) led to the 
death of the patient, and the outcome was unknown for 4 
AEs (2.5%).
Of the above‑mentioned AEs, 14 were categorized as sAE, 
which were the following: Anaemia (3 cases), pulmonary 
embolism (3 cases), haemoptysis (2 cases), deep vein throm-
bosis (2 cases), hypertension (1 case), neutropenia (1 case), 
thrombocytopenia (1 case), uraemia (1 case). 5 of these (two 
cases of pulmonary embolism, haemoptysis, hypertension and 
uraemia) led to the death of the patient.
During the study period, 16 (5.6%) of the 283 enrolled and 
evaluable patients died. The investigators reported the cause of 
death as disease progression in 11 cases (3.8%), while a serious 
adverse event was behind the death of the patient in 5 cases 
(1.7%).
In summary, the participating investigators did not 
encounter and report on any new information on the safety 
profile of BEV. Indeed, the rate of reported adverse events falls 
behind the rate expected based on literature data.
Discussion
Various randomised trials showed superior survival data 
and acceptable safety results with the use of BEV in 
Table II. Best tumor response reached during the first‑line treatment.
Response  N Patient population with evaluable data (n=133), (%) Total patient population (n=216), (%)
Complete remission 3 2.3 1.5
Partial remission  59 44.4 29.9
Stable disease 53 39.8 26.9
Progressive disease  18 13.5 9.1
Not assessable 83  ‑  32.6
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NSCLC (24,25,28,29). Most of these trials, however, were not 
concluded in an unselected, real-world environment. Of note, 
there are still several questions yet to be answered regarding 
the drug's safety, efficacy and optimal treatment protocol. The 
AVALANCHE observational cohort study (OCS) provided 
an opportunity to examine the safety and efficacy of BEV 
in combination with chemotherapy in a real‑life setting in 
Hungarian everyday practice.
Generally the results of observational studies cannot be 
directly compared with those of a randomized study. However, 
the indicators of effectiveness in the AVALANCHE study 
(which included a higher variety of patients) are consistent 
with those of several randomized trials shown in Table V.
The median PFS and OS in our study were longer than in 
the AVAiL (25,26), the E4599 (24) or the ARIES (28) studies. 
These OS outcomes are also comparable with the results of 
the phase IV SAiL trial conducted between 2006 and 2008 
in Europe. SAiL reported 14.6 months (95% CI, 13.8‑15.3) 
OS, that was shorter than the reported OS in AVALANCHE. 
The PFS in AVALANCHE was 7.162±0.282 months (CI95%: 
6.609‑7.715). SAiL trial reported TTP of 7,8 months (95% CI, 
7.5‑8.1) but not PFS. The SAiL study let the choice of platinum 
doublet chemotherapy regimen to the investigator's decision 
similarly to our study. However, non‑platinum doublets and 
single-agent chemotherapy regimens were also allowed in 
SAiL study unlike in AVALANCHE. Other differences 
included that SAiL enrolled a selected patient population that 
was generally healthier and younger (29).
ORR outcomes in AVALANCHE were also comparable 
with the ORR results of the above‑mentioned studies. The 
46.7% ORR was higher than the 34.6%, 37.8% and the 34.9% 
of the AVAiL 7.5 mg/kg, AVAiL 15 mg/kg and the E4599 trials, 
respectively. The SAiL and ARIES trials showed higher ORR. 
SAiL reported 3% CR and 48% PR (29) which is also compa-
rable to the 2.3% CR and 44.4% PR rate of AVALANCHE.
Sandler et al (24) reported that women had significantly 
lower OS in the E4599 trial. They, however, also stated that 
this difference could be the result of imbalances of treatment 
regiments or baseline prognostic factors between the two 
groups (24). The AVAiL studies (26) and our AVALANCHE 
trial, on the other hand, found comparable results between 
women and men. Women had longer PFS and OS than men in 
the AVALANCHE, however, only OS was on the boundary of 
significance (P=0.071). Although, OS was reported higher in 
both AVAiL studies and the AVALANCHE trial, this survival 
advantage of women can also be accounted for by the gener-
ally longer survival of women with lung cancer that has been 
previously reported in statistical reports (1,30).
As for the patients' age, nearly 10% of the patient popula-
tion with evaluable data were over 70 years of age and no 
significant difference was found between the two groups 
regarding PFS. Surprisingly, however, OS was reported 
to be longer in patients over 70 years of age, although this 
difference was not significant.  Contrary to our findings, the 
E4599 study found that patients older than 65 years of age 
had a significantly higher HR for death and suggested that 
these patients might not benefit from BEV treatment (24). 
The AVAiL studies reported similar HRs for OS in both 
groups. One concern in previous studies was that the risk of 
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the E4599, nor the AVAiL studies nor the SAiL study back 
up this hypothesis (31).
We observed higher PFS and OS in patients with an ECOG 
status of 0 at enrolment, although only OS showed a significant 
difference. This result is not surprising in light of the fact that 
ECOG performance status is an important prognostic factor in 
lung cancer (32-35). Of note, the E4599 and the AVAiL studies 
did not find a significant difference in the HR for OS between 
the ECOG 0 and the ECOG 1 group (24,26).
Johnson et al (22) assumed that central tumour loca-
tion might cause pulmonary haemorrhage more often thus 
decreasing the OS. However, this was not supported by subse-
quent data. Neither SAiL, nor ARIES showed significantly more 
pulmonary bleeding with centrally located tumours (36,37). 
Based on a retrospective analysis of the E4599 study data, 
Sandler et al (38) suggested that pulmonary haemorrhage was 
connected to cavitation of NSCLC instead of central location. 
Further studies did not support this assumption. Our data do 
not reinforce any of these suggestions. Neither the PFS, nor 
the OS was significantly longer with central tumours, and 
cavitated tumours were not assessed separately.
Although previous chemo‑ or radiotherapy did not influ-
ence PFS or OS, we found significantly longer PFS and OS in 
the patient group that underwent surgery before enrolment in 
this study. There is no available data to back up this finding. 
The most probable reason behind it is that the number of cancer 
sites is lower in these patients. Further assessment would be 
needed to draw further conclusions.
Platinum based chemotherapy has been shown in multiple 
studies to result in a small but significant survival benefit when 
compared to supportive care (39,40). The most commonly used 
platinum derivatives are cisplatin and carboplatin. Neither of 
the above mentioned two drugs were associated with higher 
PFS, OS or lower toxicity when compared to each other (41-46). 
Interestingly, patients treated with cisplatin were found to have a 
longer OS (16.953±1.775 months) than those receiving carbopl-
atin (OS: 12.977±1.692 months). The statistical difference was on 
the boundary of significance (P=0.06). Santana‑Davila et al (42) 
showed that oncologists more often administered cisplatin 
to relatively younger patients with less comorbidities. This 
could be a reason for the longer OS. However, it has also been 
Table IV. Summary of the adverse events reported in the 
present study.







Chest pain 5 (3.2)
Acute bronchitis 4 (2.6)
Weight loss 4 (2.6)
Bone pain 3 (2)
Diarrhea 3 (2)
Pulmonary embolism 3 (2)
Hemoptysis 3 (2)
Hyponatremia 3 (2)









Throat pain 2 (1.3)
Lung abscess 1 (0.7)
Agranulocytosis 1 (0.7)
Acute osteomyelitis (jaw) 1 (0.7)
Allergic dermatitis 1 (0.7)
Allergic reaction 1 (0.7))
Hip pain (right‑sided) 1 (0.7)
Decubitus 1 (0.7)
Dermatitis (forehead, back) 1 (0.7)
Dermatitis (generalized) 1 (0.7)
Cholesterol increased  1 (0.7)
Exsiccosis 1 (0.7)
Ulcer (in the mouth, tongue) 1 (0.7)
Gastroesophageal reflux disease 1 (0.7)
Weakness 1 (0.7)
Vomiting 1 (0.7)
Abdominal pain 1 (0.7)
Ileus 1 (0.7)
Ischemic cerebral vascular lesions 1 (0.7)
Arthralgia 1 (0.7)
Swelling of arm 1 (0.7)
Hand swelling 1 (0.7)
Leg swelling 1 (0.7)
Laryngotracheitis 1 (0.7)
Febrile neutropenia 1 (0.7)
Prostration 1 (0.7)
Leukopenia 1 (0.7)
Breast swelling 1 (0.7)
Table IV. Continued.
Adverse event n (%)
Esophageal ulcer 1 (0.7)
Duodenal ulcer 1 (0.7)
Suffusion without trauma 1 (0.7)
Dizziness 1 (0.7)
Thrombosis (left femoral vein) 1 (0.7)
Uremia 1 (0.7)
Urticaria 1 (0.7)
Iron deficiency 1 (0.7)
Bleeding following superficial injury 1 (0.7)
Clear‑cell renal carcinoma 1 (0.7)
Numbness (of the soles) 1 (0.7)
DOI:10.14753/SE.2020.2414












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































ONCOLOGY LETTERS  17:  1750-1760,  20191758
shown that morbidity is higher in patients receiving cisplatin 
and they experience a higher need for health care (42).
Our patients receiving BEV maintenance therapy showed 
significantly higher PFS and OS, which correlates with 
previous results published by Reck et al (25). In addition, 
Dranitsaris et al (47) found that BEV maintenance therapy 
contributed to a significant OS benefit. In the Phase IIIB AvaALL 
study, BEV was administered even after disease progression. A 
significantly higher PFS of 10.1 months was achieved in this 
experimental arm compared to the control arm where only 
supportive care was used after disease progression (48). There 
are several trials debating whether BEV or BEV with peme-
trexed is more effective for maintenance therapy. AVAPERL 
and POINTBREAK, two phase III trials designed to evaluate 
BEV maintenance therapy with or without pemetrexed, showed 
significantly longer PFS, however the difference regarding OS 
was not significant in either of them (49,50).
Our rate of reported adverse events falls behind that of 
expected based on previous trials. Lynch et al (28) reported 
that in the ARIES trial 19.7% of patients experienced one or 
more protocol‑specified adverse event, which is somewhat 
lower than the 20.8% of patients reported in AVALANCHE. 
However, when looking at the serious adverse events, the 10.9% 
reported in ARIES is appreciably higher than the 0.5% reported 
in AVALANCHE. Notably, the study protocols can vary in the 
qualification of serious adverse events. Crinò et al (29) reported 
a rate of 38% for serious adverse events, although only 13% was 
deemed related to BEV by the investigators. There is a special 
interest in similar studies regarding pulmonary bleeding, one 
of the most common serious adverse event following BEV 
therapy. AVAiL 7.5 mg/kg, AVAiL 15 mg/kg, E4599, ARIES 
and SAiL reported 4, 5, 4.7, 4.1 and 9.5% for the prevalence of 
any grade pulmonary haemorrhage, respectively. In contrary 
to this, pulmonary haemorrhage only occurred in 2 patients 
(0.7%) in AVALANCHE.
In summary, patients in Hungary commonly receive 
BEV for advanced NSCLC in combination with a range of 
chemotherapeutics. Despite the less strictly selected patient 
population and treatment regimens survival outcomes and 
treatment response rates are comparable with those of the 
previous large RCT (randomised clinical trials). In our study, 
both PFS and OS were significantly longer and ORR signifi-
cantly higher in patients who received BEV maintenance 
therapy. The adjuvant/neoadjuvant chemotherapy or radio-
therapy received prior to enrolment, the localization of the 
primary tumour, the presence of metastases or the age of the 
patient had no influence on the efficacy of BEV treatment. On 
the other hand, previous surgery and cisplatin chemotherapy 
were associated with better outcomes. We also found low rates 
of adverse events and acceptable safety profile.
The study design did not allow the comparison of PFS and 
OS assessed in the study, with placebo or any active compar-
ator, and the comparative assessment of the significance of the 
prognostic factors studied, either. Due to the high censoring 
rate, the median OS could not be determined after the closure 
of the study; therefore, a retrospective data collection was 
required.
The Avalanche study, like most OCSs had limitations such 
as reporting errors, missing data, potential biases regarding 
data entry and confoundment. In this study, reporting centres 
were asked to enrol all eligible patients to reduce selection 
bias, however, unintended selection bias cannot be excluded. 
All known strong confounders were collected and analysed 
to reduce confounding bias. Clinical reporting errors were 
reduced by systematic data reviews occurring every 3 months.
A further limitation of the current study was that in 12/40 
planned sites, due to their lower patient turnover, we did not 
identify eligible patients within the recruiting period. Thus, 
representing the real life setting, not all centres enrolled 
patients and there were also smaller centres where fewer 
patients were recruited.
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Abstract: Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the 
treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC 
and its role in promoting angiogenesis has been well established, its prognostic and predictive role 
in the above setting remains unclear. The association between KRAS exon 2 mutational status and 
clinicopathological variables including progression-free survival and overall survival (PFS and OS, 
respectively) was retrospectively analyzed in 501 Caucasian stage IIIB-IV LADC patients receiving 
first-line platinum-based chemotherapy (CHT) with or without bevacizumab (BEV). EGFR 
(epidermal growth factor receptor)-mutant cases were excluded. Of 247 BEV/CHT and 254 CHT 
patients, 95 (38.5%) and 75 (29.5%) had mutations in KRAS, respectively. KRAS mutation was 
associated with smoking (p = 0.008) and female gender (p = 0.002) in the BEV/CHT group. We found 
no difference in OS between patients with KRAS-mutant versus KRAS wild-type tumors in the 
CHT-alone group (p = 0.6771). Notably, patients with KRAS-mutant tumors demonstrated 
significantly shorter PFS (p = 0.0255) and OS (p = 0.0186) in response to BEV/CHT compared to KRAS 
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wild-type patients. KRAS mutation was an independent predictor of shorter PFS (hazard ratio, 
0.597; p = 0.011) and OS (hazard ratio, 0.645; p = 0.012) in the BEV/CHT group. G12D KRAS-mutant 
patients receiving BEV/CHT showed significantly shorter PFS (3.7 months versus 8.27 months in the 
G12/13x group; p = 0.0032) and OS (7.2 months versus 16.1 months in the G12/13x group; p = 0.0144). 
In this single-center, retrospective study, KRAS-mutant LADC patients receiving BEV/CHT 
treatment exhibited inferior PFS and OS compared to those with KRAS wild-type advanced LADC. 
G12D mutations may define a subset of KRAS-mutant LADC patients unsuitable for antiangiogenic 
therapy with BEV. 
Keywords: bevacizumab; non-small-cell lung cancer; advanced-stage lung adenocarcinoma; 
platinum-based chemotherapy; KRAS mutation 
 
1. Introduction 
The KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) protein, encoded by the 
KRAS proto-oncogene, is a small GTPase (guanosine triphosphatase) that plays a key role in 
regulating various cell functions [1]. Alterations of the KRAS gene are typically missense mutations 
that can lead to the oncogenic conversion of KRAS resulting in the constitutive activation of its 
effector pathways and thus cancer development and progression [2]. KRAS is frequently mutated in 
pancreatic and colorectal cancer (CRC), and in lung adenocarcinoma (LADC). With an incidence of 
up to 30%, KRAS mutation is the most common driver mutation in LADC. The most prevalent G12C 
and G12V KRAS mutation subtypes are associated with smoking, while the G12D subtype has been 
observed in those who have never smoked [3,4]. Several other rare mutations of KRAS codon 12, 13, 
and 61 have also been reported [3]. 
The prognostic and predictive power of the KRAS mutation in non-small-cell lung cancer 
(NSCLC) patients remains controversial. It was first reported in the late 1980s that KRAS mutation is 
associated with poorer survival [5,6], and since then several groups confirmed these findings [7,8]. 
However, most of these studies were rather heterogeneous in terms of histology, tumor stage, and 
methodologies of KRAS mutation detection. Although two different meta-analyses concluded that 
KRAS mutation is a negative prognosticator in LADC [9,10], the most comprehensive study of more 
than 1500 NSCLC patients (including 300 KRAS-mutant cases) from four trials of adjuvant 
chemotherapy (CHT) reported that KRAS mutation had no clear prognostic or predictive relevance 
with regards to response to CHT [11]. 
Previously, our group performed a mutation subtype-specific analysis of 505 stage III–IV LADC 
patients treated with platinum-based CHT and found that there were no significant differences in 
progression-free survival (PFS) and overall survival (OS) among patients with wild-type (WT), codon 
12, and codon 13 KRAS mutations. Importantly, however, G12V KRAS-mutant patients tended to 
have a higher response rate and a modestly longer median PFS [12]. 
The importance of subtype-specific KRAS mutation analysis was further highlighted in the 
preclinical study of Garassino et al. These authors investigated the role of different KRAS mutation 
subtypes (G12C, G12V, and G12D) in the in vitro chemosensitivity of human NSCLC cells and found 
that the expression of G12C was associated with a reduced response to cisplatin and an increased 
sensitivity to taxol and pemetrexed. In the same study, G12D mutation led to resistance to taxol and 
sensitivity to sorafenib, whereas the G12V mutation sensitized the cells to cisplatin [13]. 
Increased expression and the negative prognostic role of vascular endothelial growth factor 
(VEGF, the key angiogenic cytokine) have been reported in most solid tumors including NSCLC [14] 
[15]. Several phase 2 and 3 clinical trials demonstrated that the addition of bevacizumab (BEV, a 
humanized monoclonal antibody against the VEGF-A isoform) to CHT improves the PFS and OS of 
NSCLC patients [16–20]. Accordingly, BEV in combination with platinum-based CHT was approved 
for the first-line treatment of patients with advanced-stage NSCLC by the FDA (U.S. Food and Drug 
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Administration) and the EMA (European Medicines Agency) in 2006 and 2007, respectively. The 
efficacy of BEV in a real-life setting in Hungary was shown in the Avalanche study [21]. 
Although the RAS/RAF/MEK/ERK signaling pathway has been implicated in the regulation of 
VEGF expression and angiogenesis [22], only a few studies have investigated the effect of KRAS 
mutation on the efficacy of BEV therapy. Most studies focused on CRC, where the addition of BEV 
to CHT prolonged survival regardless of KRAS mutational status [23–26]. Two different groups, 
however, demonstrated that G12V, G12A [27], and G12D [28] KRAS mutations are associated with 
poor outcome in metastatic CRC patients receiving BEV. As for nonsquamous NSCLC, in a phase 2 
trial evaluating the addition of neoadjuvant BEV to CHT, Chaft et al. found that no patient (0 out of 
10) with KRAS mutation showed a pathological response to neoadjuvant BEV/CHT, in comparison 
to 11 of 31 KRAS WT patients [29]. In another small study of stage IV NSCLC, BEV therapy was 
associated with improved OS and PFS in KRAS WT (n = 26), but not in KRAS-mutant (n = 16) patients 
[30]. Here, we report the results of the first study, to our knowledge, of amino acid substitution-
specific KRAS mutational status analysis in a large cohort of BEV/CHT-treated stage III‒IV Caucasian 
patients. 
2. Results 
2.1. Incidence of KRAS Mutations in LADC Patients Treated with Bevacizumab and Chemotherapy 
All patients had advanced LADC and Caucasian background. Patients with tumors harboring 
an EGFR mutation were excluded. One hundred and seventy patients of the full cohort of 501 cases 
were identified as KRAS-mutant (33.9%) and 331 (66.1%) as KRAS WT (see Table 1A,B). While 38.5% 
(n = 95) of the patients treated in the BEV/CHT group were KRAS-mutant (Table 1A), in the CHT 
group (Table 1B) this ratio was 29.5% (n = 75) (p = 0.012). There were no significant differences 
between the BEV/CHT and CHT groups with respect to age (p = 0.193), smoking status (p = 0.072), 
gender (p = 0.506), and tumor stage (p = 0.610) (data not shown). The only difference was seen in 
performance status (PS): there were more ECOG (Eastern Cooperative Oncology Group) 0 (vs. EVOG 
1) patients in the BEV/CHT group than in the CHT-alone group (p = 0.031; data not shown), which 
might be due to the BEV selection criteria. In the BEV/CHT subcohort, 35 (36.8%), 19 (20%), and 20 
(21%) cases were classified as G12C, G12D, and G12V mutants, respectively (Table S1). Other rare 
(i.e., n < 3) KRAS exon 2 mutation subtypes (G12A, G12R, G12S, G13C and G13D) were also found in 
the BEV group. Subtype-specific mutations were technically not assessable in 21 cases (Table S1). 
Table 1. Patient characteristics in the bevacizumab/chemotherapy (BEV/CHT) and chemotherapy 
(CHT) groups. 
 No. of 
Patients (%) 
 KRAS Status 
p-value a 
      Wild type (%) Mutant (%) 
A. BEV/CHT 
All patients 
          
247   152 (61.5%) 95 (38.5%)   
Age (years) b   
Median: 62 58 
0.09 SD*: 9.2 8.2 
Range: 53 44 
Smoking c           
Never-smoker 30 (12%)   24 6 
0.008 
Ever-smoker 167 (68%)   93 74 
No data (n = 50)           
Gender c           
Female 106 (43%)  52 54 0.002 
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Male 141 (57%)  100 41 
ECOG c           
0 139 (56%)   87 52 
0.056 1 108 (44%)   65 43 
Stage c           
III 55 (22%)  38 17 
0.16 IV 192 (78%)  114 78 
Survival d           
Median PFS (months)     8.63 7.03 0.0255 
Median OS (months)     21.57 14.23 0.0186 
B. CHT 
All patients 254 
  
179 (70.5%) 75 (29.5%)   
  
Age (years) b  
Median: 63 61 
0.297 SD *: 7.8 8.7 
Range: 46 46 
Smoking c           
Never-smoker 21 (8%)   15 6 
0.435 
Ever-smoker 188 (74%)   135 53 
No data (n = 45)           
Gender c       
Female 118 (46.5%)  79 39 
0.27 Male 136 (53.5%)  100 36 
ECOG           
0 128 (50.5%)   94 34 
0.335 1 126 (49.5%)   85 41 
Stage       
III 66 (26%)  44 22 
0.351 IV 188 (74%)  135 53 
Survival d,e           
Median OS (months)     11 10 0.6771 
a p value is calculated between wild type and all mutant groups, b Mann‒Whitney test is used in case 
of continuous variable (age) as the data are not normally distributed (Shapiro‒Wilk test), c Fisher’s 
exact test is used between categorical variables, d survival difference between the wild type and the 
mutant group was calculated using log rank regression analysis, e PFS was not determined in the CHT 
group, * SD: standard deviation, BEV/CHT: bevacizumab/chemotherapy, KRAS: V-Ki-ras2 Kirsten rat 
sarcoma viral oncogene homolog, ECOG: Eastern Cooperative Oncology Group, PFS: progression-
free survival, OS: overall survival. 
In order to study the clinical relevance of KRAS mutations, we performed comparative statistical 
analyses of KRAS status and clinicopathological variables in both the BEV/CHT (Table 1A) and the 
CHT subcohorts (Table 1B). As for the BEV/CHT group, ever-smoking and KRAS mutational statuses 
showed a significant positive association (p = 0.008; see Table 1A). KRAS mutation was also 
significantly more common in female BEV/CHT patients (vs. males; p = 0.002; see Table 1A). ECOG 
status and clinical stage did not differ significantly between KRAS-mutant and KRAS WT patients in 
the BEV/CHT group (p = 0.056 and p = 0.16, respectively; see Table 1A). The presence of KRAS 
mutation was not associated with age in the BEV/CHT group (p = 0.09; see Table 1A). Of note, we did 
not detect significant associations of KRAS mutational status with age, smoking status, gender, 
ECOG status, stage, or OS in the CHT group (Table 1B). While the reasons for the differences in the 
associations between KRAS mutational status and clinicopathological variables in the BEV/CHT vs. 
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the CHT subcohorts are not entirely clear, a possible explanation is that they are due to the selection 
criteria for BEV therapy. 
2.2. The Presence of KRAS Mutations has Clinical Utility in Predicting Disease Outcome in LADC Patients 
Receiving Concurrent Antiangiogenic and Chemotherapy 
As expected, patients in the BEV/CHT group had significantly longer median OS than those 
receiving CHT only (p < 0.0001, log-rank test; Figure S2). This difference was even more remarkable 
when only KRAS WT patients were compared (p < 0.0001, log-rank test; see Figure 1A). Notably, the 
addition of BEV to CHT was also associated with a significant benefit in OS if KRAS-mutant patients 
were compared with those in the CHT-alone subcohort (p = 0.0002, log-rank test; see Figure 1A). 
 
Figure 1. Kaplan‒Meier plots for the overall survival (OS) (A) and progression-free survival (PFS) (B) 
in lung adenocarcinoma (LADC) patients according to V-Ki-ras2 Kirsten rat sarcoma viral oncogene 
homolog (KRAS) mutation status. (A) LADC patients with KRAS wild-type (WT) tumors and 
receiving bevacizumab/chemotherapy (BEV/CHT) had significantly increased median OS (vs. those 
with KRAS WT tumors and receiving CHT only; median OS 21.57 vs. 14.23 months, respectively, p = 
0.0186, log-rank test). Median OS was also increased in KRAS-mutant LADC patients receiving 
BEV/CHT compared to those treated with CHT only (median OSs were 18 vs. 10 months, respectively, 
p = 0.0002, log-rank test). No significant differences in OS have been observed for patients receiving 
CHT only and with KRAS WT versus KRAS-mutant tumors (median OSs were 11 vs. 10 months, 
respectively p = 0.6771, log-rank test). Of note, in the BEV/CHT group, patients with KRAS WT LADC 
had a significantly better OS than those with tumors harboring KRAS mutations (median OSs were 
39 vs. 18 months, respectively, p = 0.0186, log-rank test). (B) Similarly, in the BEV/CHT group, patients 
with KRAS WT LADC had significantly longer median PFS (vs. those with KRAS-mutant tumors; 
median PFSs were 8.63 vs. 7.03 months, respectively, p = 0.0255, log-rank test). 
We next investigated whether the KRAS mutational status influences the efficacy of CHT with 
or without BEV in advanced LADC. There was no difference in OS between patients with KRAS-
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mutant versus KRAS WT tumors in the CHT-alone group (p = 0.6771, log-rank test; see Figure 1A). 
Importantly, however, in the BEV/CHT group we found that KRAS-mutant LADC patients had a 
significantly shorter median PFS and OS than did KRAS WT patients (p = 0.0255 and p = 0.0186, 
respectively, log-rank test; see Figures 1A,B). In support of this, multivariate Cox regression analyses 
revealed that KRAS status (mutant vs. WT) at diagnosis influenced OS (hazard ratio (HR) 0.645, 95% 
confidence interval (CI) 0.458‒0.908, p =  0.012) and PFS (HR 0.597, 95% CI 0.402‒0.887, p =  0.011) 
independently from age (continuous; P values were 0.081 and 0.628, respectively), gender (female vs. 
male; p values were 0.005 and 0.001, respectively), smoking status (never vs. ever; p values were 0.907 
and 0.835, respectively), ECOG PS (0 vs. 1; P values were 0.193 and 0.177, respectively) and tumor 
stage (III. vs. IV; p values were 0.048 and 0.617, respectively; see Table 2). These analyses also 
identified more advanced tumor stage as a significant independent negative prognostic factor for OS, 
but not for PFS (p values were 0.048 and 0.617, respectively; see Table 2). Gender proved to be an 
independent prognosticator for both OS and PFS in a multivariate Cox regression model as well (p 
values were 0.005 and 0.001, respectively; see Table 2). 
Table 2. Clinicopathological variables and progression-free survival (PFS) and overall survival (OS) 
of lung adenocarcinoma (LADC) patients treated with bevacizumab/chemotherapy (BEV/CHT) in the 
multivariate Cox proportional hazards model. 
Clinicopathological Variables PFS OS 
Age (continuous)   
HR 0.628 0.978 
95% CI 0.966–1.021) (0.955–1.003) 
p 0.628 0.081 
Gender (female vs. male)  
HR 0.248 0.390 
95% CI (0.125–0.494) (0.203–0.751) 
p 0.001 0.005 
Smoking (never- vs. ever-smokers)  
HR 0.944 0.968 
95% CI (0.548–1.626) (0.562–1.669) 
p 0.835 0.907 
ECOG PS (0 vs. 1)  
HR 0.765 0.772 
95% CI (0.518–1.129) (0.523–1.140) 
p 0.177 0.193 
Stage (III vs. IV)   
HR 0.879 0.603 
95% CI (0.531–1.455) (0.365–0.996) 
p 0.617 0.048 
KRAS status (WT vs. mutant)  
HR 0.597 0.645 
95% CI (0.402–0.887) (0.458–0.908) 
p 0.011 0.012 
HR, hazard ratio; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status. 
2.3. Distinct Efficacy of BEV/CHT in Advanced LADC Patients with Different Subtype-Specific KRAS 
Mutations 
Next, we looked at the clinicopathological characteristics of KRAS codon 12-mutant LADC 
patients receiving BEV/CHT and performed a statistical analysis on their associations with amino 
acid-specific mutational status. We identified 35 (36.8%) G12C, 19 G12D (20%), 20 G12V (21%), three 
G12A (3.2%%), one G12S (1%), one G12R (1%), three G13D (3.1%), and one G13C (1%) cases. 
Significant associations of subtype-specific KRAS mutational status with age, smoking status, gender, 
ECOG PS, or tumor stage were not detected (Table S1). Importantly, patients with KRAS G12D 
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mutant tumors had a significantly shorter OS than those presenting with KRAS WT or with other 
KRAS codon 12 or 13 mutant (G12/13x) tumors (p = 0.0223 and p = 0.0144, respectively; log-rank test; 
see Figure 2A). In line with the OS data, KRAS G12D mutation conferred a significant disadvantage 
for PFS compared with KRAS WT (p < 0.0001; log-rank test; see Figure 2B) or all the other codon 12 
or 13 KRAS (G12/13x) mutations (p = 0.0032; log-rank test; see Figure 2B). Of note, the OS of G12D 
KRAS-mutant patients in the BEV/CHT group was comparable to that of patients in the CHT-alone 
subcohort (Figure S3). 
 
Figure 2. Kaplan‒Meier plots for the OS (A) and PFS (B) in LADC patients receiving BEV/CHT 
according to subtype-specific codon 12 KRAS mutations. (A) KRAS G12D mutation was associated 
with significantly shorter OS in LADC patients (vs. KRAS G12x and 13x mutations or WT KRAS; 
median OSs were 7.2, 16.1, and 21 months, respectively, p values were 0.0144 and 0.0223, respectively, 
log-rank test). (B) LADC patients with tumors harboring KRAS G12D mutations had also significantly 
shorter median PFS than those with other codon 12 (G12x) and 13 (G13x) KRAS-mutant or with KRAS 
WT tumors (median PFSs were 3.7, 8.27, and 11.7 months, respectively; p values were 0.0032 and 
<0.0001, respectively; log-rank test). 
3. Discussion 
Although KRAS is the most frequently mutated oncogene in NSCLC, our knowledge on the 
effect of KRAS mutation on the response to BEV in lung cancer is very limited. Biomarkers of BEV 
efficacy including imaging markers and circulating levels of angiogenic cytokines have been tested 
in both preclinical and clinical studies. For instance, VEGF levels in immunodepleted plasma of 
cancer patients were found to be significantly reduced following BEV treatment [31]. However, 
VEGF-A, as measured using an Enzyme-linked immunosorbent assay that recognizes all VEGF-A 
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isoforms, was not predictive in a comprehensive evaluation of four phase III trials of BEV in CRC, 
NSCLC, and renal cancer [32]. Interestingly, recent data suggest use of TP53 (tumor protein 53) status 
as a biomarker for the response to BEV in NSCLC [33,34]. Nevertheless, as in other solid tumor types, 
a reliable biomarker to identify patients with LADC who will benefit from BEV is yet to be 
discovered. Here we analyzed the KRAS exon 2 mutational status in a large Caucasian patient cohort 
(n = 501) with stage III–IV, EGFR WT LADC treated with platinum-based chemotherapy alone or in 
combination with BEV. 
In the current LADC cohort, 33.9% of the patients had a KRAS mutation. The incidence of KRAS 
mutations was higher in the BEV/CHT-treated group as compared to the CHT group (38.5% vs. 
29.5%, respectively, p = 0.012). With an incidence of 36.8%, G12C was the most frequent subtype in 
the BEV/CHT group, followed by the G12V (21.1%) and G12D (20%) subtypes. Other rare mutational 
subtypes (i.e., G12A, G12R, G12S, G13C, and G13D) were identified in 22.1% of the patients. These 
findings are in line with data previously reported by us and others in large NSCLC studies [12,35]. 
Next, we investigated whether the KRAS mutational status had an effect on the response to BEV. 
Although KRAS status had no impact on the OS of LADC patients receiving CHT alone, in the 
BEV/CHT group patients with a KRAS mutation had a significantly shorter OS. Multivariate analysis 
also confirmed the role of KRAS as a negative predictor of response to BEV. In lung cancer, so far 
only two studies have addressed the impact of KRAS mutation on the efficacy of BEV. The results 
from both of these studies are in line with our data. Chaft et al. treated 50 stage IB‒IIIA NSCLC 
patients in the neoadjuvant setting in combination with CHT and evaluated their pathological 
response [36]. None of the 10 KRAS-mutant patients responded, in comparison to 11 of 31 KRAS WT 
cases. Although these authors administered BEV in combination with CHT, based on our current 
data and also on previous reports from our group and others, the efficacy of CHT is not affected by 
KRAS status in NSCLC [11,12]. Thus, the better response rate in the KRAS WT group of the Chaft 
study can be attributed to BEV and not to CHT [29]. In further support of this, Brady et al. studied 93 
stage IV NSCLC patients receiving CHT alone or in combination with BEV and observed that, while 
CHT was as effective in KRAS WT patients as in those with KRAS-mutant tumors, BEV improved 
OS and PFS in patients with KRAS WT, but not those with KRAS-mutant tumors [30]. 
Mechanisms of resistance to antiangiogenic agents such as BEV include hypoxia-mediated 
mechanisms [37], the downregulation of target receptors and the activation of compensatory 
angiogenic pathways [38–40], proangiogenic hematopoietic or endothelial progenitor cell release 
from the bone marrow [41], inadequate intratumoral distribution of antiangiogenic drugs [42], and a 
switch from endothelial sprouting to a nonangiogenic vascularization mechanism such as vessel 
cooption (a frequently occurring vascularization pattern in primary and secondary lung tumors that 
mediates resistance to anti-angiogenic therapy) [43–46].) It is not completely clear, though, whether 
and how KRAS mutation can contribute to these resistance mechanisms. Notably, however, tumor 
spread through air spaces (STAS) [47] and “tumor islands” [48] are closely related morphological 
features to vessel cooption [49] and were found to be significantly associated with KRAS mutations 
in NSCLC [47,48]. Moreover, mutant KRAS has been shown to induce the expression of VEGF in 
transformed fibroblasts or epithelial cells in vitro. KRAS mutation led to the increased expression of 
other angiogenic growth factors such as TGF (transforming growth factor)-beta and alpha [50]. 
Elevated VEGF mRNA levels were detected in tumor cell lines expressing mutant KRAS [51]. Genetic 
disruption of the mutant KRAS allele in human colon carcinoma cells resulted in decreased VEGF 
secretion [51]. The transfection of human pancreatic epithelial cells with KRAS12V induced the 
expression of VEGF and CXC (C-X-C motif) chemokines through Erk and c-Jun signaling and 
enhanced endothelial tube formation in co-cultures, which could be inhibited by CXC receptor 2 or 
VEGF targeting [52]. Lastly, doxycycline withdrawal led to tumor regression and endothelial 
apoptosis in a doxycycline-inducible RAS (rat sarcoma)-driven INK4a (inhibitor of cyclin-dependent 
kinase 4a) deficient murine model of melanoma [22]. 
In CRC patients receiving BEV, results on associations between KRAS mutational status and 
outcome have been inconsistent, with a larger number of studies reporting no associations 
[23,25,26,53,54] than those demonstrating significant associations [27,28]. Interestingly, however, in a 
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recent CRC study, Fiala et al. demonstrated that G12V and G12A mutation were predictors of shorter 
PFS and OS, while patients with tumors harboring other KRAS mutations had a similar outcome to 
those with KRAS WT tumors [27]. Notably, another group reported that the presence of a KRAS 
G12D mutation was significantly associated with poorer outcome in CRC patients receiving BEV-
containing regimens [55]. As for NSCLC, Scheffler et al. recently found that patients with KRAS G12D 
mutation exhibit a high frequency of co-occurring mutations in the angiogenesis-associated PDGF 
(platelet-derived growth factor receptor)/PDGF-receptor pathway [56]. In line with this, among the 
three major codon 12 KRAS mutation subtypes (G12C, G12V, and G12D) G12D proved to be a 
predictor of poor outcome in our BEV/CHT subcohort. Patients with LADC harboring this mutation 
had significantly worse PFS and OS than those with tumors harboring other KRAS mutations or WT 
KRAS. 
The biological importance of KRAS mutational subtypes has been demonstrated in a study by 
Figueras et al., who introduced either a codon 12 or a codon 13 KRAS mutation into NIH3T3 cells 
and analyzed the VEGF levels and the activity of VEGF promoter in these transfected sublines. 
Despite the lower VEGF expression, codon 12 mutant tumors exhibited a higher microvessel density, 
while tumors harboring the codon 13 mutation developed angiogenic sprouts with larger diameters 
[57]. 
In our cohort, only two patients carried a codon 13 mutation of KRAS, so we could not evaluate 
the BEV response in this subgroup. Nevertheless, our study suggests that specific KRAS mutation 
subtypes can have a major impact on tumor vascularization and, potentially, on the response to anti-
angiogenic treatment. 
Like all retrospective analyses, our study has limitations. First, although we excluded patients 
with EGFR-mutant tumors from our study, we did not analyze KRAS-WT patients for additional 
oncogenic driver mutations. Second, we did not study KRAS-mutant patients for co-occurring 
mutations in additional tumor-associated pathways [56]. Third, because this large retrospective 
cohort did not include reliable RECIST (response evaluation criteria in solid tumors) data [58] for all 
patients, we did not investigate the correlation between KRAS mutational status and tumor response 
according to RECIST criteria. Finally, because there is a massive body of literature on the predictive 
and prognostic role of KRAS mutations in CHT-treated LADC patients [9–13,56,58–60] and the main 
aim of the current study was to investigate the relationship between KRAS status and the efficacy of 
BEV, only the OS but not the PFS data were used in our analyses in the CHT-alone subcohort. 
4. Materials and Methods 
4.1. Study Population 
In this single-center, retrospective study, 501 consecutive patients with advanced lung 
adenocarcinoma (LADC) were included and underwent first-line platinum-based (cisplatin or 
carboplatin) doublet chemotherapy (CHT) with or without BEV at the National Korányi Institute of 
Pulmonology, Budapest between 2007 and 2016 (Table 1, Figure S1). The addition of BEV to CHT was 
individually decided by the treating physician in line with the proof-of-concept BEV clinical trials 
[16,18] and with the EMA summary of BEV characteristics. According to our inclusion criteria, 
cytologically or histologically verified unresectable stage IIIB or IV LADC patients were included. 
Patients with uncontrollable hypertension, hypertensive encephalopathy, arterial or grade 4 venous 
thromboembolism, nephrotic syndrome (grade 4 proteinuria), pulmonary bleeding, gastrointestinal 
perforation, need for major surgery, or hypersensitivity to BEV were considered not eligible for BEV 
therapy (Figure S1). 
In the BEV/CHT group (n = 247), platinum was given together with paclitaxel (84.7%) or 
gemcitabine (15.3%). In order to rule out the potential confounding effect of different treatment 
regimens, patients receiving other nonplatinum partners, such as pemetrexed or docetaxel, were 
excluded from the CHT group (n = 254). Additionally, all patients receiving tyrosine‒kinase inhibitors 
in any further line of treatment were excluded. According to the therapy guidelines of the host 
institute, only ECOG PS 0 or 1 LADC patients were included in this study, since higher PS 
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contradicted the use of cytotoxic chemotherapy. Smoking status, TNM stage, and molecular tumor 
characteristics (EGFR and KRAS mutational status) were defined at the time of diagnosis. For the 
calculation of PFS and OS, the date of the first CHT was used. Patients with known EGFR mutations 
were excluded. Clinical follow-up closed on 1 August 2017. The median follow-up was 21 months in 
the BEV/CHT group, and 10 months in the CHT group. The study and all treatments were conducted 
in accordance with the current National Comprehensive Cancer Network guidelines, based on the 
ethical standards prescribed by the Helsinki Declaration of the World Medical Association and with 
the approval of the national level ethics committee that included a waiver for this retrospective study 
(52614-4/2013/EKU). Due to the retrospective study design and the anonymity of the patient records, 
informed consent was not recommended. 
4.2. Molecular Diagnosis 
All mutational analyses were performed at the time of diagnosis at the 2nd Department of 
Pathology of the Semmelweis University, as previously described [12,61,62]. DNA isolation was 
performed from formalin-fixed, paraffin-embedded (FFPE) tissue blocks, cytological specimens of 
primary tumors, or lymphatic or organ metastases (including pleural effusion). 
KRAS exon 2 mutations were identified by microcapillary-based restriction fragment length 
analysis, as previously described [12,61]. Briefly, a tumor-rich microscopic area on H&E staining had 
been determined by pathologists prior to macro dissection from FFPE tissue or cytological smears. 
DNA was extracted using the MasterPure™ DNA Purification Kit (Epicentre Biotechnologies, 
Madison, WI, USA) according to the instructions of the manufacturer. The microfluid-based 
restriction fragment detection system was characterized by 5% mutant tumor cell content sensitivity. 
The density ratio of the mutated band to the WT one was calculated and samples containing >5% of 
the non-WT band were considered mutation-positive due to the sensitivity threshold. The base-pair 
substitutions in the mutant samples were verified and determined by sequencing on the ABI 3130 
Genetic Analyzer System (Life Technologies, Carlsbad, CA, USA) with the BigDye® Terminator v1.1 
Kit. 
4.3. Statistical Methods 
Categorical parameters, such as gender (male vs. female), smoking status (never- vs. ever-
smoker), ECOG PS (0 vs. 1), and KRAS mutation status (KRAS-mutant vs. WT) were statistically 
analyzed by Chi-square test or Fisher’s exact test. Age, as a continuous variable, was analyzed in the 
different KRAS mutational groups by Mann‒Whitney U test as the data were not normally 
distributed in each group (as per the Shapiro‒Wilk normality test). Kaplan‒Meier survival curves 
and two-sided log-rank tests were used for univariate survival analyses. The median follow-up time 
was calculated by using the reverse Kaplan‒Meier approach. The Cox proportional hazards model 
was used for uni- and multivariate survival analyses to detect the impact of both continuous and 
categorical factors and to calculate the hazard ratios (HR) and corresponding 95% confidence 
intervals (CI). For multivariate survival analyses, the Cox regression model was adjusted for age (as 
a continuous variable), gender (female versus male), smoking (never- vs. ever-smoker), ECOG PS (0 
versus 1) and stage (IIIB versus IV). In order to establish potential predictive factors, interaction terms 
were calculated between KRAS status and other variables (age, sex, smoking status, ECOG PS, and 
stage) in the adjusted multivariate Cox regression model. p values are always two-sided and 
considered statistically significant below 0.05. Metric data are always shown as median or mean and 
corresponding range or, in the case of OS and PFS, as median and corresponding 95% CI. All 
statistical analyses were performed using the PASW Statistics 18.0 package (Predictive Analytics 
Software, SPSS Inc., Chicago, IL, USA). Graphs were created with GraphPad Prism 8 (GraphPad 
Software Inc., San Diego, CA, USA). 
5. Conclusions 
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In conclusion, when combined with standard first-line chemotherapy, BEV has led to increased 
OS and thus has been approved in patients with advanced or recurrent nonsquamous NSCLC 
without targetable molecular abnormalities [16,17,19,20,63,64]. However, although serious efforts 
have been made to identify patients responsive to BEV, there is as yet no validated predictive 
biomarker in this field. Here, we present novel evidence for use of BEV in stage III‒IV LADC patients 
with KRAS-mutant tumors- and especially with KRAS G12D-mutant tumors- demonstrating inferior 
activity of this drug compared to that in LADC patients with non-KRAS-mutant tumors. Our data 
may not only help to improve the efficacy of BEV, but, through better patient selection, could also 
help to decrease the unnecessary use of this expensive agent in subgroups of KRAS-mutant human 
LADC patients. 
Supplementary Materials: The following are available online at www.mdpi.com/xxx/s1. Figure S1. Consort 
diagram for advanced LADC cases. Consort diagram to demonstrate the selection of stage IIIB/IV LADC cases 
for BEV/CHT or CHT alone in this study. Where patients were excluded, the reasons for exclusion are indicated. 
Figure S2. Comparison of survival outcomes in patients with advanced LADC according to treatment regimen. 
Advanced LADC patients receiving BEV/CHT showed significantly higher median OS compared to those 
treated with CHT only (median OSs were 24 vs. 10 months, respectively, p < 0.0001, log-rank test). Figure S3. 
Kaplan‒Meier curves for the OS of LADC patients treated with CHTalone and LADC patients with KRAS G12D 
mutations in the BEV/CHT subcohort. Patients with tumors harboring KRAS G12D mutations and treated with 
BEV/CHT had comparable OS to that of patients with KRAS-WT or KRAS-mutant tumors in the CHT-alone 
subcohort. Table S1. Correlation of clinicopathologic features, outcome variables and KRAS codon 12 subtypes 
in patients with advanced LADC treated with BEV (n = 95). 
Author Contributions: Á.K.G., V.L., B.D., B.H., G.O., B.G., J.M., F.R-V., Z.L., M.A.H., T.K., and W.K. analyzed 
and interpreted the data and contributed to the study design. Á.K.G., B.D., and V.L. wrote the manuscript. E.R., 
T.B., and J.T. analyzed the pathological samples. Á.G., E.S., and Z.M. contributed to the data assessment. 
Funding: This work was supported by the Hungarian National Research, Development and Innovation Office 
(KH130356, BD; NVKP-16-1-2016-0020, JT; KH126753, OG) and the Austrian Science Fund (FWF I 3522, VL; FWF 
I 3977, BD).  
Acknowledgments: The authors thank the investigators who collected the data reported here and the Hungarian 
National Research, Development and Innovation Office and the Austrian Science Fund for the financial support. 
The authors take full responsibility for the content of this publication. 
Conflicts of Interest: The authors declare no conflict of interest. 
References 
1. Fernandez-Medarde, A.; Santos, E. Ras in cancer and developmental diseases. Genes Cancer 2011, 2, 
344–358, doi:10.1177/1947601911411084. 
2. O'Bryan, J.P. Pharmacological targeting of RAS: Recent success with direct inhibitors. Pharmacol Res. 
2019, 139, 503–511, doi:10.1016/j.phrs.2018.10.021. 
3. Lindsay, C.R.; Jamal-Hanjani, M.; Forster, M.; Blackhall, F. KRAS: Reasons for optimism in lung cancer. 
Eur. J. Cancer 2018, 99, 20–27, doi:10.1016/j.ejca.2018.05.001. 
4. Timar, J. The clinical relevance of KRAS gene mutation in non-small-cell lung cancer. Curr. Opin. Oncol. 
2014, 26, 138–144, doi:10.1097/CCO.0000000000000051. 
5. Rodenhuis, S.; van de Wetering, M.L.; Mooi, W.J.; Evers, S.G.; van Zandwijk, N.; Bos, J.L. Mutational 
activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N. 
Engl. J. Med. 1987, 317, 929–935, doi:10.1056/NEJM198710083171504. 
6. Slebos, R.J.; Kibbelaar, R.E.; Dalesio, O.; Kooistra, A.; Stam, J.; Meijer, C.J.; Wagenaar, S.S.; 
Vanderschueren, R.G.; van Zandwijk, N.; Mooi, W.J., et al. K-ras oncogene activation as a prognostic 
marker in adenocarcinoma of the lung. N. Engl. J. Med. 1990, 323, 561–565, 
doi:10.1056/nejm199008303230902. 
7. Kern, J.A.; Slebos, R.J.; Top, B.; Rodenhuis, S.; Lager, D.; Robinson, R.A.; Weiner, D.; Schwartz, D.A. C-
erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with 
pulmonary adenocarcinomas. J. Clin. Investig. 1994, 93, 516–520, doi:10.1172/JCI117001. 
DOI:10.14753/SE.2020.2414
Cancers 2019, 11, 1514 12 of 15 
 
8. Mitsudomi, T.; Steinberg, S.M.; Oie, H.K.; Mulshine, J.L.; Phelps, R.; Viallet, J.; Pass, H.; Minna, J.D.; 
Gazdar, A.F. ras gene mutations in non-small cell lung cancers are associated with shortened survival 
irrespective of treatment intent. Cancer Res. 1991, 51, 4999–5002. 
9. Huncharek, M.; Muscat, J.; Geschwind, J.F. K-ras oncogene mutation as a prognostic marker in non-
small cell lung cancer: A combined analysis of 881 cases. Carcinogenesis 1999, 20, 1507–1510. 
10. Mascaux, C.; Iannino, N.; Martin, B.; Paesmans, M.; Berghmans, T.; Dusart, M.; Haller, A.; Lothaire, P.; 
Meert, A.P.; Noel, S., et al. The role of RAS oncogene in survival of patients with lung cancer: a 
systematic review of the literature with meta-analysis. Br. J. Cancer 2005, 92, 131–139, 
doi:10.1038/sj.bjc.6602258. 
11. Shepherd, F.A.; Domerg, C.; Hainaut, P.; Janne, P.A.; Pignon, J.P.; Graziano, S.; Douillard, J.Y.; 
Brambilla, E.; Le Chevalier, T.; Seymour, L., et al. Pooled analysis of the prognostic and predictive 
effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell 
lung cancer in four trials of adjuvant chemotherapy. J. Clin. Oncol. 2013, 31, 2173–2181, 
doi:10.1200/JCO.2012.48.1390. 
12. Cserepes, M.; Ostoros, G.; Lohinai, Z.; Raso, E.; Barbai, T.; Timar, J.; Rozsas, A.; Moldvay, J.; Kovalszky, 
I.; Fabian, K., et al. Subtype-specific KRAS mutations in advanced lung adenocarcinoma: A 
retrospective study of patients treated with platinum-based chemotherapy. Eur. J. Cancer 2014, 50, 
1819–1828, doi:10.1016/j.ejca.2014.04.001. 
13. Garassino, M.C.; Marabese, M.; Rusconi, P.; Rulli, E.; Martelli, O.; Farina, G.; Scanni, A.; Broggini, M. 
Different types of K-Ras mutations could affect drug sensitivity and tumour behaviour in non-small-
cell lung cancer. Ann. Oncol. 2011, 22, 235–237, doi:10.1093/annonc/mdq680. 
14. Gentzler, R.D.; Yentz, S.E.; Patel, J.D. Bevacizumab in advanced NSCLC: chemotherapy partners and 
duration of use. Curr. Treat. Options Oncol. 2013, 14, 595–609, doi:10.1007/s11864-013-0255-3. 
15. Zhan, P.; Wang, J.; Lv, X.J.; Wang, Q.; Qiu, L.X.; Lin, X.Q.; Yu, L.K.; Song, Y. Prognostic value of 
vascular endothelial growth factor expression in patients with lung cancer: A systematic review with 
meta-analysis. J. Thorac. Oncol. 2009, 4, 1094–1103, doi:10.1097/JTO.0b013e3181a97e31. 
16. Sandler, A.; Gray, R.; Perry, M.C.; Brahmer, J.; Schiller, J.H.; Dowlati, A.; Lilenbaum, R.; Johnson, D.H. 
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N. Engl. J. Med. 2006, 
355, 2542–2550, doi:10.1056/NEJMoa061884. 
17. Johnson, D.H.; Fehrenbacher, L.; Novotny, W.F.; Herbst, R.S.; Nemunaitis, J.J.; Jablons, D.M.; Langer, 
C.J.; DeVore, R.F., 3rd; Gaudreault, J.; Damico, L.A., et al. Randomized phase II trial comparing 
bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously 
untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. 2004, 22, 2184–2191, 
doi:10.1200/jco.2004.11.022. 
18. Reck, M.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; 
Archer, V.; Moore, N., et al. Phase III trial of cisplatin plus gemcitabine with either placebo or 
bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J. Clin. Oncol. 
2009, 27, 1227–1234, doi:10.1200/jco.2007.14.5466. 
19. Twelves, C.; Chmielowska, E.; Havel, L.; Popat, S.; Swieboda-Sadlej, A.; Sawrycki, P.; Bycott, P.; 
Ingrosso, A.; Kim, S.; Williams, J.A., et al. Randomised phase II study of axitinib or bevacizumab 
combined with paclitaxel/carboplatin as first-line therapy for patients with advanced non-small-cell 
lung cancer. Ann. Oncol. 2014, 25, 132–138, doi:10.1093/annonc/mdt489. 
20. Patel, J.D.; Socinski, M.A.; Garon, E.B.; Reynolds, C.H.; Spigel, D.R.; Olsen, M.R.; Hermann, R.C.; Jotte, 
R.M.; Beck, T.; Richards, D.A., et al. PointBreak: a randomized phase III study of pemetrexed plus 
carboplatin and bevacizumab followed by maintenance pemetrexed and bevacizumab versus 
paclitaxel plus carboplatin and bevacizumab followed by maintenance bevacizumab in patients with 
stage IIIB or IV nonsquamous non-small-cell lung cancer. J. Clin. Oncol. 2013, 31, 4349–4357, 
doi:10.1200/jco.2012.47.9626. 
21. Tolnay, E.; Ghimessy, Á.; Juhász, E.; Sztancsik, Z.; Losonczy, G.; Dombi, P.; Vennes, Z.; Helf, L.; Csada, 
E.; Sárosi, V. The efficacy and safety of bevacizumab in addition to platinum-based chemotherapy for 
the first-line treatment of patients with advanced nonsquamous non-small-cell lung cancer: Final 
results of AVALANCHE, an observational cohort study. Oncol. Letters 2018, doi:10.3892/ol.2018.9766. 
DOI:10.14753/SE.2020.2414
Cancers 2019, 11, 1514 13 of 15 
 
22. Chin, L.; Tam, A.; Pomerantz, J.; Wong, M.; Holash, J.; Bardeesy, N.; Shen, Q.; O'Hagan, R.; Pantginis, 
J.; Zhou, H., et al. Essential role for oncogenic Ras in tumour maintenance. Nature 1999, 400, 468–472, 
doi:10.1038/22788. 
23. Hurwitz, H.I.; Yi, J.; Ince, W.; Novotny, W.F.; Rosen, O. The clinical benefit of bevacizumab in 
metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of 
bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009, 
14, 22–28, doi:10.1634/theoncologist.2008-0213. 
24. Ince, W.L.; Jubb, A.M.; Holden, S.N.; Holmgren, E.B.; Tobin, P.; Sridhar, M.; Hurwitz, H.I.; Kabbinavar, 
F.; Novotny, W.F.; Hillan, K.J., et al. Association of k-ras, b-raf, and p53 status with the treatment effect 
of bevacizumab. J. Natl. Cancer Inst. 2005, 97, 981–989, doi:10.1093/jnci/dji174. 
25. Bencsikova, B.; Bortlicek, Z.; Halamkova, J.; Ostrizkova, L.; Kiss, I.; Melichar, B.; Pavlik, T.; Dusek, L.; 
Valik, D.; Vyzula, R., et al. Efficacy of bevacizumab and chemotherapy in the first-line treatment of 
metastatic colorectal cancer: Broadening KRAS-focused clinical view. BMC Gastroenterol. 2015, 15, e37, 
doi:10.1186/s12876-015-0266-6. 
26. Stremitzer, S.; Stift, J.; Gruenberger, B.; Tamandl, D.; Aschacher, T.; Wolf, B.; Wrba, F.; Gruenberger, T. 
KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. 
Br. J. Surg. 2012, 99, 1575–1582, doi:10.1002/bjs.8909. 
27. Fiala, O.; Buchler, T.; Mohelnikova-Duchonova, B.; Melichar, B.; Matejka, V.M.; Holubec, L.; 
Kulhankova, J.; Bortlicek, Z.; Bartouskova, M.; Liska, V., et al. G12V and G12A KRAS mutations are 
associated with poor outcome in patients with metastatic colorectal cancer treated with bevacizumab. 
Tumour Biol.: J. Int. Soc. Oncodevelopmental Biol. Med. 2016, 37, 6823–6830, doi:10.1007/s13277-015-4523-
7. 
28. Bruera, G.; Cannita, K.; Di Giacomo, D.; Lamy, A.; Frebourg, T.; Sabourin, J.C.; Tosi, M.; Alesse, E.; 
Ficorella, C.; Ricevuto, E. Worse prognosis of KRAS c.35 G > A mutant metastatic colorectal cancer 
(MCRC) patients treated with intensive triplet chemotherapy plus bevacizumab (FIr-B/FOx). BMC 
Med. 2013, 11, e59, doi:10.1186/1741-7015-11-59. 
29. Chaft, J.E.; Rusch, V.; Ginsberg, M.S.; Paik, P.K.; Finley, D.J.; Kris, M.G.; Price, K.A.; Azzoli, C.G.; Fury, 
M.G.; Riely, G.J., et al. Phase II trial of neoadjuvant bevacizumab plus chemotherapy and adjuvant 
bevacizumab in patients with resectable nonsquamous non-small-cell lung cancers. J. Thorac. Oncol. 
2013, 8, 1084–1090, doi:10.1097/JTO.0b013e31829923ec. 
30. Brady, A.K.; McNeill, J.D.; Judy, B.; Bauml, J.; Evans, T.L.; Cohen, R.B.; Langer, C.; Vachani, A.; 
Aggarwal, C. Survival outcome according to KRAS mutation status in newly diagnosed patients with 
stage IV non-small cell lung cancer treated with platinum doublet chemotherapy. Oncotarget 2015, 6, 
30287–30294, doi:10.18632/oncotarget.4711. 
31. Loupakis, F.; Falcone, A.; Masi, G.; Fioravanti, A.; Kerbel, R.S.; Del Tacca, M.; Bocci, G. Vascular 
endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible 
pharmacodynamic marker for bevacizumab activity. J. Clin. Oncol. 2007, 25, 1816–1818, 
doi:10.1200/JCO.2006.10.3051. 
32. Hegde, P.S.; Jubb, A.M.; Chen, D.; Li, N.F.; Meng, Y.G.; Bernaards, C.; Elliott, R.; Scherer, S.J.; Chen, 
D.S. Predictive impact of circulating vascular endothelial growth factor in four phase III trials 
evaluating bevacizumab. Clin. Cancer Res. 2013, 19, 929–937, doi:10.1158/1078-0432.CCR-12-2535. 
33. Said, R.; Hong, D.S.; Warneke, C.L.; Lee, J.J.; Wheler, J.J.; Janku, F.; Naing, A.; Falchook, G.S.; Fu, S.; 
Piha-Paul, S., et al. P53 mutations in advanced cancers: Clinical characteristics, outcomes, and 
correlation between progression-free survival and bevacizumab-containing therapy. Oncotarget 2013, 
4, 705–714, doi:10.18632/oncotarget.974. 
34. Schwaederle, M.; Lazar, V.; Validire, P.; Hansson, J.; Lacroix, L.; Soria, J.C.; Pawitan, Y.; Kurzrock, R. 
VEGF-a expression correlates with TP53 mutations in non-small cell lung cancer: Implications for 
antiangiogenesis therapy. Cancer Res. 2015, 75, 1187–1190, doi:10.1158/0008-5472.CAN-14-2305. 
35. Martin, P.; Leighl, N.B.; Tsao, M.S.; Shepherd, F.A. KRAS mutations as prognostic and predictive 
markers in non-small cell lung cancer. J. Thorac. Oncol. 2013, 8, 530–542, 
doi:10.1097/JTO.0b013e318283d958. 
36. Chaft, J.E.; Dagogo-Jack, I.; Santini, F.C.; Eng, J.; Yeap, B.Y.; Izar, B.; Chin, E.; Jones, D.R.; Kris, M.G.; 
Shaw, A.T., et al. Clinical outcomes of patients with resected, early-stage ALK-positive lung cancer. 
Lung Cancer 2018, 122, 67–71, doi:10.1016/j.lungcan.2018.05.020. 
DOI:10.14753/SE.2020.2414
Cancers 2019, 11, 1514 14 of 15 
 
37. Rapisarda, A.; Melillo, G. Overcoming disappointing results with antiangiogenic therapy by targeting 
hypoxia. Nat. Rev. Clin. Oncol. 2012, 9, 378–390, doi:10.1038/nrclinonc.2012.64. 
38. Giuliano, S.; Pages, G. Mechanisms of resistance to anti-angiogenesis therapies. Biochimie 2013, 95, 
1110–1119, doi:10.1016/j.biochi.2013.03.002. 
39. Smith, N.R.; Wedge, S.R.; Pommier, A.; Barry, S.T. Mechanisms that influence tumour response to 
VEGF-pathway inhibitors. Biochem. Soc. Trans. 2014, 42, 1601–1607, doi:10.1042/BST20140261. 
40. Jayson, G.C.; Kerbel, R.; Ellis, L.M.; Harris, A.L. Antiangiogenic therapy in oncology: current status 
and future directions. Lancet 2016, 388, 518–529, doi:10.1016/S0140-6736(15)01088-0. 
41. Dome, B.; Timar, J.; Ladanyi, A.; Paku, S.; Renyi-Vamos, F.; Klepetko, W.; Lang, G.; Dome, P.; Bogos, 
K.; Tovari, J. Circulating endothelial cells, bone marrow-derived endothelial progenitor cells and 
proangiogenic hematopoietic cells in cancer: From biology to therapy. Crit. Rev. Oncol. Hematol. 2009, 
69, 108–124, doi:10.1016/j.critrevonc.2008.06.009. 
42. Torok, S.; Rezeli, M.; Kelemen, O.; Vegvari, A.; Watanabe, K.; Sugihara, Y.; Tisza, A.; Marton, T.; 
Kovacs, I.; Tovari, J., et al. Limited tumor tissue drug penetration contributes to primary resistance 
against angiogenesis inhibitors. Theranostics 2017, 7, 400–412, doi:10.7150/thno.16767. 
43. Dome, B.; Hendrix, M.J.; Paku, S.; Tovari, J.; Timar, J. Alternative vascularization mechanisms in 
cancer: Pathology and therapeutic implications. Am. J. Pathol. 2007, 170, 1–15, 
doi:10.2353/ajpath.2007.060302. 
44. Donnem, T.; Reynolds, A.R.; Kuczynski, E.A.; Gatter, K.; Vermeulen, P.B.; Kerbel, R.S.; Harris, A.L.; 
Pezzella, F. Non-angiogenic tumours and their influence on cancer biology. Nat. Rev. Cancer 2018, 18, 
323–336, doi:10.1038/nrc.2018.14. 
45. Frentzas, S.; Simoneau, E.; Bridgeman, V.L.; Vermeulen, P.B.; Foo, S.; Kostaras, E.; Nathan, M.; 
Wotherspoon, A.; Gao, Z.H.; Shi, Y., et al. Vessel co-option mediates resistance to anti-angiogenic 
therapy in liver metastases. Nat. Med. 2016, 22, 1294–1302, doi:10.1038/nm.4197. 
46. Bridgeman, V.L.; Vermeulen, P.B.; Foo, S.; Bilecz, A.; Daley, F.; Kostaras, E.; Nathan, M.R.; Wan, E.; 
Frentzas, S.; Schweiger, T., et al. Vessel co-option is common in human lung metastases and mediates 
resistance to anti-angiogenic therapy in preclinical lung metastasis models. J. Pathol. 2017, 241, 362–
374, doi:10.1002/path.4845. 
47. Warth, A.; Beasley, M.B.; Mino-Kenudson, M. Breaking new ground: The evolving concept of spread 
through air spaces (STAS). J. Thorac. Oncol. 2017, 12, 176–178, doi:10.1016/j.jtho.2016.10.020. 
48. Onozato, M.L.; Kovach, A.E.; Yeap, B.Y.; Morales-Oyarvide, V.; Klepeis, V.E.; Tammireddy, S.; Heist, 
R.S.; Mark, E.J.; Dias-Santagata, D.; Iafrate, A.J., et al. Tumor islands in resected early-stage lung 
adenocarcinomas are associated with unique clinicopathologic and molecular characteristics and 
worse prognosis. Am. J. Surg. Pathol. 2013, 37, 287–294, doi:10.1097/PAS.0b013e31826885fb. 
49. Y. Yagi, R.A., K. Tabata, N. Rekhtman, T. Eguchi, J. Montecalvo, K. Manova, P. Adusumilli, M. 
Hameed, W. Travis. Three-dimensional immunofluorescence analysis of dynamic vessel co-option of 
spread through air spaces (STAS) in lung cancer. J. Thorac. Oncol. 2018, 13, e327, 
https://doi.org/10.1016/j.jtho.2018.08.250. 
50. Rak, J.; Filmus, J.; Finkenzeller, G.; Grugel, S.; Marme, D.; Kerbel, R.S. Oncogenes as inducers of tumor 
angiogenesis. Cancer Metastasis Rev. 1995, 14, 263–277. 
51. Rak, J.; Mitsuhashi, Y.; Bayko, L.; Filmus, J.; Shirasawa, S.; Sasazuki, T.; Kerbel, R.S. Mutant ras 
oncogenes upregulate VEGF/VPF expression: Implications for induction and inhibition of tumor 
angiogenesis. Cancer Res. 1995, 55, 4575–4580. 
52. Matsuo, Y.; Campbell, P.M.; Brekken, R.A.; Sung, B.; Ouellette, M.M.; Fleming, J.B.; Aggarwal, B.B.; 
Der, C.J.; Guha, S. K-Ras promotes angiogenesis mediated by immortalized human pancreatic 
epithelial cells through mitogen-activated protein kinase signaling pathways. Mol. Cancer Res. 2009, 7, 
799–808, doi:10.1158/1541-7786.MCR-08-0577. 
53. Price, T.J.; Hardingham, J.E.; Lee, C.K.; Weickhardt, A.; Townsend, A.R.; Wrin, J.W.; Chua, A.; 
Shivasami, A.; Cummins, M.M.; Murone, C., et al. Impact of KRAS and BRAF gene mutation status on 
outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with 
bevacizumab and mitomycin in advanced colorectal cancer. J. Clin. Oncol. 2011, 29, 2675–2682, 
doi:10.1200/JCO.2010.34.5520. 
54. Masi, G.; Loupakis, F.; Salvatore, L.; Fornaro, L.; Cremolini, C.; Cupini, S.; Ciarlo, A.; Del Monte, F.; 
Cortesi, E.; Amoroso, D., et al. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and 
DOI:10.14753/SE.2020.2414
Cancers 2019, 11, 1514 15 of 15 
 
folinate) as first-line treatment for metastatic colorectal cancer: A phase 2 trial. Lancet. Oncol. 2010, 11, 
845–852, doi:10.1016/S1470-2045(10)70175-3. 
55. Bruera, G.; Cannita, K.; Tessitore, A.; Russo, A.; Alesse, E.; Ficorella, C.; Ricevuto, E. The prevalent 
KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse 
prognosis and potential benefit of bevacizumab-containing intensive regimens? Crit. Rev. Oncol. 
Hematol. 2015, 93, 190–202, doi:10.1016/j.critrevonc.2014.10.004. 
56. Scheffler, M.; Ihle, M.A.; Hein, R.; Merkelbach-Bruse, S.; Scheel, A.H.; Siemanowski, J.; Bragelmann, J.; 
Kron, A.; Abedpour, N.; Ueckeroth, F., et al. K-ras mutation subtypes in NSCLC and associated co-
occuring mutations in other oncogenic pathways. J. Thorac. Oncol. 2019, 14, 606–616, 
doi:10.1016/j.jtho.2018.12.013. 
57. Figueras, A.; Arbos, M.A.; Quiles, M.T.; Vinals, F.; Germa, J.R.; Capella, G. The impact of KRAS 
mutations on VEGF-A production and tumour vascular network. BMC Cancer 2013, 13, e125, 
doi:10.1186/1471-2407-13-125. 
58. Eisenhauer, E.A.; Therasse, P.; Bogaerts, J.; Schwartz, L.H.; Sargent, D.; Ford, R.; Dancey, J.; Arbuck, S.; 
Gwyther, S.; Mooney, M., et al. New response evaluation criteria in solid tumours: Revised RECIST 
guideline (version 1.1). Eur. J. Cancer 2009, 45, 228–247, doi:10.1016/j.ejca.2008.10.026. 
59. Renaud, S.; Guerrera, F.; Seitlinger, J.; Reeb, J.; Voegeli, A.C.; Legrain, M.; Mennecier, B.; Santelmo, N.; 
Falcoz, P.E.; Quoix, E., et al. KRAS-specific amino acid substitutions are associated with different 
responses to chemotherapy in advanced non-small-cell lung cancer. Clin. Lung Cancer 2018, 19, 919–
931, doi:10.1016/j.cllc.2018.08.005. 
60. Ricciuti, B.; Brambilla, M.; Cortellini, A.; De Giglio, A.; Ficorella, C.; Sidoni, A.; Bellezza, G.; Crino, L.; 
Ludovini, V.; Baglivo, S., et al. Clinical outcomes to pemetrexed-based versus non-pemetrexed-based 
platinum doublets in patients with KRAS-mutant advanced non-squamous non-small cell lung cancer. 
Clin. Transl. Oncol. 2019, doi:10.1007/s12094-019-02175-y. 
61. Lohinai, Z.; Klikovits, T.; Moldvay, J.; Ostoros, G.; Raso, E.; Timar, J.; Fabian, K.; Kovalszky, I.; 
Kenessey, I.; Aigner, C., et al. KRAS-mutation incidence and prognostic value are metastatic site-
specific in lung adenocarcinoma: Poor prognosis in patients with KRAS mutation and bone metastasis. 
Sci. Rep. 2017, 7, e39721, doi:10.1038/srep39721. 
62. Lohinai, Z.; Hoda, M.A.; Fabian, K.; Ostoros, G.; Raso, E.; Barbai, T.; Timar, J.; Kovalszky, I.; Cserepes, 
M.; Rozsas, A., et al. Distinct epidemiology and clinical consequence of classic versus rare EGFR 
mutations in lung adenocarcinoma. J. Thorac. Oncol. 2015, 10, 738–746, 
doi:10.1097/JTO.0000000000000492. 
63. Reck, M.; von Pawel, J.; Zatloukal, P.; Ramlau, R.; Gorbounova, V.; Hirsh, V.; Leighl, N.; Mezger, J.; 
Archer, V.; Moore, N., et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo 
as first-line therapy for nonsquamous non-small-cell lung cancer: Results from a randomised phase III 
trial (AVAiL). Ann. Oncol. 2010, 21, 1804–1809, doi:10.1093/annonc/mdq020. 
64. Shimizu, R.; Fujimoto, D.; Kato, R.; Otoshi, T.; Kawamura, T.; Tamai, K.; Matsumoto, T.; Nagata, K.; 
Otsuka, K.; Nakagawa, A., et al. The safety and efficacy of paclitaxel and carboplatin with or without 
bevacizumab for treating patients with advanced nonsquamous non-small cell lung cancer with 
interstitial lung disease. Cancer Chemother. Pharmacol. 2014, 74, 1159–1166, doi:10.1007/s00280-014-2590-
x. 
 
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access 
article distributed under the terms and conditions of the Creative Commons Attribution 
(CC BY) license (http://creativecommons.org/licenses/by/4.0/). 
 
DOI:10.14753/SE.2020.2414
